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            Abstract 
 
 
Donation of haematopoietic stem cells (HSCs), either through bone marrow (BM) or 
peripheral blood stem cell (PBSC) collection, is a generally safe procedure for healthy 
donors, although adverse reactions (ARs) are a known and definable risk. The 
physical reactions to donation have been established for some time, but less is known 
about factors predicting poorer experiences.  
 
In my thesis, I explore the donation experience in a prospective study involving 275 
PBSC and 37 BM donors and focus attention on health-related quality of life (HRQOL) 
factors associated with recovery. Detailed interviews of 14 PBSC donors explore 
these findings using qualitative methodology. In addition, I characterise donors at risk 
of not meeting the HSC dose requested by transplant centres and therefore at risk of 
additional procedures and associated ARs. 
 
My key finding was that pre-donation HRQOL markers were the strongest predictors 
of time to recovery; poorer pre-donation physical health was associated with longer 
recovery (p = 0.017) and certain side-effects in PBSC donors, and poorer mental 
health was associated with longer recovery in BM donors (p = 0.03) and pain following 
PBSC donation (p = 0.003). Physical HRQOL scores declined significantly from pre-
donation to 4 weeks post-donation, but returned to pre-donation values at 3 months. 
This decline was greater for BM donors. Mental HRQOL scores remained high 
throughout for PBSC donors, this may be explained by the strong, intrinsic motivation 
as well as remarkable determination donors described in the qualitative analysis. 
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Understanding that toxicity profiles vary with certain donor characteristics is crucial 
as this knowledge could influence future practice in numerous ways including 
modification of joining policies and provision of tailored donor information, pre-
emptive analgesia and donor follow-up. Based on my study findings, I initiated a pilot 
study that offers a different approach to donors at higher risk of a delayed recovery.  
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 Definition 
Allogeneic 
haematopoietic 
stem cell transplant 
(allo-HSCT) 
In humans, allo-HSCT refers to the use of donated HSC from another 
individual for transplantation. Examples of HSC sources for allo-
HSCT include: syngeneic (twin) donor, HLA-identical sibling donor, 
haploidentical related donor, unrelated adult donor, cord blood unit. 
Anthony Nolan 
(AN) 
AN is a UK charity that works in the area of HSCT. It manages and 
recruits donors to the AN Register, which is the largest UK registry. It 
is aligned with the Welsh Bone Marrow Donor Registry and the 
National Blood Service ran British Bone Marrow Registry (BBMR). It 
also carries out research to help make bone marrow transplants more 
effective.  
Apheresis Apheresis is a technique in which the blood of a donor or patient is 
passed through a machine that separates out one particular 
constituent (haematopoietic stem cells in the case of PBSC donation) 
and returns the remainder to the circulation.  
BM See ‘Bone Marrow’ 
BMDW Bone Marrow Donors Worldwide. A global collaborative collation 
system designed to provide a searchable interface for unrelated 
donors listed by participating registries. 
Bone Marrow The soft blood-forming tissue that fills the cavities of bones and 
contains fat and immature and mature blood cells, including white 
blood cells, red blood cells, and platelets. 
BSBMT The British Society of Blood and Marrow Transplantation 
CD 34 CD34 molecule is a cluster of differentiation molecule present on 
certain cells within the human body and has been a focus of interest 
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ever since it was found expressed on a small fraction of human bone 
marrow cells. The CD34+-enriched cell population from marrow or 
mobilised peripheral blood appears responsible for most of the 
haematopoietic activity and CD34 has therefore been considered to 
be the most critical marker for HSCs. 
CIBMTR The Center for International Blood & Marrow Transplant Research, or 
CIBMTR, collaborates with the global scientific community to 
advance haematopoietic cell transplantation and cellular therapy 
research worldwide. A combined research program of the National 
Marrow Donor Program and the Medical College of Wisconsin, 
CIBMTR facilitates critical research that has led to increased survival 
and an enriched quality of life for thousands of patients. 
Collection centre A medical centre equipped to carry out collection of haematopoietic 
stem cells, either by peripheral blood stem cell apheresis or bone 
marrow harvest. Many will also undertake medical assessment of 
donors to establish fitness to donate. 
Conditioning A chemotherapy regimen with or without radiotherapy or 
immunotherapy designed to prepare the recipient bone marrow or 
immune system for receipt of donor HSC. Regimens may be 
myeloablative (full-intensity) or non-myeloablative (reduced-
intensity). 
Confirmatory 
typing (CT) 
Blood sample confirmation for possible donor/recipient HLA match 
Cord blood unit 
(CBU) 
A donation of blood, rich in HSC, derived from the umbilical cord and 
placenta of a new born infant. Cord blood units are generally 
cryopreserved and may be used for allo-HSCT if found to be 
appropriately matched to a patient. 
DLI See ‘Donor Lymphocyte Infusion’ 
Donor Any individual, living or dead, providing solid organs, tissues or cells 
for the purposes of transplantation or transfusion. For the purposes 
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of this thesis, a donor is an individual providing haematopoietic stem 
cells or lymphocytes for the allogeneic transplantation. 
Donor lymphocyte 
infusion 
The process of giving lymphocytes from a donor to a recipient 
following allo-HSCT, usually for treating disease relapse or mixed 
donor/recipient chimerism. The lymphocytes may be stored from the 
original donation, or the donor may need to undergo further apheresis 
to provide the cells. 
EBMT The European Group for Blood and Marrow Transplantation 
FDA The Food and Drug Administration or FDA is a Consumer Protection 
Agency of the U.S. Government responsible for protecting the public 
health by assuring the safety, efficacy, and security of human and 
veterinary drugs, biological products, medical devices, the nation’s 
food supply, cosmetics, and products that emit radiation. The FDA 
also provides accurate, science-based health information to the 
public. 
G-CSF G-CSF or granulocyte colony stimulating factor is a haematopoietic 
cytokine glycoprotein produced by monocytes, fibroblasts, and 
endothelial cells whose principal role in normal haematopoiesis is to 
regulate production, differentiation, and functional activation of 
neutrophils. Recombinant G-CSF given at pharmacological doses 
stimulates the development of primitive HSCs and the release of 
CD34+ progenitors from the marrow into the circulation. 
Graft-vs-host 
disease (GvHD) 
Immune cells (white blood cells) in the graft recognise the recipient 
(the host) as "foreign". The transplanted immune cells then attack the 
host's body cells. It can affect several organs including the skin, 
gastrointestinal tract and liver. 
Graft-vs-leukemia 
effect (GVL) 
A desired effect of allo-HSCT, describing the immunological activity 
of the engrafted donor immune system against malignant recipient 
cells. 
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Haematopoietic 
stem cell (HSC) 
A multipotent immature cell capable of self-replication and 
differentiation into cells of myeloid, erythroid or lymphoid lineage. 
CD34 has been considered to be the most critical marker for HSCs. 
HSCT Haematopoietic stem cell transplantation, which may be autologous 
(self-transplant), or allogeneic (donor, allo-HSCT) 
HTA See ‘Human Tissue Authority’ 
Human leukocyte 
antigen (HLA) 
The human leukocyte antigen (HLA) system is the locus of genes that 
encode for proteins on the surface of cells that are responsible for 
regulation of the immune system in humans. Any cell displaying some 
other HLA type is "non-self" and is seen as an invader by the body's 
immune system, resulting in the rejection of the tissue bearing those 
cells. This is particularly important in the case of transplanted tissue, 
because it could lead to transplant rejection.  
Human Tissue 
Authority (HTA) 
The UK legislative authority responsible for regulation pertaining to 
the handling of human cells, tissues and organs. 
JACIE Joint Accreditation Committee ISCT-EBMT. A Collaborative global 
organisation providing standards, inspection and accreditation of 
organisations involved in the collection, processing and 
transplantation of haematopoietic stem cells and related products. 
Mobilisation Mobilisation is a process in which certain drugs (for example G-CSF) 
are used to cause the movement of HSCs from the bone marrow into 
the blood. 
NHS Blood and 
Transplant 
(NHSBT) 
The National Health Service department responsible for collection 
and provision of blood-products, tissues, organs and cells for the 
purpose of transfusion or transplantation. 
NMDP The National Marrow Donor Program. It is the largest HSC registry in 
the United States. 
PBSC See ‘Peripheral blood stem cells’ 
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Peripheral blood 
stem cells  
Peripheral blood stem cells (PBSC) are HSCs that circulate in the 
blood. Most of the HSCs in the body can actually be found in the bone 
marrow. However, a small proportion of HSCs - PBSC - circulate in 
blood. This proportion can be increased by a process called 
mobilisation, when HSCs from the BM move into the blood. 
RD See ‘related donor’ 
Related donor   A related donor can be a syngeneic (twin) donor, HLA-identical sibling 
donor or a haploidentical related donor (half-matched related donor) 
SAR See ‘Serious adverse reaction’ 
Serious adverse 
reaction 
Any life-threatening adverse event or adverse event leading to death, 
hospitalization (initial or prolonged), disability or permanent damage. 
SF-36 The SF-36 or short-form 36 is a widely used questionnaire for 
measuring self-reported physical and mental health status. It contains 
36 questions. The original SF-36 came out from the Medical Outcome 
Study. 
TC See ‘Transplant centre’ 
Transplant centre A unit (usually within a hospital) capable of carrying out 
haematopoietic stem cell transplantation. For the purposes of this 
thesis, these centres carry out allogeneic HSCT. 
Unrelated donor When the donor has no family connection to the recipient it is called 
unrelated donor. These donors are found through an unrelated donor 
registry and are volunteers.  
URD See ‘unrelated donor’ 
WMDA The World Marrow Donor Association. The WMDA was founded in 
order to provide a global forum for all matters relating to donors of 
haematopoietic stem cells. 
Work-up The pre-donation work-up involves the clinical evaluation of the 
potential donor. The potential donor’s state of health must be 
evaluated, as must the presence of criteria for exclusion from 
donation and risk factors related to the type of donation. It involves a 
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detailed history, clinical examination, blood tests and often a chest X-
ray and ECG.  
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Thesis overview 
 
The primary aim of my thesis is to provide an in depth analysis of the short and long-
term physical and psychological donation experience as well as an analysis of factors 
influencing donor recovery and the identification of donors who are at risk of poorer 
donation experiences. The results will help towards more targeted strategies 
concerning donor recruitment, selection, work-up and donor follow-up and I believe 
such strategies will improve the donation experience.  
 
I started my research with a review of the literature, which is outlined in chapter 1. 
This chapter explores the donation experience, both from a physical and 
psychological perspective. It gives in insight into factors that are associated with a 
poorer donation experience, and details methods that are currently in place to 
optimise donor safety. 
 
I subsequently designed the prospective study described in chapters 4 and 5. This 
study is the core of my thesis and assesses the physical and psychological donation 
experience and defines groups at increased risk of a poorer donation experience. I 
evaluate both the impact of demographic factors (chapter 4) and baseline health 
related quality of life scores (chapter 5). This study was designed by myself in close 
collaboration with my supervisors. As part of the preparation of my prospective study 
and in order to ensure the adequate capture of my outcome data (adverse reactions 
at certain time points and time to complete recovery), I audited the collection of donor 
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follow-up data for our register. The first part of chapter 3 describes this audit as well 
as the subsequent changes I implemented based on this. 
 
Following the analysis of my prospective study, I designed a study that further 
explores the main findings of the study in a qualitative matter (chapter 7). This study 
involves 14 in depth donor interviews and assesses the influence of pre-donation 
physical health on the donation experience. Additionally, the study evaluates the role 
of donor preparedness and donor ambivalence in our donor population, factors that 
have previously shown to influence the donation experience, but that were not 
investigated in the prospective study.  
 
Chapters 3 and 6 investigate the PBSC (chapter 3) and BM (chapter 6) donor and 
collection characteristics that are more likely to be associated with reaching the stem 
cell dose requested by the transplant centre. The reason I decided to investigate 
these areas are twofold. Firstly, additional procedures may be needed if the requested 
dose is not reached after 1 day; these procedures may be associated with increased 
adverse reactions and hence the importance of characterising donors who are at risk 
of not reaching the requested dose. Secondly, if we aim to change policies (e.g. 
recruitment) for donors at high risk of adverse reactions, it is important to realise how 
this change in practice will affect the yields. Similar factors that are analysed 
concerning donor safety in chapter 5 (e.g. BMI, weight and age) are therefore 
investigated with regards to their influence on yields. 
 
The methodology of all the studies is described in chapter 2. Chapter 8 summarises 
the thesis, discusses some of the challenges I faced, and presents future directions 
this work may take
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Chapter 1 - background 
 
 
A review article based on the text of this introduction was published in the journal of 
Bone Marrow Transplantation in January 2014, entitled “A review of the 
haematopoietic stem cell donation experience: is there room for improvement?” 
(See Appendix 3) 
 
1.1 Introduction 
1.1.1 General principles of haematopoietic stem cell transplantation 
Haematopoietic stem cell transplantation (HSCT) is the treatment of choice for 
several malignant and non-malignant haematological diseases. It involves eliminating 
a patient’s haematopoietic system by chemotherapy and/or radiotherapy in a 
procedure called conditioning and replacing it with healthy haematopoietic stem cells 
(HSCs). This conditioning is designed to eradicate the patient’s haematopoietic 
system and, if present, malignancy. In addition, it helps to suppress the host immune 
system and thereby prevents rejection of “foreign” stem cells. In allogeneic SCT, 
these stem cells are from another individual.  
 
HSCT is mainly used in haematological malignancies, for example acute and chronic 
leukemia, but it also has a role in the treatment of non-malignant haematological 
diseases. The exact role of HSCT in each of these diseases is complex and depends 
on several factors including disease severity, remission status, age of the patient and 
availability of a donor. Although allogeneic HSCT can be curative, it has a significant 
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morbidity and mortality associated with it. One of the major reasons for this is any 
immunological incompatibility between donor and patient, therefore matching for the 
human leukocyte antigens (HLA) is critical and determines whether or not a transplant 
can go ahead. Despite HLA matching complications may still occur and may be due 
to numerous different factors beyond the scope of this thesis. The complications may 
manifest as immunodeficiency, graft-versus-host disease (GvHD) or graft failure. 
GvHD is a condition caused by donor-derived immune cells reacting against recipient 
tissues. It can affect several organs including the skin, gastrointestinal tract or liver. 
Paradoxically, there is also a graft-versus-leukemia (GVL) effect which underlies 
much of the success of the procedure. Another major cause of transplant-related 
complications is the risk of bacterial, fungal and viral infections due to an impaired 
immune system. Disease relapse may also occur.  
 
A major evolution in allogeneic HSCT is the shift that has occurred from myelo-
ablative conditioning regimens to non-myeloablative conditioning. Myeloablative 
regimens completely eradicate the patient’s bone marrow, whereas non-myelo-
ablative regimens cause enough immunosuppression to allow engraftment but 
without completely eradicating the patient’s own bone marrow. These “mini-
transplants” have reduced the morbidity and mortality of allogeneic HSCT and have 
extended the age range for transplantation (Mielcarek et al., 2002). They rely heavily 
on the ability of GVL effect to cure the underlying malignant disease. The relapse 
rates in “mini-transplants” are higher (McSweeney et al., 2001) and in this context, 
they are associated with a higher use of donor lymphocyte infusions (DLI).  The 
principle of DLI is that peripheral blood mononuclear cells are collected from the 
original allograft donor and directly infused into the patient at the time of disease 
relapse or to prevent relapse by strengthening the graft. DLI infusions encourage 
complete engraftment and can induce GVL effects. 
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Ideally patients receive stem cells from a matched related (sibling) donor. But as there 
is only a 25% chance for a sibling to be HLA matched, only about 30% of patients 
have a sibling matched donor and this number is expected to continue to drop as the 
average family size keeps going down in the Caucasian population. An alternative 
donor source is an unrelated HLA matched donor that can be identified through 
volunteer unrelated donor registries. Strong evidence for significantly improved 
transplant outcome in unrelated donor HSCT by matching for HLA using high 
resolution typing between patient and donor has been published over recent years 
(Petersdorf, 2004, Petersdorf et al., 2007, Petersdorf, 2008, Flomenberg et al., 2004). 
Surveys from Europe and the United States show that there are now more unrelated 
than related haematopoietic stem cell donations in these areas (Pasquini and Wang, 
2012). This increase can be explained by the improved outcome of unrelated donor 
transplantation owing to more precise HLA typing and advances in patient care during 
the last decade. Even though the unrelated donor pool steadily expands, 
approximately 90% of Caucasians but as low as 40% of non-Northern Europeans are 
able to find a match (NHSBT, 2010, Lown and Shaw, 2013). Non-HLA factors that 
also need to be taken into account for donor selection include CMV status, ABO blood 
group and donor age. An alternative approach for patients without HLA-matched 
donors is the use of a haploidentical donor or umbilical cord blood. Haploidentical 
donors have one haplotype in common with the recipient, so they match in at least 
half of their HLA loci. These are most commonly relatives, such as parents, children 
or siblings.  
 
1.1.2 Collection of HSCs 
Stem cells can be collected from the bone marrow (BM), the peripheral blood 
(peripheral blood stem cells or PBSC) or from umbilical cord blood.  
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BM donation involves the repeated insertion of large bore needles into the donor’s 
posterior iliac crests to remove up to 2 litres of marrow under general or spinal 
anaesthesia. The amount of extracted BM depends on the donor weight, but should 
not exceed 20 mls/kg (based on international recommendations). The average 
hospital stay is 8-72 hours and many collection centres routinely admit their donors 
following donation (Favre et al., 2003, Gandini et al., 2001, Nishimori et al., 2002). 
 PBSC are collected using a cell-separator machine connected to the donor via a 
peripheral cannula or a central venous catheter if donors have inadequate veins. 
Blood is taken from the donor and circulated in the machine where mononuclear cells 
are collected by centrifugation before the red cells are returned to the donor, a 
process called leukapheresis. This process may take several hours and PBSC donors 
are generally not admitted to hospital. A second day leukapheresis may be needed if 
insufficient HSCs were harvested on day 1. Peripheral blood contains too few HSCs 
for successful transplantation, hence growth factors (granulocyte colony stimulating 
factor or G-CSF) are injected daily the 4 or 5 days preceding the leukapheresis. G-
CSF is a haematopoietic cytokine glycoprotein produced by monocytes, fibroblasts, 
and endothelial cells whose principal role in normal haematopoiesis is to regulate 
production, differentiation, and functional activation of neutrophils. Recombinant G-
CSF given at pharmacological doses stimulates the development of primitive HSCs 
and the release of CD34+ progenitors from the marrow into the circulation (Pamphilon 
et al., 2008). CD34 has been considered to be the most critical marker for HSCs.  
 
In the last decade, PBSC have replaced BM as the main source of HSCs. The cell 
composition of unmanipulated PBSC and BM allografts differs significantly. The total 
numbers of T cells, monocytes, and natural killer cells contained in a PBSC allograft 
are more than 10 times higher than those in a BM allograft (Ottinger et al., 1996). 
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Also, Russell et al demonstrated that G-CSF causes the mobilisation of large 
numbers of type 2 dendritic cells and the presence of large numbers of CD4 cells 
expressing the T-helper 2 phenotype (Klangsinsirikul and Russell, 2002), which 
contrasts with the predominantly type 1 dendritic cell and T-helper 1 phenotype in BM 
harvests . As a consequence, there is a major difference in the proportion of Th1 and 
Th2 cells infused in BM and PBSC recipients. This difference in graft composition 
may explain the increased risk of acute and chronic GvHD reported in several large 
randomised controlled trials (Schmitz et al., 1995, Bensinger et al., 1995, Blaise et 
al., 2000, Powles et al., 2000, Bensinger et al., 2001, Morton et al., 2001, Couban et 
al., 2002, Schmitz et al., 2002) when using a PBSC source. 
 
PBSC also have a much higher content of blood progenitor cells compared to bone 
marrow. This is associated with faster haematological recovery in recipients (Tanaka 
et al., 1994, Bensinger et al., 1995, Anasetti et al., 2012). The recipient might also 
profit by an enhanced GVL reaction exerted by the high number of natural killer cells 
contained in such grafts and several authors have reported a decreased relapse rate, 
especially among patients with high-risk blood cancers (Powles et al., 2000, Nagler 
et al., 2012). However, most studies found no significant differences in long-term 
survival rates between PBSC and BM; this may be explained by the finding that PBSC 
reduces the risk of graft failure whereas bone marrow reduces the risk of chronic 
GvHD (Powles et al., 2000, Friedrichs et al., 2010, Anasetti et al., 2012). Another 
consideration when deciding on the HSC source should be the donation perspective. 
Several authors have reported a delayed recovery and an increased risk of serious 
adverse reactions in BM donors, whereas G-CSF has been a topic of debate 
concerning its long-term safety. 
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1.1.3 The donation experience 
Although the donation process is generally considered safe, adverse reactions (ARs) 
are a well-established risk. Optimizing the donation experience is essential for several 
reasons. Most importantly, the act of donating BM or PBSC for HSCT  is a 
humanitarian gesture rewarded only by the potential sense of satisfaction derived 
from an altruistic act (Boo et al., 2011). Hence, care must be taken to minimize the 
potential of harm and donor safety should be a first priority for everyone involved. In 
addition, stem cell donation requires that we balance the conflict between ensuring 
there are a sufficient number of willing donors while protecting their safety.  
 
The overall experience of the donor includes both physical and psychological aspects, 
from the time of their first contact with the registry until full recovery. Common physical 
adverse reactions of BM and PBSC donation are well known (de la Rubia et al., 2008, 
Holig et al., 2009, Miller et al., 2008, Pulsipher et al., 2009b, Pulsipher et al., 2013, 
Siddiq et al., 2009), although studies examining the psychological aspects of donation 
and examining which groups of donors are at increased risk have been limited 
(Pulsipher et al., 2009b, Pulsipher et al., 2013, Murata et al., 1999, Chen et al., 2011, 
Miller et al., 2008, Gandini et al., 2001, Billen et al., 2014, Switzer et al., 1996, 
Stroncek et al., 1996, Yuan et al., 2010). The latter are important as it could help to 
identify strategies to improve donor safety and result in a more personalized approach 
to higher risk groups. In this chapter, I will review the most common physical and 
psychological reactions to the donation process and concentrate on groups of donors 
that are at increased risk of adverse reactions. I will also discuss procedures that are 
already in place to ensure donor safety and outline the aims of my thesis. 
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1.2 Physical adverse reactions 
Almost all BM donors will experience some mild to moderate common side effects 
such as pain, nausea, vomiting, throat pain and headache (table 1.1) (Karlsson et al., 
2004, Pulsipher et al., 2013, Favre et al., 2003, Miller et al., 2008, Gandini et al., 2001, 
Nishimori et al., 2002, Stroncek et al., 1993). Although rare, BM donation can also be 
associated with several potentially more serious risks. Bone and soft tissue trauma at 
the harvest site may cause pain, bleeding or nerve damage. Damage to a nerve root 
or penetration into the pelvic cavity may cause severe morbidity. Anaesthesia carries 
an unavoidable risk of life-threatening cardiac or respiratory events, as well as the 
possibility of reactions to anaesthetic agents. Removal of large volumes of blood may 
cause symptoms of hypovolemia or anaemia. In many centres, autologous red cell 
units are collected prior to the harvest and re-infused after the harvest, in order to 
prevent post-operative anaemia and associated tiredness. Others see no need to 
collect autologous units arguing that red cell donation renders donors anaemic on the 
day of surgery, making transfusion – autologous or even allogeneic – more likely. 
Transfusion is associated with limited, but potentially fatal risks including immune-
related transfusion reactions. These reactions most often occur because of errors 
made in matching the recipient's blood to the blood transfused. In addition, red cell 
donations often expire due to postponement of the donation.  
 
Almost all PBSC donors will experience mild to moderate short-term side effects of 
G-CSF. They include bone pain, headache, nausea, vomiting and fatigue (table 1.1) 
(Karlsson et al., 2004, de la Rubia et al., 2008, Pulsipher et al., 2013, Pulsipher et al., 
2009b, Murata et al., 1999, Chen et al., 2011, Miller et al., 2008, Holig et al., 2009, 
Fortanier et al., 2002, Martino et al., 2009). Haematological effects include an 8-fold 
increase in the absolute number of neutrophils (D'Souza et al., 2008). Other 
complications of PBSC donation can be related to the insertion of a catheter and the 
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process of apheresis. As a consequence of venepuncture, bruising, bleeding or nerve 
injury may occur. Apheresis might cause symptomatic hypovolemia and 
hypocalcaemia is common as a result of the use of citrate anticoagulation in the 
circuit. A reduction in platelet count is an inevitable consequence of PBSC donation. 
This is due to platelet depletion by the leukapheresis procedure itself (Majolino et al., 
1997, Rhodes and Anderlini, 2008), as well as a temporary suppression of 
megakaryopoiesis by G-CSF and a significant increase in spleen size (Stroncek et 
al., 2003). The platelet count rarely drops to a level where the bleeding risk is 
significantly increased (Stroncek et al., 1999, Murata et al., 1999). Murata et al 
reported a decrease in platelet count of approximately 33% after one apheresis. Rarer 
side effects of PBSC donation may be associated with the G-CSF-induced rapid 
expansion of the myeloid pool and PBSC donation has been associated with the 
exacerbation of gouty arthritis and with an increase in spleen size. This effect is 
transient, but at least 3 separate case reports of spontaneous splenic rupture after G-
CSF administration in healthy donors have been reported (D'Souza et al., 2008). 
Other rare events related to G-CSF include flare-ups of autoimmune activity and 
cardiovascular complications secondary to a transient prothrombotic state.   
 
Table 1. 1 Common side effects of BM and PBSC donation 
(Karlsson et al., 2004, de la Rubia et al., 2008, Pulsipher et al., 2013, Pulsipher et al., 
2009b, Murata et al., 1999, Chen et al., 2011, Miller et al., 2008, Holig et al., 2009, Fortanier 
et al., 2002, Martino et al., 2009, Gandini et al., 2001, Nishimori et al., 2002, Favre et al., 
2003, Stroncek et al., 1993) 
Adverse Reaction BM donation PBSC donation 
Bone pain 23%-87% 61%-97% 
Fatigue 38%-88% 33%-77% 
Headache 15%-18% 27%-74% 
Chapter 1 - Background 
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Joint pain Rare 40% 
Insomnia 10%-15% 1%-48% 
Myalgia 22%-25% 29%-90% 
Anorexia 8%-10% 11%-22% 
Nausea  6%-26% 11%-26% 
Throat pain 30%-33% Not applicable 
Harvest site reactions 11%-15% Not applicable 
 
Several prospective studies describing common toxicities in BM and PBSC unrelated 
donors (URDs) have been published recently (Pulsipher et al., 2013, Pulsipher et al., 
2009b, Miller et al., 2008, Gandini et al., 2001, Holig et al., 2009, Kennedy et al., 
2003, Nishimori et al., 2002), some comparing BM and PBSC donation (Pulsipher et 
al., 2013, Miller et al., 2008, Kennedy et al., 2003).  The earlier studies only reported 
descriptions of general toxicity, and serious adverse reactions were ill defined. A 
uniform grading system for common toxicities was not used, making it difficult to 
compare toxicity outcomes with other studies. The NMDP was the first register to add 
Common Toxicity Criteria Adverse Event (CTCAE) toxicity grading to donor reporting 
requirements in 2004. These recent studies show that the discomfort following PBSC 
donation usually starts within 24-48 hours of administration of G-CSF but resolves 
fairly quickly after collection, with just over 10% of donors reporting discomfort at 1 
week post collection (Pulsipher et al., 2013). For BM donors, pain had resolved for 
80% at 1 month after donation (Miller et al., 2008) and complete recovery was 
reported in 67% of donors at 1 month (Pulsipher et al., 2013). Most BM donors 
experience substantial pain and physical limitations, but general health scores remain 
high (Nishimori et al., 2002). Although the peak symptom burden of PBSC donors 
does not differ from those reported by BM donors, the temporal patterns are different 
with some studies showing that discomfort peaks on day +5 of G-CSF for PBSC 
donors compared to 48 hours after collection for BM donors (Pulsipher et al., 2013, 
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Rowley et al., 2001). The latter tend to experience a delayed recovery compared to 
PBSC donors (Pulsipher et al., 2013, Favre et al., 2003, Heldal et al., 2002, Bredeson 
et al., 2004, Siddiq et al., 2009).  
 
1.2.1 Serious adverse reactions (SARs) 
Prospective studies have reported an incidence of serious adverse reactions (SARs) 
ranging from 0.6-1.1% in PBSC and from 1.34% to 2.38% in BM donors (Pulsipher et 
al., 2014, de la Rubia et al., 2008, Pulsipher et al., 2009b, Miller et al., 2008, Holig et 
al., 2009). The definition of SARs has not been well defined in all studies, which 
makes the incidence challenging to compare. Most SARs have been reported as case 
reports or by retrospective studies, hence causality can usually not be determined 
(Halter et al., 2013). Some of these SARs, such as thrombotic and cardiovascular 
events or splenic rupture may be explained by the biological effects of G-CSF (Halter 
et al., 2013, Halter et al., 2009, Anderlini and Champlin, 2008, D'Souza et al., 2008, 
Pamphilon et al., 2008, McCullough et al., 2008) or are associated with the collection 
procedure used (harvest site pain with subsequent disability, anaesthesia or central 
venous catheter related) (Halter et al., 2013, Favre et al., 2003, Halter et al., 2009, 
Kennedy et al., 2003, Pulsipher, 2012, Pulsipher et al., 2014). Two cases of heparin-
induced thrombocytopenia associated thrombo-embolic disease (Halter et al., 2009) 
due to the systemic use of heparin as an anti-coagulant have been described. This 
practice is now not longer recommended. Fat embolism syndrome following bone 
marrow harvesting has also been reported (Baselga et al., 1991). A large study from 
the European Group for Blood and Marrow Transplantation (EBMT), reported 7.25 
serious adverse reactions (SARs) per 10 000 and significantly less in BM than PBSC 
donors (Halter et al., 2009). This is however a questionnaire based retrospective 
study and has very low overall rates of serious adverse reactions so might represent 
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underreporting. The same author reported that the incidence of donor fatalities was 
0.98 per 10 000 donors, all in related donors, four after PBSC and one after BM 
donation (Halter et al., 2009). The cases reported included cardiac arrest and 
pulmonary embolus. In most of these donors, pre-existing medical conditions were 
identified post-mortem, highlighting the need for strict medical eligibility criteria and 
assessment of donors. Death in unrelated donors (URDs) is exceedingly rare with 
only one death reported to the WMDA between 2003 and 2012 (Shaw et al., 2013). 
This was caused by an extensive haemothorax secondary to traumatic jugular vein 
catheter insertion. Second donations of stem cells are not associated with an 
increased risk of donor adverse reactions, however the need for informed consent is 
clear (Confer et al., 2011). Table 1.2 provides an overview of studies that have 
evaluated short term physical outcomes in URDs and related donors (RDs). 
 
Table 1. 2 Overview of studies assessing adverse reactions (ARs) and serious adverse 
reactions (SARs) in BM and PBSC donors 
Study Method (n) URD/RD ARs SARs 
Chang 
(Chang et 
al., 1998) 
BM (77) URD vs 
RD 
More acute physical pain in 
related donors 
Not specified 
Murata 
(Murata et 
al., 1999) 
PBSC (94) URD 67% reported bone pain, 
31% reported fatigue 
1 donor reported grade 3 
bone pain with need for 
opioids 
Anderlini 
(Anderlini 
et al., 
2001) 
PBSC 
(1488) 
RD No end point 15 events (1.1%), one 
third was catheter related 
Gandini 
(Gandini et 
al., 2001) 
BM (103) URD 77% reported pain, 40% 
reported fatigue 
No acute life threatening 
events 
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Rowley 
(Rowley et 
al., 2001) 
PBSC (31) 
vs BM (38) 
RD Similar symptom burden in 
PBSC and BM donors,  but 
PBSC donors recover faster 
than BM donors 
BM: 2 (DVT, autologous 
transfusion), PBSC: 1 
(haematoma) 
Fortanier 
(Fortanier 
et al., 
2002) 
PBSC (33) 
vs BM (31) 
RD 61% suffered with bone pain 
or headache during G-CSF 
administration 
Highest pain scores similar 
for PBSC and BM, timing of 
highest pain is different 
Not specified 
Heldal 
(Heldal et 
al., 2002) 
PBSC (30) 
vs BM (31) 
RD AR in 60% PBSC, 93% of 
BM donors 
Symptom burden in PBSC 
donors lower than in BM 
donors 
Not specified 
Nishimori 
(Nishimori 
et al., 
2002) 
BM (565) URD 112/565 donors reported 
donation site pain all of the 
time 
Donors experience 
considerable pain and 
physical limitations 1 week 
following donation 
Quality of life is back to 
baseline at 3 months 
Not specified 
Favre 
(Favre et 
al., 2003) 
 
PBSC (163) 
versus BM 
(166) 
RD AR in 65% PBSC, 57% of 
BM donors 
PBSC less of a burden than 
BM donation in terms of 
duration of hospitalization 
and recovery time 
PBSC: 7%, BM: 1% 
Kennedy 
(Kennedy 
BM (30) vs 
PBSC (29) 
RD 20/25 bone marrow donors 
experienced harvest site pain 
No SAR reported 
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et al., 
2003) 
(both G-CSF 
stimulated) 
Similar AR in both groups 
apart from more back pain in 
BM group, similar recovery 
times 
Bredeson 
(Bredeson 
et al., 
2004) 
PBSC (91) 
vs BM (93) 
RD BM donors experienced 
worse fatigue and lack of 
energy 1 week after donation 
compared to PBSC donors 
Not specified 
Karlsson 
(Karlsson 
et al., 
2004) 
PBSC (116) 
vs BM (55) 
RD Moderate or severe pain in 
68% of PBSC, 85% in BM 
donors 
Duration of pain longer in BM 
donors, more significant 
fatigue in BM donors 
BM: 2, PBSC: 3 
De la Rubia 
(de la 
Rubia et 
al., 2008) 
PBSC 
(1278) 
RD AR in 68% 
Clinical side effects of PBSC 
donation are generally mild 
<1 % 
Miller 
(Miller et 
al., 2008) 
BM (2505) 
vs PBSC 
(4476) 
URD 89% of PBSC donors 
reported pain (bone pain at 
various sites) and 82% of BM 
donors reported pain (back 
or hip) 
59% of BM donors reported 
fatigue versus 70% of PBSC 
donors 
PBSC donors reported faster 
recovery from their donation 
than BM donors 
SAR occurred more 
frequently in BM donors 
(1.34% versus 0.6% for 
PBSC) and a few led to 
long-term complications 
not reported by PSBC 
Halter 
(Halter et 
al., 2009) 
BM (24 099) 
vs PBSC (15 
111) 
URD/RD No end point Death: 0.98 per 10 000 
transplants, all in related 
donors (5 cases: medical 
error, pulmonary 
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embolus, subarachnoid 
haemorrhage, cardiac 
arrest) 
SAR: 7.25 per 10 000, 
significantly fewer in BM 
than PBSC 
Holig (Holig 
et al., 
2009) 
PBSC 
(3928) 
URD AR (bone pain) in 93.5% Less or equal than 1.1% 
of donor population 
during follow-up period of 
5 years 
Leitner 
(Leitner et 
al., 2009) 
PBSC (171) RD 70/95 donors experienced G-
CSF related side effects 
Not specified 
Martino 
(Martino et 
al., 2009) 
PBSC (184) RD 71% reported bone pain No SAR reported 
Pulsipher 
(Pulsipher 
et al., 
2009a) 
PBSC 
(2408) 
URD 80% experienced bone pain, 
other common AR were 
myalgia  and headache 
6% experienced grade 
III-IV CALGB toxicities 
and 0.6% experienced 
toxicities that were 
considered serious and 
unexpected 
Siddiq 
(Siddiq et 
al., 2009) 
(Cochrane 
review) 
 
BM (264) vs 
PBSC (254) 
 
RD PBSC donors experienced 
more pain prior to donation 
(G-CSF related) 
BM donors experienced 
more overall adverse events 
and more days of restricted 
activity 
More SARS in BM 
donors compared to 
PBSC donors 
(Haemorrhage, anaemia, 
hypotension) 
Yuan 
(Yuan et 
al., 2010) 
PBSC 
(15763) 
URD No end point 0.37% 
19 pre-syncope/syncope 
(PS), 4 citrate reaction 
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(CR), 17 PS + CR, 12 
vascular injuries 
Chen 
(Chen et 
al., 2011) 
PBSC (516) URD Most common AR was bone 
pain in 64.9% 
2 donors discontinued 
GCSF (severe 
hypertension, 
anaphylaxis) 
Kodera 
(Kodera et 
al., 2013) 
PBSC 
(3264) 
RD Not defined 1.44%, some SARs were 
potentially life-threatening 
(subarachnoid 
haematoma, interstitial 
pneumonitis) 
Pulsipher 
(Pulsipher 
et al., 
2013) 
BM (2726) 
vs PBSC 
(6768) 
 
 
 
 
 
URD 60-70% of AR in BM and 
PBSC donors, peak of AR on 
D2 (BM) versus D5 GCSF 
(PBSC) 
Similar AR for BM and PBSC 
donors in peri-collection 
period. 
At later evaluations, BM 
donors more likely to report 
persistent pain and have 
delayed recovery 
3% of female PBSC 
donors needed 
hospitalisation and 1% of 
male PBSC donors 
No full recovery in 3% of 
BM donors at 6 months 
compared to 0% in PBSC 
donors 
 
Wiersum-
Osselton 
(Wiersum-
Osselton et 
al., 2013) 
PBSC (268) RD Few short-term problems in 
both eligible and deferrable 
(donors who would be 
deferred for unrelated 
donation) related donors 
2% 
Pulsipher 
(Pulsipher 
et al., 
2014) 
PBSC  
(6768) and 
BM (2726) 
URD No end point 2.38% in BM vs. 0.56% in 
PBSC donors (p < 0.001) 
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1.2.2 Long term safety debate regarding G-CSF 
A dilemma facing the medical community is whether the use of G-CSF is related to 
an increased risk of developing malignancies, especially haematological diseases 
(Hasenclever and Sextro, 1996, Confer and Miller, 2007, Kaplinsky et al., 2007, 
Anderlini and Champlin, 2008, Avalos et al., 2011). An early study by Nagler and 
colleagues suggested that epigenetic changes characteristic of malignancy were 
present in the lymphocytes of related donors previously administered G-CSF (Nagler 
et al., 2004). However, Hirsch and colleagues could not find evidence of G-CSF 
induced chromosomal instability (Hirsch et al., 2011) and this is supported by a recent 
UK study (Nacheva E. personal communication). No epidemiological studies in 
related or unrelated donors to date suggest an increased risk of haematological 
malignancy following PBSC donation (Holig et al., 2009, Makita et al., 2004, de la 
Rubia et al., 2008, Confer and Miller, 2007, Cavallaro et al., 2000), but vigilance in 
monitoring post donation should remain the rule. 
 
1.2.3 Related donors 
Literature on the topic of related (RD) donor safety has been scarce (Karlsson et al., 
2004, Rowley et al., 2001, Heldal et al., 2002, Favre et al., 2003, Leitner et al., 2009, 
de la Rubia et al., 2008, Wiersum-Osselton et al., 2013, Bredeson et al., 2004, 
Fortanier et al., 2002, Kennedy et al., 2003, Martino et al., 2009, Anderlini et al., 2001, 
Kodera et al., 2013) and adverse reactions are not as well categorised in terms of 
frequency and severity compared to URDs. Current research suggests that the risks 
associated with donation seem to be higher for RDs compared to URDs with the 
caveat of the lack of an adequate amount of prospective follow-up data in the related 
donor setting (Halter et al., 2009). This increased risk has several explanations. 
Transplant centres may use less stringent criteria to determine donor eligibility in RDs 
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(Wiersum-Osselton et al., 2013). The percentage of RDs who have a contagious 
disease, who are pregnant or who have other medical conditions that would be 
considered contraindications in URDs is unknown. Moreover, the same transplant 
centre and occasionally the same physician caring for the recipient may evaluate the 
RD (O'Donnell et al., 2010). This could represent potential conflict of interest in favour 
of the recipient.  To the benefit of the donor, an independent physician for donor 
clearance and counselling ought to be provided (O'Donnell et al., 2010, Shaw, 2010, 
van Walraven et al., 2010). Special attention to the clinical, psychological and social 
needs should be paid to children who are being evaluated as potential donors. Often 
parents are expected to consent for their children, which may create additional conflict 
of interest circumstances (Horowitz and Confer, 2005, O'Donnell et al., 2010). In 
Europe, any potential donation of bone marrow or PBSC from adults or children who 
lack competence to consent, must be assessed by an Accredited Assessor (Human 
Tissue Authority, 2007). As opposed to URDs, RDs are not self-nominated, have 
personal motivations and are likely to be willing to take more risks and underreport 
conditions that could impact adverse reactions. Additionally, as data show better 
survival after transplantation when a younger donor is used, this has led to clinicians 
choosing the youngest available URD. This differs with RDs who often match the age 
of their recipients. These donor groups have specific problems (increased end organ 
dysfunction and cancer in older donors and size issues in paediatric donors). Studies 
comparing RD and URD outcomes are limited (Chang et al., 1998). This study 
reported that related marrow donors experience more acute physical pain, possibly 
resulting from higher stress levels being manifested by an increased vulnerability to 
pain. The NMDP is currently running a study comparing RD and URD outcomes 
(Pulsipher et al., 2010).  
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1.3 Donors at increased risk of adverse reactions 
There are a limited number of studies examining which donors are at increased risk 
of experiencing adverse reactions. The findings of these studies are important as they 
could lead to a more personalised approach to higher risk groups. Table 1.3 lists 
donor and treatment related characteristics that have been found to influence the 
donation experience. 
 
Apart from headache and moderate to severe pain (Pulsipher et al., 2013, Murata et 
al., 1999), younger donors do not appear to be at increased risk of experiencing 
complications during PBSC donation (Pulsipher et al., 2013, Chen et al., 2011, Yuan 
et al., 2010, Stroncek et al., 1996). Moreover, they have not been found to experience 
more pre-syncopal and syncopal events as demonstrated in whole blood donors 
(Yuan et al., 2010, Eder et al., 2008, Wiltbank et al., 2008). On the other hand, older 
PBSC donors were more likely to experience citrate toxicity and persistent toxicities 
at 1 week (Yuan et al., 2010, Pulsipher et al., 2013), reflecting a slower recovery 
period compared to younger donors. The latter has also been described in older BM 
donors (Pulsipher et al., 2013). However, the day of donation is generally tolerated 
better in older donors (Pulsipher et al., 2013, Switzer et al., 1996). This may be a 
result of older donors being more experienced with medical procedures in general 
(Switzer et al., 1996).   
 
Multiple studies have shown that female gender is associated with a higher risk of 
apheresis related adverse reactions compared to men, ((Martino et al., 2009), 
Pulsipher et al., 2013, Pulsipher et al., 2009b, Murata et al., 1999, Chen et al., 2011, 
Stroncek et al., 1996). Women experience more fatigue, pain, nausea, vomiting and 
side effects of hypocalcaemia. Female gender is also associated with more pain, 
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fatigue and toxicities following BM donation (Gandini et al., 2001, Switzer et al., 1996, 
Yuan et al., 2010, (Horowitz and Confer, 2005). Women are also more likely to 
experience SARs (Miller et al., 2008, Yuan et al., 2010) and are twice as likely to 
require extended hospitalization (Pulsipher et al., 2013, Pulsipher et al., 2009b).  
 
There is some evidence that donors who are overweight or obese tend to experience 
more pain during PBSC donation (Pulsipher et al., 2009b, Pulsipher et al., 2013, Chen 
et al., 2011). This could partially be explained by the relatively higher doses of G-CSF 
received in this group. Several studies have illustrated that many G-CSF side effects 
are dose dependent and more common at higher doses (Kroger et al., 2002, Murata 
et al., 1999, Chen et al., 2011, Engelhardt et al., 1999). Likewise, the life-threatening 
side effect of splenic rupture has mostly been reported when doses higher than 10 
mcg/kg/day were given (Nuamah et al., 2006, Balaguer et al., 2004). There have been 
no studies examining the influence of weight on adverse reactions in BM donors and 
most collection centres already have strict body mass index (BMI) restrictions for BM 
donors due to procedural difficulties in donors with higher BMIs.  
 
There are limited studies that compare general versus regional anaesthesia for BM 
harvesting (Miller et al., 2008, Machaczka et al., 2010, Lavi et al., 1993, Knudsen et 
al., 1995, Burmeister et al., 1998). Most studies found no difference in the numbers 
of adverse events. This strongly implies that the choice of anaesthesia should depend 
on the anaesthetist’s or donor’s preference (Machaczka et al., 2010). Blood donors 
had more physical difficulty with BM donation, and their previous experience with 
blood donation may have led them to underestimate the physical impact of bone 
marrow donation (Switzer et al., 1996). Being a blood donor is also correlated with 
higher number of days off work, this may be secondary to lower baseline haemoglobin 
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levels in those donors (Gandini et al., 2001). Jobs involving mild to moderate daily 
work activities have been associated with fewer days off work following BM donation 
compared to jobs involving more heavy duties (Gandini et al., 2001). An increased 
length of the BM harvest procedure has also been consistently associated with 
increased post-donation physical limitations and adverse reactions (Miller et al., 2008, 
Nishimori et al., 2002). 
 
Table 1. 3 Factors influencing donor adverse reactions (in PBSC donation, BM donation or 
both) 
Factor Outcome PBSC or BM 
donation 
Age   Older donors at less risk of pain in the peri-
collection period, but more likely to experience 
persistent pain, fatigue and other toxicities at 1 
week following donation (Pulsipher et al., 
2013)  
 Older donors at risk of more serious 
complications (Miller et al., 2008) 
 Higher incidence of headache in donors aged 
under 35 (Murata et al., 1999)  
 Older donors more likely to experience citrate 
related toxicity (Yuan et al., 2010)  
 No influence on ARs (Chen et al., 2011, 
Stroncek et al., 1996)  
 Older donors reported somewhat less difficulty 
with donation (Switzer et al., 1996) 
 PBSC 
and BM 
 
 
 
 PBSC 
and BM 
 
 PBSC 
 
 PBSC 
 
 PBSC 
 
 BM 
Female 
gender  
 More likely to require extended hospitalization 
following donation (Pulsipher et al., 2013) 
 PBSC 
and BM 
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 Greater physical difficulty with donation 
(Pulsipher et al., 2013, Switzer et al., 1996, 
Nishimori et al., 2002, Horowitz and Confer, 
2005) 
 Associated with more serious complications 
(Yuan et al., 2010, Miller et al., 2008) 
 Higher incidence of most apheresis related 
adverse reactions (Pulsipher et al., 2009b, 
Pulsipher et al., 2013, Chen et al., 2011, 
Stroncek et al., 1996)  (Murata et al., 1999, 
Martino et al., 2009, Stroncek et al., 1996)   
 More likely to require a line (Pulsipher et al., 
2009b)  
 More fatigue following donation (likely due to 
higher relative blood volume depletion) 
(Gandini et al., 2001) 
 Longer period of convalescence (Gandini et 
al., 2001) 
 Less likely to experience complete recovery 
(Pulsipher et al., 2013) 
 PBSC 
and BM 
 
 
 PBSC 
and BM 
 PBSC 
 
 
 
 
 PBSC 
 
 BM 
 
 
 
 
 BM 
 
 
 BM 
Weight   Higher BMI (>25) associated with more G-CSF 
side effects (fatigue, myalgia, sweats) (Chen et 
al., 2011) 
 Obese donors experienced more pain and 
toxicity (Pulsipher et al., 2013, Pulsipher et al., 
2009b) 
 PBSC 
 
 
 PBSC 
Donors with 
smaller total 
blood 
volumes  
 Higher incidence of adverse reactions (Yuan et 
al., 2010)  
 PBSC 
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Lower net 
fluid 
balance  
 Associated with pre-syncopal complications 
(Yuan et al., 2010) 
 PBSC 
Higher G-
CSF doses  
 Doses of 16 mcg/kg associated with higher 
toxicity compared to 10 mcg/kg (Kroger et al., 
2002) 
 Associated with more toxicity (Chen et al., 
2011, Engelhardt et al., 1999)  
 Doses > 9 mcg/kg associated with higher 
incidence of headache and fatigue (Murata et 
al., 1999, Martino et al., 2009)  
 PBSC 
Regional vs 
general 
anaesthesia  
 No difference found (Machaczka et al., 2010, 
Lavi et al., 1993, Knudsen et al., 1995, 
Burmeister et al., 1998)  
 Regional anaesthesia associated with serious 
complications (Miller et al., 2008)  
 BM 
Longer 
duration of 
harvest  
 Associated with physical limitations (Nishimori 
et al., 2002)  
 Associated with serious complications (Miller 
et al., 2008)  
 BM 
 
 BM 
Average 
blood 
volume 
depletion  
 Associated with higher number of days off 
work in female donors (Gandini et al., 2001) 
 BM 
Blood 
donors  
 More physical difficulty with donating (Switzer 
et al., 1996) 
 Correlated with higher number of days off work 
in male donors (Gandini et al., 2001)  
 BM 
 
 BM 
Active vs 
sitting job  
 Active job associated with more number of 
days off work (Gandini et al., 2001) 
 BM 
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Peripheral 
blood White 
Blood Cell 
Count 
(WBC) 
 Higher WBC count post the 3rd dose of G-CSF 
associated with fatigue (Chen et al., 2011)  
 High WBC (> 50 x 109/l) following 5 doses of 
G-CSF not associated with more side effects 
during mobilization than those with WBC < 50 
x 109/l (Chen et al., 2011) 
 Baseline mononuclear cell count > 2.7 x 10^9/l 
associated with increased fatigue and pain 
peri-collection (Pulsipher et al., 2013)  
 PBSC 
 
 
Related vs 
unrelated  
 More moderate to severe pain in related 
donors (Chang et al., 1998)  
 BM 
 
1.4 Psychological aspects of donation 
Most studies have concentrated on the physical outcomes following donation and 
only few have evaluated the psychological impact (Simmons et al., 1993, Butterworth 
et al., 1993, Munzenberger et al., 1999, Christopher, 2000, Switzer et al., 2001, 
Fortanier et al., 2002, Williams et al., 2003, Bredeson et al., 2004, Pillay et al., 2012). 
The psychological reactions following donation are generally positive (Butterworth et 
al., 1993, Switzer et al., 2001) and most subjects feel deep personal satisfaction and 
gratitude for an opportunity to donate (Christopher, 2000). Common experiences 
include feeling like a better person as a result of donation (Butterworth et al., 1993). 
A large NMDP study found that donors believed to be distinct from others in the 
centrality of the traits of helpfulness and generosity. This belief often stemmed from 
a strong emphasis on helping in their families (Simmons et al., 1993). The 
psychological outcomes appear to be associated with physical adverse reactions 
experienced during the donation process, the outcome in the recipient and the 
psychological state of ambivalence (table 1.4). The term ambivalence involves doubts 
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and worries, feeling unsure about donation and wishing someone else would donate 
in one’s place (Switzer et al., 2013).  
 
Butterworth and colleagues assessed the psychosocial effects of BM donation in 493 
URDs (Butterworth et al., 1993). The authors found that donors with longer collection 
times or lower back pain were more likely to have less positive psychosocial 
outcomes. A large Canadian randomized trial assessed mood states and health-
related quality of life (HRQOL) prior to donation and 1 week and 4 weeks following 
donation in BM and PBSC donors (Bredeson et al., 2004). Both the mood and 
HRQOL scores were worse after BM donation, compared to PBSC donation. The 
authors commented that physical morbidity can affect mood and this is in keeping 
with a generally reported delayed physical recovery in BM versus PBSC donors. 
 
One study looking into reactions of unrelated bone marrow donors when the recipient 
dies, found that death of the recipient produced feelings of grief and was often 
surprisingly intense, given the fact that the recipient was a stranger (Butterworth et 
al., 1992). Studies in related donors are complicated by the direct affiliation of donors 
with the patient. Poor outcomes can have devastating effects and “survivor’s guilt” is 
well documented in the literature. A study in BM donors found that donors whose 
sibling died had significantly higher scores on the Beck Depression Inventory (BDI) 
compared to those whose siblings remained alive (Chang et al., 2003). The BDI is a 
21-question multiple-choice self-reported inventory, one of the most widely used 
instruments for measuring the severity of depression 
 
The psychological state of the donor should be assessed prior to donation, in 
particular the donor’s motivations for considering donation. Switzer reported that a 
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psychological state of ambivalence was a better predictor of a negative donation 
experience than actual physical difficulty with donation (Switzer et al., 1996). 
Ambivalence was assessed using a 7-item ambivalence scale. Items asked about 
doubts and worries about donating (e.g. “I sometimes feel unsure about donating”) 
and commitment to donating (e.g. “I would really want to donate myself even if 
someone else could do it”). All items were dichotomised (0 [item not endorsed], 1 
[item endorsed]) and an index of ambivalence was performed by summing the 
number of items endorsed by the respondent (0 [no items endorsed, not at all 
ambivalent]), to 7 [all items endorsed, extremely ambivalent) (Switzer et al., 1996). 
People who were less happy in general, less optimistic about the patient’s chances 
to survival, more educated and less likely to have been blood donors were more likely 
to experience pre-donation ambivalence (Switzer et al., 1996, Switzer et al., 2003, 
Switzer et al., 1997, Switzer et al., 2005). Donors who were driven by an intrinsic 
commitment to donate, rather than extrinsic pressure, were less ambivalent about 
donating (Switzer et al., 2003). The same author reported ethnic variation in the 
donation experience and found that Asian Americans were more ambivalent and 
more anxious than other US ethnic groups (Switzer et al., 2005). 
 
Related donors may have different motivations from unrelated donors and may be 
subject to increased emotional and physical stress associated with donation 
(Christopher, 2000). A more positive experience has been reported if there is a better 
emotional support from family, friends and hospital staff (Pillay et al., 2012). Routine 
provision of psychosocial support to donors as well as recipients is therefore 
important. 
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Table 1. 4 Factors influencing psychological outcomes 
Factor Outcome 
More 
physical 
difficulty with 
donation 
 Associated with feeling less positive  
psychologically about the donation (Switzer et al., 1996)  
 BM donation was associated with more physical morbidity and 
negative effects on QOL up to 1 month after donation than was 
PBSC donation (BM vs PBSC) (Bredeson et al., 2004)  
 BM donors mood scores were worse 1 week after compared to 
before donation, whereas PBSC scores did not change (BM vs 
PBSC) (Bredeson et al., 2004)  
 More likely to experience donation as stressful (Butterworth et 
al., 1993, Christopher, 2000) 
Longer 
collection 
times/large 
volumes 
collected 
 Less positive psychological outcomes (Butterworth et al., 1993) 
 Less willing to donate again in future (Butterworth et al., 1993) 
 
Death of the 
recipient/ 
worse 
outcome in 
recipient 
Unrelated donors:  
 Grief was often surprisingly intense, given the fact that the 
recipient was a stranger, feelings of guilt were rare (Butterworth 
et al., 1992) 
 Donors demonstrated a range of feelings such as sadness, 
disappointment, grief, and helplessness. These feelings were 
often unexpectedly intense given the fact that the recipient was 
a stranger (Wanner et al., 2009) 
 
Related donors:  
 Associated with a more stressful experience (Christopher, 2000)  
 Recipient deterioration may significantly adversely impact donor 
psychosocial status (Wolcott et al., 1986)  
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 Significantly higher Beck depression scores 6 months following 
donation (Chang et al., 2003)  
 Donors felt less as if their donation had really helped their 
sibling as time passed. However, bereaved donors experienced 
global psychological gains including enhanced self-esteem, 
happiness and life-satisfaction compared to donors whose 
siblings were still living (Switzer et al., 1998)  
Ambivalence  Greater ambivalence associated with more physical and 
psychological difficulties with donation (Switzer et al., 1996)  
 Factors associated with higher ambivalence: higher education, 
donors who were discouraged by others (Switzer et al., 1996), 
exchange motives (weighing costs and benefits), idealized 
helping motives (Switzer et al., 1997), extrinsic pressure 
(Switzer et al., 2003), some ethnicities (Asian Americans) 
(Switzer et al., 2005)  
 Factors associated with lower ambivalence: more frequent 
blood donors, happier individuals, those who believed the 
patient’s chances of survival were better (Switzer et al., 1996), 
empathy motives (Switzer et al., 1997), intrinsic commitment 
(Switzer et al., 2003)  
Related vs 
unrelated 
 Depression scores significantly higher in related donors, pre and 
post donation (Chang et al., 1998)  
Family 
dynamics 
and 
emotional 
support 
 More positive experience if better emotional support from family, 
friends and hospital staff (Pillay et al., 2012, Christopher, 2000)   
 Married donors had fewer negative psychological reactions 
shortly following donation (Switzer et al., 1996) 
Preparation 
for donation 
 Adequacy of preparation for donation influences experience 
(Pillay et al., 2012) 
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1.5 Procedures to ensure donor safety 
Unrelated donor safety is guided through published World Marrow Donor Association 
(WMDA) standards covering donor recruitment, consent, medical assessment, donor 
follow-up and a global combined effort in adverse event reporting (Petersdorf, 2010, 
Shaw et al., 2010). No equivalent standards currently exist for related donor care. 
Although less prescriptive than the WMDA standards, guidelines developed by 
accreditation systems - the Foundation for Accreditation of Cell Therapy (FACT) in 
the USA and the Joint Accreditation Committee of ISCT (Europe) and the EBMT 
(JACIE), termed the FACT-JACIE Standards (FACT-JACIE, 2008) - also contain 
some requirements for the selection, evaluation and management of donors and the 
reporting of adverse events. Other legally-binding requirements are those of the 
National Competent Authorities in Europe who are required to implement the EU 
Directive on Tissues and Cells via specific regulations (Human Tissue Authority, 
2007) and those of the US Food and Drug Administration (FDA) (US Food and Drug 
FDA, 2013, US Food and Drug FDA, 2010).  
 
Several procedures aimed at optimising donor safety are summarised in table 1.5.  
There are three stages in the typical pathway of an unrelated HSC donor from joining 
a registry to donation, namely: recruitment, confirmatory typing (CT) stage and work-
up stage. The intensity of the assessment differs at each stage in the process, and 
there may be conditions that necessitate deferral at certain stages in the process but 
not in others (Lown et al., 2014). There are two main reasons for thorough medical 
assessments, namely recipient safety and donor safety. Donation of HSC is an act of 
altruism and donors must be protected from harm as much as possible. Medical 
criteria for conditions that may increase donor risk are necessarily stringent, and more 
so than would be the case if the individual were undergoing a procedure for 
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therapeutic benefit. Assessing the risk for both donors and recipients requires a 
targeted screening history, a search for physical signs of disease and laboratory 
testing for specific pathogens or traits.  
 
There are numerous infectious agents that, if present in the donor, pose a definite or 
theoretical risk to the transplant recipient. HSCT can transmit the same infectious 
agents transmissible by blood transfusion (including hepatitis B and C virus and 
human immunodeficiency virus). Additionally, some congenital or acquired 
conditions, such as genetic defects, immune deficiencies or cancers, are potentially 
transmissible to the recipient.  
 
Screening questionnaires at recruitment and CT stage typically pick up permanent 
conditions that warrant deferral for donor reasons (for example insulin dependent 
diabetes mellitus or cardiac disease). The medical consultation during donor work-up 
is more detailed and focuses on all matters relevant for the anticipated donation, 
including psychological issues. For all donors, this includes a review of known health 
problems, allergies, and family history. Marrow donors should be questioned about 
prior anaesthesia and have a careful review of systems directed toward neurological, 
respiratory, cardiovascular and musculoskeletal problems. Peripheral blood donors 
should be questioned about prior whole blood or apheresis donations as well as 
specific questions about a history of venous access problems, autoimmune diseases, 
splenic disorders and haemoglobinopathies. The donor’s physical examination 
should focus upon the neurological, respiratory and cardiovascular systems (Horowitz 
and Confer, 2005). In general, donors with moderate or severe organ impairment are 
deferred and this usually includes those with coronary artery disease, renal, 
pulmonary or hepatic impairment (Lown and Shaw, 2012). Many other medical 
Chapter 1 - Background 
58 
 
conditions may prevent donation for the sake of donor safety. For example, donors 
with pre-existing back pain tend to be excluded from BM donation as there is a 
potential causal link between bone marrow harvest and back injury.  
 
Table 1. 5 Current procedures to optimise donor safety 
Time point Procedure in place 
Recruitment and 
Confirmatory Typing 
(unrelated donors) 
Medical screening and exclusion of donors who have medical 
conditions that would increase their risk 
 Questionnaire based 
Medical consultation Formal medical assessment and exclusion of donors who have 
medical conditions that would increase their risk 
 History: addresses risks both to the donor and the 
recipient, including psychological issues 
 Clinical examination 
 ECG 
 Often urine dip, chest X-ray 
Informed consent 
Donation Up-to-date harvest centre facilities 
Experienced harvest physicians 
Post-donation Reporting of serious adverse events through the WMDA (only 
for unrelated donors) 
Donor follow-up 
 
Potential donors must receive a full description of the procedure and its risks at the 
time of their medical assessment. Donors should be educated about common as well 
as rare, but potentially life-threatening complications (for example splenic rupture in 
PBSC donors). Emergency contact details ought to be provided. It is recommended 
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that donors are counselled about the possibility of subsequent donations of stem cells 
or lymphocytes before their first donation (Confer et al., 2011).  
 
The Worldwide Network for Blood and Marrow Transplantation (WBMT) and WMDA 
recommend that unrelated donor registries should follow-up donors in the short term 
and for at least 10 years after donation (Halter et al., 2013). The reporting of serious 
events and adverse reactions (SEARs) is mandatory for all WMDA-accredited 
registries, representing the vast majority of unrelated adult donations worldwide. 
Anonymised summary reports of SEARs are published and distributed on an annual 
basis.  
 
1.6 Stem cell yields 
Several days of apheresis are frequently required for PBSC donors to ensure a 
sufficient collection of CD34+ cells and around 20% of donors need a second day of 
apheresis (Holig et al., 2009). A further reduction in platelet counts and increased 
psychological stress are potential risks associated with additional days of apheresis 
(Stroncek et al., 1999). In order to reduce the discomfort and possible additional risks 
to the donor, the WMDA recommends that registries have policies in place concerning 
the total number of days of apheresis allowed (WMDA, 2010) and a recent survey 
showed that most registries allow a total of 2 days of apheresis (WMDA, 2009). If 
insufficient HSCs are harvested during the days of apheresis, a group defined as 
“poor mobilisers”, bone marrow harvesting is performed as a salvage procedure. 
There are well described additional risks associated with this procedure. 
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It is therefore of clinical importance to characterize donors who are at risk of not 
meeting the HSC dose requested by the transplant centres, as this group may benefit 
from an alternative mobilisation regimen in order to avoid additional days of apheresis 
or bone marrow harvesting. In addition, this knowledge may allow registries to focus 
on the recruitment of donors who are more likely to mobilise sufficient CD34+ cells. 
The advantages of such a strategy are clear both for the donors and the recipients. 
Because patients have already received therapy by the time donor cells are collected 
in most centres, the lack of availability of adequate stem cells is a significant and 
potentially life threatening problem.  
 
Previous studies have reported that several donor characteristics influence PBSC 
mobilisation. Table 1.6 lists all the factors that have been previously found to affect 
the PBSC yield in allogeneic donors. Table 1.7 lists all the factors that have shown to 
affect the BM yield. 
 
Table 1. 6 Factors influencing CD34+ yield in PBSC donors 
Factor Associations References 
Female gender Lower CD34+ yield  (Ings et al., 2006, Miflin et al., 
1996, Martino et al., 2006, 
Wang et al., 2008, Platzbecker 
et al., 2005, Engelhardt et al., 
1999, Fischer et al., 2005) 
 No influence on CD34+ yield (Suzuya et al., 2005, Sohn et 
al., 2003, Anderlini et al., 1997, 
Lysak et al., 2005) 
 Lower pre-apheresis CD34+ 
count peripheral blood 
(Vasu et al., 2008) 
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BMI Higher BMI associated with 
higher CD34+ yield 
(Favre et al., 2003, Wang et 
al., 2008, Chen et al., 2014) 
 No influence on CD34+ yield (Platzbecker et al., 2005) 
Weight Higher weight associated with 
higher CD34+ yield 
(Ings et al., 2006, Favre et al., 
2003) 
 No influence on CD34+ yield (Sohn et al., 2003, Shimizu et 
al., 2002) 
 Higher weight associated with 
higher pre-apheresis CD34+ 
count peripheral blood 
(Vasu et al., 2008) 
Age Higher age associated with 
lower CD 34+ yield 
(Anderlini et al., 1997, Shimizu 
et al., 2002, Martino et al., 
2006, Wang et al., 2008, de la 
Rubia et al., 2008, Lysak et al., 
2005, Diaz et al., 2003, 
Suzuya et al., 2005, de la 
Rubia et al., 2002, de La Rubia 
et al., 2001, Engelhardt et al., 
1999, Anderlini et al., 1999) 
 No influence on CD34+ yield (Miflin et al., 1996, Arbona et 
al., 1998, Sohn et al., 2003, 
Platzbecker et al., 2005) 
 Higher age associated with 
lower pre-apheresis CD34+ 
count peripheral blood 
(Suzuya et al., 2005, Ings et 
al., 2006, Vasu et al., 2008) 
Ethnicity Pre-harvest CD34+ count 
peripheral blood count highest 
in Asian/Pacific donors, 
followed by blacks, Hispanics 
and then whites 
(Vasu et al., 2008) 
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Once vs twice 
daily filgrastim 
Twice daily dosing associated 
with higher CD34+ yield  
(de la Rubia et al., 2002, 
Kroger et al., 2000, Arbona et 
al., 1998) 
 No influence on CD34+ yield (Anderlini et al., 2000) 
Type of G-CSF Higher CD34+ yield with 
lenograstim compared to 
filgrastim, but only in males 
(Fischer et al., 2005) 
 No influence on CD34+ yield (Suzuya et al., 2005, Ings et 
al., 2006, Martino et al., 2006) 
Total amount of 
G-CSF given 
Higher total amount associated 
with higher CD34+ yield 
(Anderlini et al., 1997, 
Engelhardt et al., 1999, 
Martinez et al., 1999) 
 Higher total amount associated 
with higher pre-harvest CD34+ 
counts peripheral blood 
(Tanaka et al., 1996, Grigg et 
al., 1995, Vasu et al., 2008) 
CD34+ count in 
preapheresis 
blood 
Higher count associated with 
higher CD34+ yield 
(Suzuya et al., 2005, Okano et 
al., 2008, Sohn et al., 2003, 
Platzbecker et al., 2005, 
Moncada et al., 2003, Arbona 
et al., 1998) 
CD34+ yield 
mid-point 
harvest 
Higher mid-point yield 
associated with higher final 
CD34+ yield 
(Ings et al., 2006) 
Serum level of 
G-CSF 
No influence (Suzuya et al., 2005) 
Preapheresis 
platelet count  
Higher platelet count 
associated with higher CD34+ 
yield 
(Suzuya et al., 2005, Lysak et 
al., 2005) 
Baseline platelet 
count 
Higher platelet count 
associated with higher pre-
(Vasu et al., 2008) 
Chapter 1 - Background 
63 
 
apheresis CD34+ count 
peripheral blood and CD34+ 
yield 
Preapheresis 
WBC count 
Higher WBC count associated 
with higher CD34+ yield 
(Sohn et al., 2003, Wang et al., 
2008, Martino et al., 2006) 
 No influence on CD34+ yield (Anderlini et al., 1997, Shimizu 
et al., 2002) 
Baseline WBC 
count 
No influence on CD34+ yield (Anderlini et al., 1997) 
Preapheresis 
MNC count 
Higher MNC count associated 
with higher CD34+ yield 
(Moncada et al., 2003) 
 No influence on CD34+ yield (Anderlini et al., 1997) 
Baseline MNC 
count 
Higher MNC count associated 
with higher CD34+ yield 
(Lysak et al., 2005) 
 No influence on CD34+ yield (Anderlini et al., 1997) 
 Higher MNC count associated 
with higher pre-apheresis 
CD34+ count peripheral blood 
(Vasu et al., 2008) 
Pre-apheresis 
circulating 
immature cell 
count 
Higher count associated with 
higher CD34+ yield 
(Wang et al., 2008, Kozuka et 
al., 2004, Yang et al., 2010) 
Type of cell 
separator 
No influence on CD34+ yield (Suzuya et al., 2005) 
Type of access Arterial access (as opposed to 
venous access) associated 
with higher CD34+ yield 
(Wang et al., 2008) 
 No influence on CD34+ yield (Suzuya et al., 2005, Holig et 
al., 2012) 
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Large volume 
leukapheresis 
Associated with higher CD34+ 
yield 
(Diaz et al., 2003) 
 
Table 1. 7 Factors influencing harvest yields in BM donors 
Factor Associations References 
BMI Higher BMI associated with higher CD34+ 
yield 
(Favre et al., 2003) 
Weight Higher weight associated with higher CD34+ 
yield 
(Favre et al., 2003) 
 Higher weight associated with higher TNC/ml (Kao et al., 2009, 
Wang et al., 2011) 
Gender No influence on CD34+ yield (Favre et al., 2003) 
 No influence on TNC/kg (Gandini et al., 2001) 
Age No influence on CD34+ yield (Favre et al., 2003) 
Baseline 
WBC count 
Higher WBC count associated with higher 
TNC/ml 
(Kao et al., 2009, 
Wang et al., 2011) 
Volume 
harvested 
Negatively associated with TNC/ml (Kao et al., 2009, 
Wang et al., 2011) 
Collection 
procedure 
Small volume aspirations and multiple 
puncture sites associated with higher TNC/kg 
and minimal contamination by peripheral blood 
(Spitzer et al., 1994, 
Bacigalupo et al., 
1992, Batinic et al., 
1990) 
Aspiration 
needle with 
multiple holes 
No influence on CD34+ yield, but 50% 
reduction in operating time 
(Lannert et al., 2008) 
 Associated with higher TNC/ml (Wang et al., 2011) 
Checking 
midway TNC 
count 
Associated with higher TNC/ml (Wang et al., 2011) 
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Raising room 
temperature 
during 
procedure 
No influence on cell yield, but associated with 
reduction in BM harvest time 
(Zeller et al., 1995) 
G-CSF 
stimulated 
Associated with increased TNC/kg donor 
weight 
(Ji et al., 2002) 
 Not associated with increased TNC or CD34+ 
count, but associated with more rapid 
engraftment 
(Isola et al., 1997) 
 
1.7 Conclusion and aims of this thesis 
Voluntary donation of BM or PBSC for haematopoietic cell transplantation is a well-
established altruistic act, performed by thousands of healthy related or unrelated 
donors throughout the world. Although allogeneic stem cell donation is a safe 
procedure with very low rates of serious adverse reactions, there are some potential 
risks and every effort should be made to minimalize this. This introduction provides 
an overview of adverse and serious adverse reactions following PBSC and BM 
donation. In addition to the known procedural risks and associated symptoms, other 
important issues that have not received as much attention are the factors that may be 
implicated in delayed donor recovery and the psychosocial and longer-term post-
donation physical and psychological effects of donation. Several mechanisms to 
ensure donor safety are already in place, but no customised donor care currently 
exists. Data on donors that are at increased risk of adverse reactions may allow 
registries to tailor donor care; this may include the alteration of joining and recruitment 
policies, management of expectations and the improvement of supportive measures 
and donor follow-up procedures.  
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While stem cell registers are the most valuable source of unrelated donor outcome 
data, only a fraction of these data are currently published. Most registers collect some 
level of donor outcome data but a small number have large scale follow-up programs. 
Further effort should be directed to standardise operational definitions on post 
donation physical and psychological outcomes and adverse reactions and to develop 
a prospective global data collection (Pamphilon et al., 2009). Recently, the EBMT 
developed a reporting system for both related and unrelated donor outcomes, but this 
is not a mandatory requirement yet and only covers EBMT centres (EBMT, 2013). 
Additionally, a sustained effort to develop clinical trials is required.  
 
The primary aim of my thesis is to provide an in depth analysis of the short and long-
term physical and psychological donation experience as well as an analysis of factors 
influencing donor recovery. In Chapter 3, I will describe an audit of the unrelated 
donor outcome data collection for our register and the changes which I implemented 
based on this to investigate novel methods of donor follow-up. In chapters 4 and 5, I 
will prospectively assess the physical and psychological donation experience in our 
donors and define groups at increased risk of a poorer donation experience. I will 
evaluate both the impact of demographic factors (chapter 4) and baseline health 
related quality of life scores (chapter 5).  Chapter 7 will describe a qualitative study 
that further explores the influence of general health on side effects and recovery in 
PBSC donors. It will also assess how well informed and prepared donors felt prior to 
donation as well as the role of ambivalence in our donor population. Chapter 6 will 
investigate which donors are more likely to reach the stem cell doses requested by 
the transplant centres. 
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Overall, the main aim of this thesis is to illuminate the donor and collection 
characteristics associated with poorer donation experiences. The results will help 
towards more targeted strategies concerning donor recruitment, selection, work-up 
and donor follow-up and we believe such strategies will improve the donation 
experience.  
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Chapter 2 - Materials and methods  
 
2.1 Introduction 
This chapter details the methodology used in the four studies detailed later in this 
thesis, namely the audit examining the donor follow-up system at Anthony Nolan 
(AN), a retrospective study of factors influencing donor yields in PBSC donors, the 
prospective study assessing the predictors of the haematopoietic stem cell donation 
experience and assessing the factors influencing yields in BM and PBSC donors and 
the qualitative study described in chapter 7. 
 
2.2 An audit examining the donor follow-up system at AN 
Thirty donor files were reviewed in alphabetical order for the year 2011, these 
included 15 PBSC and 15 BM donor files. The presence of pre-defined donor follow-
up forms (table 3.1) in the donor files was evaluated, as well as the completeness of 
the forms and the amount of medical information derived from the forms. The donor 
follow-up forms are outlined in our internal AN standard operating procedures and 
based on WMDA recommendations (WMDA, 2014). Medical information was defined 
as any documentation of donor physical or psychological symptoms, serious adverse 
reactions or details on donor recovery. Medical information was defined “adequate” if 
enough information was provided in order to comply with WMDA standards (WMDA, 
2014).The haematopoietic stem cell (HSC) collection procedures are outlined in 
section 2.4.1.2. 
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In accordance with The Anthony Nolan policy, the G-CSF injections for PBSC donors 
were given by a fully qualified nurse from our home care provider, an independent 
company that provides healthcare services to individuals within their own homes or 
work place in the UK. Under normal circumstances, the nurse remains with the donor 
for 1 hour after each injection to ensure that no adverse events have occurred. This 
is done for a total of 3 days. The fourth injection is given at the blood stem cell 
collection centre. The home care provider nurse is fully trained to manage adverse 
reactions, should they occur, and carries the appropriate emergency kit to deal with 
any allergic response to the drug. 
 
2.3 A retrospective study of factors influencing donor yields in PBSC donors 
2.3.1 Donor characteristics 
All sequential PBSC collections facilitated by Anthony Nolan (n = 323) from January 
through December 2011 were analysed retrospectively. Donors for paediatric 
recipients were excluded (n = 15) with 308 donors remaining for analysis. All subjects 
were healthy unrelated donors at least 18 years of age with a BMI < 35. All donors 
passed a rigorous medical history, clinical examination, blood tests including 
haematology, biochemistry and virology (Lown, 2013), ECG and chest X-ray and 
gave written, informed consent.  
 
2.3.2 Mobilisation and apheresis 
All donors were mobilised with lenograstim (glycosylated G-CSF; Chugai Pharma, 
London UK). Lenograstim was given at a dose of 10 μg/kg/day subcutaneously ± 10% 
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for 4 consecutive days and apheresis was commenced on day 5. If the CD34+ target 
yield was not achieved, a further dose of G-CSF was given. A maximum of two 
aphereses were performed. Donors remained outpatients during the days of 
collection, even if a second day collection was required. Apheresis was carried out in 
1 of 4 collection centres using the Spectra COBE v. 4.0 MNC Manual technique, 6.1 
auto PBSC or Spectra Optia v 5.0 or 7.0 separator (Terumo BCT, USA).  The end 
point for the procedure on the COBE separators was 2-2.5 times the total blood 
volume (n = 147). The end point on the Spectra Optia separators was 240 minutes (n 
= 161). Acid citrate dextrose solution was used as the anticoagulant. Requests of up 
to 4 x 106 CD34+ per kg were considered routine. Requests exceeding 5 x 106 CD34+ 
per kg required detailed information and were reviewed by our medical director prior 
to acceptance 
 
The CD34+ cell concentration in the leukapheresis product was measured according 
to international standards (Barnett et al., 1999). Harvest CD34+ cells were 
determined by flow cytometry using phycoerythrin (PE)-conjugated CD34 monoclonal 
antibody staining (Beckton Dickinson, San Jose, CA, USA). In order to exclude 
incomplete red cell lysis, a CD45 fluorescein isothiocyanate (FITC) antibody (Beckton 
Dickenson) was added. 7-amino actinomycin D (7-AAD) (Beckton Dickenson) was 
added to determine cell viability. This was followed by red cell lysis (Coulter Q-prep) 
and flow cytometry (Coulter FC-500, Beckman Coulter, High Wycombe, Beds, UK). 
The CD34+ cell profile was taken from the total leukocyte population determined by 
forward/side scatter, followed by CD45 discrimination to exclude platelet aggregation 
and incomplete red cell lysis. The viability of total cells and CD34- cells were 
determined from the 7-AAD region. 
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2.3.3 Statistical analysis 
The primary outcome of the study was whether the target yield was reached, this was 
analysed both as a binary (yes/no) and a continuous outcome (the difference between 
the obtained yield and the requested yield). For the binary outcome, we allowed the 
obtained CD34+ dose to be up to 10% less than the requested dose. This is our cut-
off used in deciding the need for a second day collection. Our secondary outcome 
was poor mobilisation. This was defined as a mobilisation of less than 2 x 106 CD34 
cells per recipient weight after 1 day of apheresis. Associations between continuous 
donor variables and the continuous outcome were determined using linear regression 
analysis. Differences in characteristics between 2 groups were determined using the 
t-test or Mann-Whitney-U test as appropriate. Chi square tests were used to 
determine differences between categorical variables. All the variables that were 
significant in univariate analyses were included in a multivariate stepwise logistic 
regression analysis. Statistical analysis was performed using SPSS software. A two-
tailed p value < 0.05 was considered significant.  
 
2.4 A prospective study in unrelated haematopoietic stem cell donors 
assessing the predictors of the haematopoietic stem cell donation experience  
2.4.1 Patients and methods 
2.4.1.1 Study population 
The study population comprised of unrelated donors from the UK whose bone marrow 
or G-CSF mobilised PBSC donation was facilitated by Anthony Nolan between 
February and November 2013. All donors passed a rigorous physical eligibility 
screening according to World Marrow Donor Association (WMDA) recommendations 
(Lown, 2013) and were at least 16 years of age with a BMI of < 35 for BM donors and 
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< 40 for PBSC donors. Donors gave informed written consent for the donation process 
as per normal practice, as well as additional verbal informed consent for the health 
related quality of life (HRQOL) assessment questionnaires. Written study information 
was provided (Figure S1 appendix 1). Ethical approval was obtained from the 
registry’s ethics review board. 
 
2.4.1.2 Stem cell collection methods 
All PBSC donors were mobilised as described in section 2.3.2. Apheresis was carried 
out in 1 of 4 collection centres using the Spectra Optia v 5.0 or 7.0 separator (Terumo 
BCT, USA). The end point on the Spectra Optia separators was 2-2.5 times the total 
blood volume or 240 minutes. CD34+ enumeration is described in section 2.3.2.  
 
Donors who donated BM underwent harvest from both iliac crests under general 
anesthesia. In line with WMDA guidelines no more than 20 mls per kg donor weight 
was extracted. BM donation took place in 1 of 4 collection centres. The number of 
puncture holes was not recorded. Our policy is to admit BM donors the evening before 
the harvest and to discharge them the day after the procedure. Acid citrate dextrose 
solution was used as the anticoagulant. The total volume of the harvested BM was 
obtained by subtracting the volume of anticoagulant from the volume of the mix. The 
total nucleated cell (TNC) counts of the harvested BM were determined using an 
automatic haematology analyzer. The TNC density or the quality of the harvested BM 
was determined by dividing the number of TNCs by the volume of the harvested BM. 
 
2.4.2 Data collection 
2.4.2.1 Demographic and donor follow-up data 
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Donors were recruited at the time of the donor’s medical evaluation, which took place 
on average 17 days (range 8-30) prior to donation. Data collection continued  on day 
-4, day -3 and day -2 prior to donation for PBSC donors (figure S2 appendix 1) and 
on the day of collection for both types of participants (day 0) (figures S4, S5 appendix 
1). Our donor provision team subsequently contacted BM and PBSC donors via 
telephone 2 or 3 days after donation (figure S6 appendix 1). Donors were contacted 
again using an online questionnaire 1 week following donation and weekly thereafter 
up until complete recovery (http://www.surveymonkey.com/s/PCT3GWY, last 
accessed March 2015). The forms that were used are fully described in chapter 3. 
 
Complete recovery was determined on the day 2-3 or weekly questionnaire and 
defined as the absence of ongoing symptoms as well as return to pre-donation health. 
The assessment at each time point involved a self-reported checklist of specific 
adverse reactions, including allergy, anorexia, back pain, bleeding, bruising, 
dizziness, fatigue, fever, headache, infection, injection site reaction, insomnia, 
myalgia, nausea, any other pain and vomiting. Each adverse reaction was scored 
using the CTCAE (Common Terminology Criteria for Adverse Events) toxicity index. 
Demographic factors analysed as potential influencing factors of time to recovery or 
adverse reactions were gender, age, BMI (body mass index), support network 
(number of dependents, marital status) and being a blood donor.  
 
2.4.2.2 Health related quality of life (HRQOL) 
HRQOL was measured using the SF-36v2 questionnaire (Figure S7 appendix 1), 
given to donors (either by post or email) before donation, 4 weeks and 3 months 
following donation. The SF-36 is a generic indicator of HRQOL derived from the 245-
item Medical Outcomes questionnaire. The SF-36 questionnaire is the most widely 
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used health status assessment tool in clinical trials, with more than 1300 published 
articles documenting randomised controlled trials utilising the SF-36 score (Ware, 
2008). It has been validated both in patients with acute and chronic diseases as well 
as in healthy volunteers (Ware, 2008). Several studies examining the HSC donation 
experience (Bredeson et al., 2004, Nishimori et al., 2002) have also used the SF-36 
questionnaire. A recent study by Switzer et al used the SF-8 questionnaire (Switzer 
et al., 2014). The SF-8 was developed to replicate the SF-36 with one question for 
each health domain. The SF-8 could potentially increase return rates, as it is quicker 
to complete compared to the SF-36. However, it covers a narrower range of health 
than the SF-36 with a potential of loss of information. Other HRQOL questionnaires 
(e.g. QLQ-C30, QWB and CDC HRQOL-14) were reviewed, but they were deemed 
to be less suited given their rather limited assessment of mental health status.  
 
The SF-36 includes multi-item scales to measure the following 8 dimensions: physical 
functioning (PF), role limitations due to physical health problems (RP), bodily pain 
(BP), general health perception (GH), vitality (VT), social functioning (SF), role 
limitations due to emotional problems (RE) and general mental health (MH). The 
Physical Component Summary (PCS) and Mental Component Summary (MCS) 
scores provide a broad physical and mental health perspective (Ware, 2008). Norm 
based scoring was used to interpret the different dimensions’ and summary scores 
(Ware, 2008). This scoring is created by computing the 0-100 score for a scale and 
then adjusting this score by the general population’s average and standard deviation 
on that scale.  As a consequence, the population mean and standard deviation of all 
scores are 50 and 10 respectively with higher scores reflecting more positive health 
states.  
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2.4.3 Statistical analysis 
2.4.3.1 Factors influencing time to recovery and individual adverse reactions 
The primary endpoints were time to recovery and individual adverse reactions at 
different time points as defined earlier. Characteristics analysed as potential 
influencing factors were the previously defined demographic factors and the PCS and 
MCS measures.  
 
The probabilities of complete recovery were calculated using the Kaplan-Meier 
estimator and groups were compared using the log rank test. PCS and MCS 
measures were split into 4 groups, based on the 25th, 50th and 75th percentiles. 
Factors significant in univariate analysis at the ≤ .0.05 level were entered into a 
stepwise proportional hazards regression analysis.  
 
The influence of the previously defined demographic and HRQOL factors on 
individual adverse reactions was examined using either a chi square for categorical 
variables (for example gender, number of dependents) or t-test or mann-Whitney-U 
test as appropriate for continuous variables (for example age, weight). Binary 
summary scores were established for pain (headache, myalgia, back pain and any 
other pain) and any adverse reaction for each time point. In addition, summary scores 
for each adverse reaction involving all the time points from D0 onwards were 
established. Factors with a p-value ≤ .0.20 in the univariate analysis were included in 
a stepwise logistic regression analysis.   
 
Comparison between BM and PBSC donors was performed using the chi square test 
for categorical variables and the t-test or Mann-Whitney-U test for continuous 
variables. 
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2.4.3.2 Changes in SF-36 scores over time 
Our secondary end points included the assessment of changes in SF-36 scores 
before, 4 weeks after and 3 months after donation. Paired sample t-tests were used 
to compare the SF-36 scores before and after donation. Stepwise linear regression 
analysis was performed to identify significant variables that could be used to predict 
HRQOL (using PCS and MCS scores) at 4 weeks following donation.  
 
2.4.3.3 Factors influencing PBSC and BM yields 
Another secondary outcome of the study was whether the target yield was reached, 
this was analysed as per section 2.2.3. Linear regression analysis was used to 
evaluate the relationship between continuous variables and the quality of the BM 
harvest (TNC/ml). One-way ANOVA or Kruskall-Wallis ANOVA were used to 
determine differences of BM harvest quality and volumes collected between the 
different collection centres. 
 
All statistical analysis was performed using SPSS software. A two-tailed p value < 
0.05 was considered significant. 
 
2.5 A qualitative analysis of the donation experience  
2.5.1 Participants 
Fourteen PBSC donors who had previously participated in the prospective study 
(described in 2.3 and chapters 4 and 5) were selected. The donors were purposively 
selected based on their pre-donation SF-36 Physical Component Summary (PCS) 
scores; seven out of 53 donors with scores in the lowest quartile (≤ 56) as well as 
seven out of 53 donors with scores in the highest quartile (> 60) were selected and 
approached. There was no purposive sampling with regards to age or gender. 
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Recruitment was completed when saturation on key themes was reached. Saturation 
was defined as the point in data collection when new data produced little or no change 
to the thematic framework process and analysis (Bryman, 2001). All 14 individuals 
approached gave verbal informed consent for the telephone interview and ethical 
approval was obtained from the registry’s ethics review board.  
 
2.5.2 Methods 
All participants were interviewed over the telephone by myself and audiotaped for 
between 25 and 70 minutes. Interviews took place between 1 and 1.5 years following 
donation. The interview schedule is described in document S3. The interview 
schedule consisted of three question areas designed to engage the participants and 
allow a variety of viewpoints to be expressed. The question areas were health-related 
quality of life during the donation process, donor preparedness and ambivalence. 
Open semi-structured format questions were used flexibly, being omitted, adapted or 
elaborated according to the demands of individual interviews. Whilst trying to avoid 
directive or closed questions or interpretations, an approach of responding to the 
participants’ answers was adopted. In this way, questions were used to promote a 
two-way dialogue.  
 
All audiotaped interviews were fully transcribed and analysed. The thematic analysis 
for the second part of the qualitative study was performed in line with Braun and 
Clarke’s outline of the process involving 6 phases (familiarisation with data, 
generating of initial codes, searching for themes, reviewing themes, defining and 
naming themes and production of a report) (Braun and Clarke, 2006). Detailed 
reading and re-reading of transcripts led to the generation of initial codes. Codes were 
generated in a systematic fashion across the entire data set. Subsequently, codes 
were combined under overarching themes (tables S5 and S6 appendix 1). Themes 
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were chosen so that they were internally coherent and consistent and without 
overlapping too much. Both supervisors (Andre Strydom and Katrina Scior) read 3 
transcripts prior to discussing and agreeing the resulting themes to ensure themes 
captured the full range of data.  
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Chapter 3 – A review of the donor follow-up system and a 
retrospective and prospective analysis of factors influencing 
PBSC yields 
 
3.1 Introduction 
This chapter details three studies, namely an audit reviewing our registry’s (Anthony 
Nolan) donor follow-up system and a retrospective and prospective analysis 
examining the factors that influence donor yields in PBSC donors.  
 
3.2 An audit examining the donor follow-up system at Anthony Nolan (AN) 
3.2.1 Introduction 
In chapter 1, I reviewed the donor’s experience, both physically and psychologically 
and the factors that are believed to influence this. As part of the preparation of my 
prospective study (chapter 4 and 5); a study that aims to further describe and predict 
the donation experience, I evaluated our registry’s existing donor follow-up program.  
 
3.2.2 Methods 
The methods of this study are outlined in section 2.2. 
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3.2.3 Results  
Table 3.1 outlines the follow-up forms that were used in our registry at the time of the 
audit, their presence in the donor file and the degree of medical information derived 
from the form. 
 
Table 3. 1 Donor follow-up contacts at different time points 
Time point Form Presence Content 
Days -4 until day -
2 prior to donation 
Home care provider form on days of 
G-CSF administration (PBSC only) 
53% Limited 
medical 
information 
Day 0 (day of 
donation) 
Visit form filled out by volunteer or 
Anthony Nolan visitor 
100% No medical 
information  
Day 2-3 post 
donation 
Telephone call (PBSC only) 87% Limited 
medical 
information 
Day 8 post 
donation 
telephone call (BM only) 87% Limited 
medical 
information 
Day 28 post 
donation 
Day 28 questionnaire 60% No medical 
information  
Day 28 post 
donation 
Full blood count and GP surgery 
nurse review (BM only) 
93% Adequate 
medical 
information 
Annually post 
donation (every 
year until year 6, 
then at year 8 and 
year 10) 
Annual follow-up form  33% Adequate 
medical 
information 
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3.2.3.1 Home care provider form 
Results 
This form is filled out by nurses who administer the G-CSF injections. We collect this 
form on the days that the injection is given via our home care provider (from day -4 
until day -2). Only 53% (24/45) of these forms were present in the donor file. It was 
not possible to determine whether the responsibility of this poor result lay with the 
home care provider not sending the form, the postal services or with Anthony Nolan. 
The donor and drug details (dose, route, batch number) were documented correctly 
in 100% of returned forms. A pregnancy test was performed in 100% (1/1) of female 
donors on the first day of injection. The duration of the visit was documented in 100% 
of cases, however 3/24 (13%) of visits were less than an hour and 2 of these 3 (75%) 
were first time visits. This incorporates a potentially high risk as there is a risk of 
anaphylaxis, especially on the first day of G-CSF. Adverse reactions were only 
documented in a limited number of cases (14/24) (the form did not require this 
information). Only 3/14 adverse reactions had a grading documented. This grading 
was using subjective terms such as “mild” or “moderate”, rather than following the 
international CTCAE grading (NIH, 2010) The documentation of observations (pulse, 
temperature, blood pressure and respiratory rate) was also suboptimal, with 4/24 
(17%) lacking any documentation of observations. An additional 4/24 forms had 
missing post-GCSF observations on the first day, when the risk of anaphylaxis is the 
highest. 
 
Recommendations 
I presented the results of this audit internally at our Medical Affairs meeting. Following 
this meeting, I drafted a letter to our home care provider outlining the results. This 
was followed by several meetings with myself, representatives of the Quality and 
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donor provision department and our home care providers. Rather than using hand 
filled forms that require posting, we suggested the introduction of electronic forms. 
This electronic system was effectively introduced in May 2013. Nurses now use a 
laptop to fill out the form and this is transferred directly via a portal which can be 
accessed by the Anthony Nolan medical team in real time. The content of the new 
form was specified based on the findings of this audit (figure S2 appendix 1). It now 
includes a checklist of common adverse reactions (allergy, anorexia, dizziness, 
fatigue, fever, headache, infection, injection site reaction, insomnia, myalgia, nausea, 
other pain, rash, vomiting and any other adverse reactions). Nurses are required to 
go through each adverse reaction and add a CTCAE grading if the adverse reaction 
is present. Forms with CTCAE grading scales are provided to assist nurses with this 
task (figure S3 appendix 1).  The added advantage of an electronic form is the ability 
to make certain fields mandatory. This introduction of mandatory fields was 
implemented in July 2014 and this led to a further improvement of the quality of the 
forms. Our Service-Level Agreement (SLA) was changed in May 2013 and now 
specifies that every first visit should last an hour and that pre and post G-CSF 
observations should be taken during this visit. Subsequent visits should last at least 
half an hour. The SLA also states that unexplained events or severe predicted 
adverse events aught be reported to the Medical Officer and the Quality team. We 
now organise teaching sessions for the nurses twice a year. 
 
3.2.3.2 Visit form 
Whilst donors are at the Collection Centre, a volunteer visitor or member from the 
donor follow-up team visits the donor. 
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Recommendations 
Given that, in general, 100% of the donor visits take place I realized it was a wasted 
opportunity not to collect any formal medical information from this visit, especially 
since the peak of adverse reactions for PBSC donors is around the day of donation 
(Pulsipher et al., 2009b). Following the presentation of this audit, it was agreed to 
introduce a medical questionnaire for PBSC (figure S4 appendix 1) and BM donors 
(figure S5 appendix 1). This questionnaire contains a checklist of adverse reactions 
and a CTCAE grading, which is identical to the Home care provider form. Several 
teaching sessions for our donor follow-up team and our donor visitors have taken 
place, in order to educate them in how to fill out this form.  
 
3.2.3.3 Telephone call day 2-3 and day 8 following donation 
Results 
An Anthony Nolan donor coordinator is responsible for a telephone call on day 2 or 3 
(PBSC donors) or day 8 (BM donors) following donation. This telephone call is 
intended to pick up any adverse reactions and encourages the donor to address any 
concerns or questions present at that stage. This form was present in the majority of 
donor files. However, the format was more a follow-up “chat” rather than a formal 
checklist of medical symptoms. 
 
Recommendations 
Similar to the previous time point, it seemed a wasted opportunity not to collect any 
medical information from this phone call. I introduced a standardised form (figure S6 
appendix 1 for PBSC donors), containing the same checklist with adverse reactions 
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as specified previously. In order to create consistency, it was decided that the 
telephone call would take place on day 2 or 3 both for PBSC and BM donors.  
 
3.2.3.4 Weekly follow-up 
Recommendations 
The major limitation of the follow-up system was felt to be the “gap” in the collection 
of medical information between the day 2-3 phone call and the annual follow-up form, 
which makes it impossible to define the time to complete recovery for the majority of 
donors. The lack of any documentation of psychological wellbeing was another 
limitation. This led to the introduction of the day 7 electronic medical questionnaire 
(http://www.surveymonkey.com/s/PCT3GWY, last accessed March 2015), using 
Surveymonkey. If a donor has no access to the internet, this is replaced by a 
telephone call.  This questionnaire is sent out weekly until the donor has fully 
recovered. All the forms from donors that have not fully recovered are reviewed by a 
Medical Officer and donors are contacted as required. As with previous forms it 
contains a checklist with adverse reactions and a grading. 
 
3.2.3.5 Day 28 post donation 
Results 
Four weeks following donation, a donor feedback form is sent to the donor. This 
document contains questions regarding donor experience, wish to stay on the register 
and helping Anthony Nolan further in other ways. It does not contain any medical 
information. The return of this form was only 60%. 
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In addition, bone marrow donors attend a check-up and have a full blood count one 
month after donation. This check-up is usually carried out by the donor’s GP and the 
results of this appointment are returned by the GP surgery. My audit found a good 
return rate.   
 
Recommendations 
It was not deemed necessary to change the content of this part of the follow-up 
system. The day 28 feed-back questionnaire was changed to an electronic form and 
is now sent out automatically. This has increased the return rate considerably. 
 
3.2.3.6 Annual follow-up 
Results 
The aim of the annual follow-up form is two-fold. Firstly, to ensure donor safety and 
to allow the reporting of SARs to the WMDA (including the development of auto-
immune conditions and malignancies following donation). Secondly, to pick up donors 
who have developed a medical condition that would make them not eligible to remain 
on the register. The return of this form was only 30%. The degree of medical 
information on the form was felt to be adequate, as it served the goals mentioned 
above.  
 
Recommendations 
It was not deemed necessary to change the content of this part of the follow-up 
system. The form was changed to an electronic form in order to increase the returns.  
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3.2.4 Conclusion 
This small audit showed that the donor follow-up system within our register was 
generally not compliant with WMDA standards. The main concern was the lack of 
standardised medical questions and the possibility of missing serious adverse 
reactions. The other major limitation was the “gap” of any medical information derived 
between the day 2-3 phone call and the annual follow-up form, making it impossible 
to determine the time to recovery for a significant number of donors. Time to recovery 
is a strong and necessary end point for research purposes, for example when 
examining the impact of certain donor characteristics on the donation experience. 
With donor eligibility criteria constantly changing – for example the allowance of BMIs 
up to 40 for PBSC donors or the allowance of 16 and 17-year olds- it would seem 
incorrect not to record this information, as it will not be possible to establish whether 
these new groups are at increased risk of a delayed recovery or adverse reactions. 
Another limitation is the lack of any psychological donor follow-up. The new system 
now involves standardised medical questions on the days of G-CSF administration, 
the day of donation, 2-3 days following donation and weekly until complete recovery. 
It also assesses the donor’s psychological state following donation. Our current donor 
follow-up system is based on NMDP practice, the first donor register to introduce a 
comprehensive follow-up (CIBMTR, 2014) 
(http://www.cibmtr.org/DataManagement/TrainingReference/eLearning/Documents/
777_sample.pdf). There has not been a formal follow-up audit yet after the instigation 
of these changes. As part of a global data collection effort, we are currently examining 
the possibility of linking our donor follow-up system with the EBMT database Promise 
(EBMT, 2013) 
(http://www.ebmt.org/Contents/DataManagement/Registrystructure/MED-
ABdatacollectionforms/Documents/Donor%20Outcome%20Manual.pdf). This 
database has been recently set up to store and analyse short and long term donor 
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follow-up reports from related and unrelated donors and is available for EBMT 
registered centres.  
3.3 A retrospective and prospective study of factors influencing donor yields in 
PBSC donors 
 
A paper based on the findings of this study was published in the journal 
Transfusion in  May 2014, entitled: Female donors and donors who are 
lighter than their recipient are less likely to meet the CD34+ cell dose 
requested for peripheral blood stem cell transplantation. (See appendix 3) 
 
3.3.1 Introduction 
Registry staff involved in the medical assessment and consent of donors are obliged 
to ensure that the risk to the donor (and recipient) is minimized by allowing only the 
fittest to donate. In addition, registries have a duty to make sure that the cells collected 
meet the transplant centre’s requested dose and other requirements. This is not 
necessarily a conflict of interest; by establishing which donors are more likely to meet 
the requested dose, additional apheresis procedures or even an emergency bone 
marrow harvest could potentially be avoided. 
 
During the last decade, peripheral blood stem cells (PBSC) have superseded bone 
marrow (BM) as the main source of haematopoietic stem cells (HSCs). Commonly 
requested CD 34+ doses vary between 3 and 5 x 106 per kg of recipient weight, 
although the minimum dose to ensure engraftment for allogeneic transplantation 
remains controversial (Mavroudis et al., 1996, Shpall et al., 1998, Mehta et al., 2009, 
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Pulsipher et al., 2009a, Heimfeld, 2003). Advantages of higher doses are the reduced 
risk of graft rejection and the increased graft-versus-tumour effect (Nakamura et al., 
2008). A dose-response relationship between the number of cells infused and the rate 
of haematopoietic recovery has also been described (Mehta et al., 2009, Shpall et al., 
1998, Pulsipher et al., 2009a). Some authors have reported an association between 
lower cell doses and higher transplant related mortality (Pulsipher et al., 2009a, 
Heimfeld, 2003). On the other hand, higher cell doses have been found to increase 
the risk of acute (Przepiorka et al., 1999) and chronic (Przepiorka et al., 2001, Zaucha 
et al., 2001, Heimfeld, 2003) graft versus host disease.  
 
Several days of apheresis are frequently required for PBSC donors to ensure a 
sufficient collection of CD34+ cells and around 20% of donors need a second day of 
apheresis (Holig et al., 2009). Our registry allows a maximum of 2 days of apheresis. 
The physical side effects of PBSC donation have been well described and common 
side effects include fatigue, bone pain and bruising (Pulsipher et al., 2013, Pulsipher, 
2012). A further reduction in platelet counts and increased psychological stress are 
potential risks associated with additional days of apheresis (Stroncek et al., 1999). If 
insufficient HSCs are harvested during the days of apheresis, bone marrow 
harvesting is performed as a salvage procedure. There are well described additional 
risks associated with this procedure, such as the risk of general anaesthesia, blood 
loss and mechanical injury. 
 
It is therefore of clinical importance to characterize donors who are at risk of not 
meeting the HSC dose requested by the transplant centres, as this group may benefit 
from an alternative mobilisation regimen in order to avoid additional days of apheresis 
or bone marrow harvesting. In addition, this knowledge may allow registries to focus 
  Chapter 3 – Three studies 
 
91 
 
on the recruitment of donors who are more likely to mobilise sufficient CD34+ cells. 
The advantages of such a strategy are clear both for the donors and the recipients. 
Because patients have already received therapy by the time donor cells are collected 
in most centres, the lack of availability of adequate stem cells is a significant and 
potentially life threatening problem.  
 
These studies were performed to evaluate the frequency of PBSC collections that 
meet the transplant centre’s requested dose, therefore taking the transplant centres’ 
requirements into account. The role of potential donor factors including age, gender, 
weight and difference between donor and recipient weight was examined.  
 
3.3.2 Retrospective analysis 
3.3.2.1 Methods 
The methods of this study are outlined in section 2.3. 
 
3.3.2.2 Results  
3.3.2.2.1 Donor and collection characteristics 
Donor and collection characteristics are listed in table 3.2. Of the 295 donors with 
recorded ethnicities, 96% (n = 284) were white, the remaining donors were of African, 
African-Caribbean, Asian, Mediterranean, Middle Eastern or of a mixed origin.  
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Table 3. 2  Donor and collection characteristics 
Characteristic  
Age (Years) 
Median (range) 
 
32 (18-58) 
Gender (Male/Female) 247/61 
Weight (kg) 
All - Median (range) 
Female – Median (range) 
Male - Median (range) 
 
81 (52-125) 
66.5 (52-111) 
83 (55-125) 
Central lines (percentage) 3/324 (< 1%) 
Blood volume processed day 1 (l) 
Median (range) 
 
12.2 (3-22) 
Blood volume processed day 2 (l) 
Median (range) 
CD34+ cells (x 106)/kg recipient weight day 1 
Median (range) 
CD34+ cells (x 106)/kg recipient weight day 2 
Median (range) 
 
10.8 (4-17) 
 
2.75 (0.44-14.0) 
 
2.3 (0.55-7.6) 
 
 
3.3.2.2.2 Association between demographic data and reaching the target yield  
The median cell dose requested was 4 x 106 CD34+cells/kg recipient weight (range 
2-10). There were 16 requests exceeding 5 x 106 CD34+ per kg (table 3.3). The 
median CD34 dose collected was 6.3 x 106/kg (median 145% of requested dose, 
range 20-495% of requested dose).  75% of requests were met after 1 day of 
apheresis and 94% of requests were met after 2 days of collection.   
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Table 3. 3 Indications for higher requested stem cell doses (CD 34 > 5 x 106/kg) (n=16) 
Disease (n) Reason given (n) 
AML(5) High risk disease (3) 
  Previous allograft – graft failure (1) 
  Unknown (1) 
MDS (3) High risk disease (3) 
CML (1) Unknown 
Myelofibrosis (2) Risk of poor engraftment (1) 
  Previous allograft – graft failure (1) 
CLL (1) High risk disease 
Hodgkin Disease (1) High risk disease 
Philadelphia positive ALL (1) Previous allograft – graft failure 
Unknown (2) Unknown (2) 
 
 
In univariate analyses (figure 3.1, tables 3.4 and 3.5), we found that reaching the 
target yield was significantly associated with: a higher donor weight (85.6 kg vs 75.3 
kg, p < 0.001), male donor gender (82% vs 44%, p < 0.001), a positive difference in 
weight between donor and recipient (4.3 kg vs -8 kg, p < 0.001) and a higher volume 
of blood processed (13.8 l  vs 11.9 l, p < 0.001). If I categorise the difference in weight 
between donor and recipient as being either negative or positive, the odds ratio of 
reaching the target for a positive difference was 2.6 (95% CI 1.5, 4.4) after 1 day of 
collection and 4.0 (95% CI 1.2, 12.8) after 2 days of collection. Donor age was not 
significantly associated with reaching the requested cell dose.  All the above findings 
were valid both after 1 day and 2 days of collection 
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Figure 3. 1 Associations of obtaining the requested yield according to gender, weight, 
difference between donor and recipient weight and volume of blood processed. A: Box plot 
with the horizontal line representing the median, the box the 25th percentile and the whiskers 
the 75th percentile. Female donors were significantly less likely to meet the requested cell 
dose. A lower weight (B) and a negative difference between donor and recipient weight (C) 
were associated with not meeting the requested dose. Lower volumes of blood processed 
(D) were associated with not reaching the requested dose. 
           A.                                                                                   
 
        
                    B. 
 
 
 
  Chapter 3 – Three studies 
 
95 
 
 
                         C. 
 
                       D. 
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Table 3. 4 Univariate analysis of factors associated with reaching the requested yield on day 
1 and day 1+2 of collection (yield obtained as a binary outcome). Values are expressed 
using mean (range) for continuous variables. 
Variable Yield obtained day 1 
 
Yield obtained day 1+2 
 Value 
not 
reached 
(n = 78) 
Value 
reached 
(n = 
230) 
p-value Value 
not 
reached 
(n = 16) 
Value 
reached 
(n = 287) 
p-
value 
Age 34.5 
(19, 54) 
32.8 
(18, 58) 
0.17 35.4 
(19, 54) 
33.2 (18, 
58) 
0.35 
Donor weight 
(kg) 
75.3 
(52, 
122) 
82.6, 
(53, 
125) 
< 0.001 69.3 
(56, 89) 
81.5 (52, 
125) 
< 
0.001 
 -8 (-
79.5, 
56) 
4.3 (-54, 
58) 
< 0.001 - 12.8 (-
46, 21) 
1.8 (-79.5, 
58) 
< 0.01 
Blood volume 
processed (l) 
11.9 
(2.6, 
20.1) 
13.8 
(4.7, 
22.2) 
< 0.001 20.2 
(9.8, 
28.2) 
22.8 (6.9, 
35.1) 
< 
0.001 
Gender (M/F) 44/34 203/27 < 0.001 6/10 239/48 < 
0.001 
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Table 3. 5 Univariate analysis of factors associated with reaching the requested yield on day 
1 and day 1+2 of collection (yield obtained as a continuous variable) 
 Variable Yield obtained minus 
yield requested day 1 
(continuous) 
 
Yield obtained minus yield 
requested day 1+2 
(continuous) 
Continuous Age  p = 0.94 p = 0.66 
 Donor weight p < 0.001 p < 0.001 
 Donor minus 
recipient weight 
Blood volume 
processed 
p < 0.001 
 
p  < 0.001 
p < 0.001 
 
p = 0.10 
Categorical Gender p < 0.001 p < 0.001 
 
Only gender (p < 0.001) and a positive difference between donor and recipient weight 
(p = 0.005) remained significantly associated with the target yield being met after 1 
day of collection after stepwise binary logistic regression analysis (table 3.6).  
 
Table 3. 6 Multivariate logistic regression of factors influencing the likelihood of reaching the 
target yield on day 1a and day 1+2b of collection 
 
Variable OR 95% CI p-value 
 
Donor minus recipient weight 
(kg) 
 
 
1.02a 
 
1.03b 
 
1.01 - 1.03a 
 
1.003-1.052b 
 
= 0.005a 
 
= 0.025b 
Gender 
           Female 
           Male 
 
 
1.00 
4.76a 
5.3b 
 
 
2.5 - 9.6a 
1.8-15.1b 
 
 
<0.001a 
= 0.002b 
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Interestingly, donor weight lost significance after adjusting for gender (p = 0.94). 
When excluding the donors with cell dose requests exceeding 5 x 106 CD34+ per kg, 
the analysis produced very similar results (table 3.7).  
 
Table 3. 7 Multivariate logistic regression of factors influencing the likelihood of reaching the 
target yield on day 1 of collection (analysis excluding requests exceeding 5 x 106 CD34+ per 
kg) 
 
Variable OR 95% CI p-value 
 
Donor minus recipient weight 
(kg) 
 
 
1.03 
 
1.01 - 1.04 
 
= 0.001 
Gender 
           Female 
           Male 
 
 
1.00 
3.69 
 
 
1.8 – 7.6 
 
 
<0.001 
 
3.3.2.2.3 Poor mobilisers 
Poor mobilisers were defined as a mobilisation of less than 2 x 106 CD34 cells per 
recipient weight after 1 day of apheresis. In univariate analyses, I found that poor 
mobilisation was significantly associated with: a lower donor weight (65.8 kg vs 81.7 
kg, p < 0.001), female donor gender (63% vs 17%, p < 0.001), a negative difference 
in weight between donor and recipient (-23.0 kg vs 2.7 kg, p < 0.001) and a lower 
volume of blood processed (9.6 l vs 13.5 l, p < 0.001). Only the difference between 
donor and recipient weight (p < 0.001) and the volume of blood processed remained 
significant after multivariate analysis (p < 0.001) (table 3.8). 
 
 
  Chapter 3 – Three studies 
 
99 
 
Table 3. 8 Multivariate logistic regression of factors influencing poor mobilisation 
Variable OR 95% CI p-value 
 
Donor minus recipient weight 
(kg) 
 
 
1.05 
 
1.02 - 1.08 
 
< 0.001 
Blood volume processed (l) 1.4    1.2-1.7 
 
    < 0.001 
 
3.3.3 Prospective analysis 
Our prospective study described in chapters 4 and 5 assesses the influence of pre-
donation characteristics on the donation experience. A secondary end point of this 
study was to evaluate the frequency of PBSC collections meeting the transplant 
centre’s requested dose, but now in a prospective manner. I examined the role of 
potential donor and collection characteristics in accordance with our retrospective 
study and I also examined the role of BMI and baseline haematology results, such as 
baseline platelet and white cell count.  
 
3.3.3.1 Methods 
The full material and method can be found in chapter 2 (section 2.4.3.3). 
 
3.3.3.2 Results 
3.3.3.2.1 Donor and collection characteristics 
Participants were donors who were recruited in our prospective study described in 
chapters 4 and 5 and they all donated in 2013.  Donors for paediatric recipients were 
  Chapter 3 – Three studies 
 
100 
 
excluded from this analysis (n = 15) as well as donors with incomplete documentation 
of yields data (n = 7), with 253 donors remaining for analysis. Characteristics are 
shown in table 3.9. 248 donors were of Northern European origin, the remaining were 
of other white background (n = 3), mixed ethnicity (n = 2), Asian (n = 2), African and 
Caribbean (n = 1) or unknown ethnicity (n = 4). 
 
Table 3. 9  Donor and collection characteristics 
Characteristic  
Age (Years) 
Median (range) 
 
30.8 (17-63) 
Gender (Male/Female) 195/58 
Weight (kg) 
Median (range) 
 
81 (51.9-125) 
BMI 
Median (range) 
 
25.9 (17-41.6) 
Central lines (percentage) 260/274 (5%) 
2 day collections (percentage) 74/274 (27%) 
Blood volume processed day 1 (l) 
Median (range) 
 
10.5 (3-17.6) 
Blood volume processed day 2 (l) 
Median (range) 
CD34+ cells (x 106)/kg recipient weight day 1 
Median (range) 
CD34+ cells (x 106)/kg recipient weight day 2 
Median (range) 
 
10.5 (4.6-15.3) 
 
2.9 (0.6-3.9) 
 
2.5 (0.6-6.7) 
 
3.3.3.2.2 Association between demographic data and reaching the target yield  
The median cell dose requested was 4 x 106 CD34+cells/kg recipient weight (range 
3-6). Only 4 requests exceeded 5 x 106 CD34+ per kg (table 3.10). The median CD34 
  Chapter 3 – Three studies 
 
101 
 
dose collected was 6.0 x 106/kg. 67.7% of requests were met after 1 day of apheresis 
and 87% of requests were met after 2 days of collection.   
 
Table 3. 10 Indications for higher requested stem cell doses (CD 34 > 5 x 106/kg) (n=4) 
Disease (n) Reason given (n) Dose requested 
AML(2) High risk disease (2) 6 x 106/kg 
MDS (1) High risk disease (1) 6 x 106/kg 
Hodgkin Disease (1) Relapse (1) 6 x 106/kg 
 
I found that a higher donor weight (85.9 vs 75.3 kg, p < 0.001), a higher donor BMI (27.3 vs 
24.6, p < 0.001), male gender (83% vs 64%, p = 0.001) and a positive difference in weight 
between donor and recipient (8.5 kg vs -9.2 kg) were significantly associated with reaching 
the target yield in univariate analysis (table 3.11). All these findings were valid both after 1 day 
and 2 days of collection. A younger age (32.2 vs 35, p = 0.024) and a higher blood volume 
processed (12.3 l vs 11l, p < 0.001) were also associated with reaching the target yield, but 
only on day 1 of collection. When I categorised the difference in weight between donor and 
recipient as being either negative or positive, the odds ratio of reaching the target for a positive 
difference was 3.2 (95% CI 1.8, 5.6) after 1 day of collection and 3.0 (95% CI 1.3, 7.2) after 2 
days of collection. The baseline white cell count and the pre-harvest white cell count were not 
significantly associated with reaching the requested dose after 1 or 2 days of collection. A 
higher baseline platelet count was significantly associated with reaching the target after 2 days 
of collection (248 vs 215 x 109/l; p = 0.002), but not after one day. 
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Table 3. 11 Univariate analysis of factors associated with reaching the requested yield on 
day 1 and day 1+2 of collection (yield obtained as a binary outcome). Values are expressed 
using mean (range) for continuous variables. 
Variable Yield obtained day 1  
 
Yield obtained day 1+2 
 Value not 
reached 
(n = 77 ) 
Value 
reached 
(n = 176 ) 
p-value Value not 
reached 
(n = 27) 
Value 
reached 
(n =226 ) 
p-
value 
Age 35 
(17-62) 
32.2 
(21-60) 
0.024 34.6 
(2-58) 
32.9 
(17-62) 
0.35 
Donor  
weight (kg) 
75.3 
(51.9-119.2) 
85.9 
(53-125) 
< 0.001 72.9 
(51.9-99) 
83.9 
(53-125) 
< 
0.001 
Donor  
minus 
recipient 
weight (kg) 
-9.2 
(-65.3-39.2) 
8.5 
(-49.2-
61.5) 
< 0.001 -14.5 
(-65.3-34) 
5.2 
(-60.5-61.5) 
< 
0.001 
BMI 24.6 
(17-36.8) 
27.3 
(17.9-
41.6) 
< 0.001 24.4 
(19.5-36.8) 
26.7 
(17-41.6) 
0.005 
Blood 
volume 
processed 
(l) 
11.0 
(3-17.6) 
12.3 
(5.6-21.5) 
< 0.001 21.5 
(17.8-28.7) 
21.1 
(13.2-32) 
0.79 
Baseline 
platelet 
count (x 
109/l) 
237 
(140-438) 
248 
(146-407) 
0.13 215 
(140-438) 
248 
(146-407) 
0.002 
Baseline 
white cell 
count (x 
109/l) 
6.6 
(4-11.3) 
6.6 
(3.2-12.9) 
 
0.87 6.5 
(4-8.9) 
6.6 
(3.2-12.9) 
0.66 
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Pre-harvest 
white cell 
count (x 
109/l) 
40.9 
(22.5-73.7) 
42.6 
(19.7-
76.0) 
0.37 38.2 
(22.5-53.2) 
42.4 
(19.7-76.0) 
0.24 
Gender 
(M/F) 
49/28 146/30 0.001 15/12 180/46 0.013 
 
Central line 
(N/Y) 
73/4 166/9 0.99 25/2 214/11 0.63 
 
After stepwise binary logistic regression analysis (table 3.12), male gender, a positive 
difference between donor and recipient weight, higher BMI, lower age and a higher 
baseline platelet count were significantly associated with the target yield being met 
after 1 day of collection.  
 
Table 3. 12 Multivariable logistic regression of factors influencing the likelihood of reaching 
the target yield on day 1a and day 1+2b of collection 
Variable OR 95% CI p-value 
Age  0.95a 0.92-0.99a 0.005a 
BMI 1.12a 
1.06b 
1.01-1.24a 
0.91-1.24b 
0.027a 
0.45b 
Donor minus recipient weight  
 
1.04a 
1.04b 
1.02 - 1.06a 
1.02-1.07b 
<0.001a 
0.002b 
Baseline platelet count 1.008a 
1.03b 
1.002-1.02a 
1.02-1.04b 
0.014a 
< 0.001b 
Gender 
           Female 
           Male 
 
 
1.00 
2.2a 
5.22b 
 
 
1.03 – 4.8a 
1.8-15.5b 
 
 
0.041a 
0.003b 
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3.3.3.2.3 Poor mobilisers 
Poor mobilisers were defined as a mobilisation of less than 2 x 106 CD34 cells per 
recipient weight after 1 day of apheresis. We found that a lower donor weight (66.1 
vs 83.8 kg, p < 0.001), a negative difference in weight between donor and recipient (-
28.1 vs 5.1 kg, p < 0.001), lower BMI (23.2 vs 26.7, p = 0.002) and female gender 
(68.8% vs 19.7%,p < 0.001) were associated with poor mobilisation in univariate 
analysis (table 3.13).  
 
Table 3. 13 Univariate analysis of factors associated with poor mobilisation. Values are 
expressed using mean (range) for continuous variables. 
Variable Poor mobilisation 
 Yes 
(16) 
No 
(244) 
p-value 
Continuous Age 32.7 (21-50) 33.1 (17-62) 0.90 
 Donor  weight 
(kg) 
66.1 (51.9-74.7) 83.8 (53-125) < 0.001 
 Donor  minus 
recipient weight 
(kg) 
-28.1 (-65.3-2.6) 5.1 (-60.5-61.5) < 0.001 
 BMI 23.2 (19.5-36.8) 26.7 (17-41.6) 0.002 
 Blood volume 
processed (l) 
10.7 (9-13.4) 12.1 (3-21.5) 0.088 
 Baseline 
platelet count 
232 (173-333) 244 (128-438) 0.35 
 Baseline white 
cell count 
6.1 (4.1-7.8) 6.7 (3.2-12.9) 0.18 
 Pre-harvest 
white cell count 
33.9 (22.5-42.4) 42.4 (19.7-76.0) 0.059 
Categorical Gender (M/F) 5/11 196/48 < 0.001 
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Only the difference between donor and recipient weight remained significant after 
stepwise binary logistic regression analysis (table 3.14). 
 
Table 3. 14 Multivariable logistic regression of factors influencing poor mobilisation 
Variable OR 95% CI p-value 
Donor minus 
recipient weight 
(kg) 
1.15 
 
1.03 - 1.29 0.014 
 
3.3.4 Discussion 
Previous studies have reported that several donor characteristics influence PBSC 
mobilisation. Table 1.6 lists all the factors that have been previously found to affect 
the PBSC yield in allogeneic donors. Most of these studies have used the stem cell 
yield, either per donor or recipient weight, as a primary outcome. This study was 
performed to evaluate the frequency of PBSC collections that meet the transplant 
centre’s requested yield (allowing for yields within 10% of the requested yield), 
therefore taking the transplant centres’ requirements into account.  
 
 
My retrospective study found that a lower donor weight, a negative difference 
between donor and recipient weight, female gender and lower volumes of blood 
processed were associated with not reaching the target yield in univariate analysis. 
Only 3 donors needed insertion of a central line so the effect of this could not be 
examined statistically. In contrast to several other studies, age was not significantly 
associated with reaching the requested cell yield. The difference between donor and 
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recipient weight and gender remained statistically significant in the multivariate 
analysis.  
 
Donor weight was found to be positively associated with yields in previous studies. 
To our knowledge, the influence of the difference between donor and recipient weight 
has not been studied previously. Our study showed that any negative difference 
between donor and recipient was significantly associated with not reaching the 
requested cell dose. Based on these results, transplant centres and registries could 
consider selecting donors who are heavier than their recipient, if more than one fully 
HLA-matched donor is available. For example, at CT stage, a warning could be sent 
to the transpant centre when a donor is selected who is lighter than the recipient. This 
practice may however compromise donor safety as several studies have shown that 
heavier donors experience more bone pain (Pulsipher et al., 2013, Pulsipher et al., 
2009b, Chen et al., 2011). In addition, vascular access may be more problematic in 
heavier donors.  
 
Gender was considered to have an effect in many previous studies (table 3.9) 
(Fischer et al., 2005, Martino et al., 2006, Vasu et al., 2008, Miflin et al., 1996), 
although no correlation was found by others (Anderlini et al., 1997, Lysak et al., 2005, 
Sohn et al., 2003). Vasu et al reported that gender lost significance after adjusting for 
weight and the total amount of G-CSF administered (Vasu et al., 2008). We found 
that gender retained significance after adjusting for weight and total volume of blood 
processed. The finding that gender remained significant after taking donor weight into 
account may be explained by the possible influence of sex steroids on 
haematopoiesis (Lopez-Holgado et al., 2005). This has only been reported in 2 other 
studies to date (Martino et al., 2006, Miflin et al., 1996). Lopez-Holgado et al reported 
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a higher production of all types of progenitors in males compared to females and, 
moreover, a better stromal confluence and hence a better microenvironment. Other 
possible influencing factors may be the difference in fat distribution and body 
constitution and subsequent different pharmacological profiles of G-CSF.  
 
Similarly to the retrospective study, the prospective analysis found that male gender 
and a positive difference between donor and recipient weight were significantly 
associated with the target yield being met in multivariate analysis. In addition, the 
prospective analysis showed that a lower donor age, a higher BMI and a higher 
baseline platelet count were significantly associated with the target yield being met. 
 
Lower donor age was associated with reaching the target on day 1 of collection. 
Lower age has been found to be associated with higher CD34+ yields in several other 
studies (table 3.9) (Anderlini et al., 1997, Shimizu et al., 2002, Suzuya et al., 2005, 
Martino et al., 2006, Wang et al., 2008, Anderlini et al., 1999). Previous authors have 
identified 38 years (de la Rubia et al., 2002) and 55 years (Anderlini et al., 1999, Ings 
et al., 2006) as ages above which progenitor yields are, on average, reduced. In our 
data set, donors aged 55 years or more were significantly less likely to reach the 
target yield on day 1 of collection (70% target reached if < 55 years vs 25% target 
reached if ≥ 55;p = 0.032). The reason we did not find this effect in our retrospective 
study may be related to the smaller age range of donors in that study (18-58 versus 
17-63).  
 
BMI was considered to have an effect on cell yield in several previous studies (table 
3.9) (Favre et al., 2003, Wang et al., 2008, Chen et al., 2014). In my data set, donors 
with a BMI of 30 or more were significantly more likely to reach the target yield on day 
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1 of collection (90% target reached if  BMI ≥ 30 vs 65% target reached if BMI < 30; p 
< 0.001).The finding that overweight or obese adult donors who are otherwise healthy 
had better responses to G-CSF is interesting. Firstly, recent animal studies have 
demonstrated that adipose tissue contains significant numbers of HSCs (Han et al., 
2010, Cousin et al., 2003, Minana et al., 2008). However, it is yet to be confirmed 
whether these HSCs are also present in human adipose tissues. Additionally, the 
exact mechanisms determining the number of HSCs in fat tissue are currently 
unknown. Secondly, we based the G-CSF dose on donor weight. Donors with higher 
BMI’s may have received relatively higher doses of G-CSF than if ideal body weight 
was used for determination of G-CSF dose. The efficacy of the G-CSF dose as 
determined by ideal body weight remains to be investigated. Thirdly, improved 
responses to G-CSF mobilisation in donors with higher BMI’s may be accounted for 
by other intrinsic biomedical factors that are associated with obesity.  
 
A higher baseline platelet count was also associated with reaching the target yield. 
This has been described in one previous study (Vasu et al., 2008). An explanation of 
this finding may be due to common pathways of thrombopoiesis and progenitor cell 
mobility. Increased plasma levels of SDF-1 have been shown to enhance human 
thrombopoiesis and mobilise human colony forming cells in mice (Perez et al., 2004).  
 
When using poor mobilisation (defined as a mobilisation of less than 2 x 106 CD34 
cells/kg) as an outcome, both the retrospective and prospective analysis found that a 
negative difference between donor and recipient weight remained significantly 
associated with poor mobilisation in the multivariate analysis. My retrospective data 
showed that a lower volume of blood processed was significantly associated with poor 
mobilisation, this was not confirmed in the prospective analysis. The optimal volume 
of blood to be processed during apheresis remains an area of debate. Some authors 
  Chapter 3 – Three studies 
 
109 
 
have suggested that apheresis of large volumes may be more efficient than standard 
volume leukapheresis (Passos-Coelho et al., 1997, Diaz et al., 2003, Bojanic et al., 
2011), however several comparative studies have not been able to confirm this 
(Demirer et al., 2002, Schwarer et al., 2000, Anderlini et al., 2000). 
 
The subject of improving CD34+ yields has been picked up recently by several 
registries and some have already started to alter their recruitment strategies. The 
preferential recruitment of male donors has been adopted by several. Increasing the 
minimum weight allowance at recruitment can also be considered. However, donor 
weight may have changed over time between joining and donation, given that some 
donors remain on the register for decades prior to being selected. One could also 
consider the preferential recruitment of younger donors. This has already been 
adopted by several registries, but mainly due to a different reason; several studies 
have shown that a lower donor age is associated with improved overall survival in the 
recipient (Kroger et al., 2013, Lanino et al., 2008). This finding has also led to 
transplant centres choosing the youngest donor at CT stage, if there is a choice of 
more than one fully HLA-matched potential donor. 
 
Alternatively, groups at risk of poor mobilisation may benefit from a different 
mobilisation regimen in order to avoid additional procedures. Some studies have 
shown that G-CSF administered every 12h at doses of 5 or 6 μg/kg is associated with 
better yields compared to a dose of 10 μg/kg once daily, without an increase in 
morbidity (Kroger et al., 1999, Arbona et al., 1998, Kroger et al., 2000). The 
justification for a twice-daily schedule is based on the fact that the elimination half-life 
of G-CSF after subcutaneous injection is only 3 to 4 hours (de la Rubia et al., 2002). 
This twice-daily regimen is however associated with logistical difficulties and 
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increased costs as it involves twice daily nurse visits. It may also result in more donors 
having to take time off work during the injections. Most registries including our registry 
don’t allow the self-administration of G-CSF given the low, but potentially life-
threatening risk of anaphylaxis (Tulpule et al., 2009). 
 
Plerixafor, a CXCR4 antagonist, could be of benefit in groups at risk of poor 
mobilisation. Plerixafor reversibly inhibits chemokine (CXC motif) receptor 4 (CXCR4) 
binding to stromal cell derived factor -1a (SDF -1a). Stem cells express CXCR4 and 
are known to migrate to the bone marrow through a chemo-attractant effect of SDF-
1a that is produced locally by bone marrow stromal cells. Once in the marrow, it is 
also believed that stem cell CXCR4 can act to anchor these cells to stromal cell 
surface SDF-1a. Plerixafor induced leucocytosis and elevations in haematopoietic 
progenitor cell levels are thought to result from a disruption of these chemo-attractant 
and cell adhesion effects, resulting in the appearance of both mature and pluripotent 
stem cells in the systemic circulation (Broxmeyer et al., 2005). The pharmacokinetic 
behaviour of plerixafor is characterised by peak plasma levels occurring 0.5 – 1 hour 
after administration (Stewart et al., 2009, Cashen et al., 2008) and an elimination half-
life of approximately 3 hours. The peripheral blood CD34+ count increases rapidly, 
with peaks seen 9-14 hours after administration. Plerixafor is currently only licensed 
for autologous donations.  It was licensed for this indication following 2 large 
randomised clinical trials indicating safety and efficacy (table 3.15).  
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Table 3. 15 Core evidence for the use of plerixafor + G-CSF in autologous transplantation 
Trial Regimen Outcome 
Multiple 
myeloma 
randomised 
clinical trial (n = 
302) (DiPersio et 
al., 2009b) 
Salvage use following G-CSF monotherapy 
Failure to collect at least 0.8 × 106 CD34+ 
cells/kg 
after two apheresis days or 2 × 106 CD34+ 
cells/kg in four apheresis days 
Safe and efficient 
HPC mobilisation for 
autologous BMT 
Non Hodgkin 
lymphoma 
randomised 
clinical trial (n = 
298) (DiPersio et 
al., 2009a) 
Salvage use following G-CSF monotherapy 
Failure to collect at least 0.8 × 106 CD34+ 
cells/kg after two apheresis days or 2 × 106 
CD34+ cells/kg in four apheresis days 
Safe and efficient 
HPC mobilisation for 
autologous BMT 
 
Studies using plerixafor in unrelated donors are limited, some have used plerixafor in 
monotherapy (table 3.16), others in combination with G-CSF (table 3.17).  
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Table 3. 16 Studies of PBSC mobilisation with plerixafor only 
Study Number 
of donors 
(n) 
Plerixafor 
dose 
Number 
of doses 
Yield > 2 x 106 per 
kg of recipient 
weight n (%) 
(Devine et al., 
2008) 
25 240 μg/kg Up to 2 16/24 (67%) after 1 
dose 
22/24 (92%) after 2 
doses 
(Leotta et al., 
2011) 
1 240 μg/kg (in 
addition to 1 
dose of G-CSF) 
1 1 (100%) 
(Lemery et al., 
2011) 
21 Variable doses 
up to 480 μg/kg 
2 Not reported 
 
 
Plerixafor appeared to be at least as safe as G-CSF in the short term, as no healthy 
unrelated donor experienced more than grade 1 toxicity (Devine et al., 2008, Hauge 
et al., 2013). The most frequently adverse reactions reported are injection site 
reactions, diarrhoea, nausea, paraesthesias and headache (Liles et al., 2003, Hubel 
et al., 2004, Devine et al., 2008). Devine et al reported no long-term consequences, 
with at least a median follow-up of 9 months after donation (Devine et al., 2008). 
Longer follow-up and greater numbers of donors will be needed to ascertain the 
overall safety of plerixafor in healthy volunteer donors.   
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Table 3. 17 Studies or case reports of PBSC mobilisation with G-CSF and plerixafor 
Study Number 
of 
donors 
(n) 
Timing of plerixafor Plerixafor 
dose 
Yield > 2 x 106 per kg of 
recipient weight n (%) 
(Hauge et al., 
2013) 
6 After 2 days of 
collection (n = 2) 
After 1 day of 
collection (n = 2) 
Based on peripheral 
blood CD34+ counts, 
before apheresis (n = 
2) 
240 μg/kg 6 (100%) 
(Neumann et 
al., 2011) 
1 After 1 day of 
collection 
240 μg/kg 1 (100%) 
(Schriber et 
al., 2011) 
1 After 2 days of 
collection 
240 μg/kg 1 (100%) 
 
Combinations of G-CSF and plerixafor, using plerixafor as a salvage treatment, are 
promising and additive effects on the number of circulating progenitor cells when 
administered with G-CSF have been described (Liles et al., 2005). This off label use 
of plerixafor may be considered as an alternative to an emergency bone marrow 
harvest after failed mobilisation with G-CSF. Plerixafor incorporation in first-line 
mobilisation protocols in donors who are predicted to be poor mobilisers should be 
clarified in the future. Plerixafor has also been used as an “emergency” PBSC 
mobiliser in a normal donor for whom a routine bone marrow harvest attempt failed 
unexpectedly and the recipient had already undergone conditioning (Leotta et al., 
2011). In this situation, the short time required for PBSC mobilisation with plerixafor 
may be a clear advantage. Studies in animal models have shown that delaying the 
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infusion of haematopoietic stem cells after conditioning with total body irradiation for 
longer than 4 days can lead to a significant risk of non-engraftment or graft failure 
(Ding et al., 2009). Mobilising with G-CSF alone would delay haematopoietic stem 
cell infusion by 5 to 6 days, which would increase the risk of rejection. However, the 
use of this agent in healthy donors is clearly limited by the fact that it is still unlicensed 
for this indication. I would recommend that registries set up or participate in clinical 
trials using plerixafor in this setting (http://clinicaltrials.gov/show/NCT01954914).  
 
In conclusion, these studies show that female gender, a negative difference between 
donor and recipient weight, lower BMI and lower donor age are associated with a 
decreased likelihood of meeting the transplant physician’s requested dose. This is 
clinically significant if there is a choice of more than one fully HLA-matched potential 
donor, in that a male or heavier or younger donor would be preferable. These findings 
may also influence future recruitment and mobilisation strategies. 
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Chapter 4. A prospective study to investigate the predictors 
of the donation experience in unrelated haematopoietic stem 
cell donors: Part I 
A paper based on the findings of the study was published in the journal of Biology of 
Blood and Marrow Transplantation in February 2015 entitled “Pre-donation health 
related quality of life scores predict time to recovery in haematopoietic stem cell 
donors” (See Appendix 3) 
   
4.1 Introduction 
In the first chapter, I reviewed the most common physical and psychological reactions 
to the donation process and concentrated on groups of donors that are at increased 
risk of adverse reactions (table 1.4). The primary aim of this prospective study is to 
better understand the factors that influence donor recovery and that are most 
commonly associated with certain adverse reactions. Factors assessed include both 
demographic factors such as gender, age, ethnicity, weight, BMI, number of 
dependants, being a blood donor and marital status (outlined in this chapter) and 
baseline health related quality of life (HRQOL) scores using the Short-Form 36 Health 
Survey (SF-36) questionnaire, which will be described in the next chapter. The 
secondary aims of this study involve a description of the physical and psychological 
donation experience by comparing pre- and post-donation HRQOL markers (chapter 
5). Other secondary aims also include an analysis of demographic and collection 
characteristics influencing PBSC (chapter 3) and BM yields (chapter 6).  
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An analysis of donor characteristics associated with poorer donation experiences is 
important, as donor stratification based on the anticipated donation risk may lead to 
changes in donor selection criteria, tailored donor counselling approaches or tailored 
supportive measures or follow-up procedures. As a preparation of this study, our 
regular donor follow-up system was altered in order allow for the collection of 
standardised donor follow-up data (section 3.2). 
 
4.2 Materials and Methods 
The full material and method can be found in chapter 2 (section 2.4). 
 
4.3 Results 
4.3.1 Characteristics, adverse reactions and recovery of BM and PBSC donors 
Tables 4.1 and 4.2 show clinical and collection characteristics of BM and PBSC 
donors enrolled in the study. A central line was inserted in 5% of PBSC donors. 2% 
of male donors compared to 15% of female donors (p < 0.001) needed insertion of a 
central line. There was no difference in BMI between donors needing and not needing 
a central line (p = 0.14). 27% of PBSC donors (74/275) required a two day collection.  
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Table 4. 1 Donor characteristics at time of donation 
Characteristic PBSC (n) % BM (n) % 
Number of donors 275 88 37 12 
Number of apheresis/ harvest 
centres 
4  4  
Gender 
Male 
Female 
 
210 
65 
 
76 
24 
 
33 
4 
 
89 
11 
Ethnicity 
United Kingdom and Ireland 
Europe (White) 
Other (White) 
Asian 
African and Caribbean 
Mixed ethnicity 
Decline/unknown 
 
99 
161 
4 
3 
2 
2 
4 
 
36 
58 
2 
1 
0.5 
0.5 
2 
 
11 
22 
1 
0 
1 
0 
2 
 
29 
61 
2 
0 
2 
0 
6 
Donor age at donation 
16-30 
31-40 
41-63 
Median (range) 
 
122 
93 
60 
30.9 (17, 63) 
 
44.5 
33.5 
22 
 
21 
6 
10 
27.9 (19, 55) 
 
55 
18 
27 
Donor BMI 
Underweight (< 18.5) 
Normal (18.5, 24.9) 
Overweight (25, 29.9) 
Obese (> 30) 
Unknown 
Median (range) 
 
3 
100 
108 
53 
11 
25.9 (17, 41.6) 
 
1 
36 
40 
19 
4 
 
 
0 
14 
13 
10 
0 
26.7 (19.7, 
33.9) 
 
0 
37 
37 
26 
0 
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Table 4. 2 Collection characteristics for PBSC and BM donors 
Characteristic  
PBSC collection (n = 275) 
2 day collection  
n (%) 
 
74 (27%) 
Volume of blood processed on day 1 (litres) 
Median (range) 
 
10.5 (3-17.6) 
Volume of blood processed on day 2 (litres) 
Median (range) 
 
10.5 (4.6-15.3) 
Presence of a central line 
n (%) 
 
14 (5%) 
BM collection (n = 37) 
Volume of bone marrow collected (ml) 
Median (range) 
 
1350 (290-1740) 
Volume of bone marrow collected (ml)/kg donor weight 
Median (range) 
 
15.0 (3.9-23.0) 
Duration of procedure (mins) 
Median (range) 
 
40 (20-120) 
Difference (g/dl) between haemoglobin prior to donation 
and haemoglobin post donation 
Median (range) 
 
 
2.6 (1.1-5.9) 
 
Figures 4.1 and 4.2 show common adverse reactions experienced in PBSC donors 
and BM donors. Short term adverse reactions for both types of donation were very 
similar, but the temporal pattern differed. Pain in PBSC donors consisted mainly of 
bone pain or headache. Pain peaked during administration of G-CSF with 85% of 
donors experiencing pain of any type on the third day of G-CSF administration. The 
pain was graded as CTCAE 1 in 80% of cases, only 1 donor experienced grade 3 
pain. Pain in BM donors was generally localised to the site of donation or the throat 
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(following incubation). The peak of pain for BM donors was reported on day 2-3 
following donation for back pain (76.5 %) and on the day of donation for throat pain 
(48.6%). For BM donors, most side-effects were classified as CTCAE grade 1, no 
donors experienced grade 3 or 4 side-effects in this small cohort. All apart from 1 
donor were discharged from hospital the day following BM harvest. Fatigue and 
bruising were the most common other adverse reactions of both BM and PBSC 
donors.  
 
Figure 4. 1  Frequency of common side-effects following PBSC donation 
 
 
Figure 4. 2  Frequency of common side-effects following BM donation 
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The peak of these symptoms was day 2-3 following donation for both types of 
donation. Fatigue was experienced in 40.0% of PBSC donors; bruising in 34.2 %. For 
BM donors, fatigue was experienced in 73.5% and bruising in 53.4% of donors.  Only 
one BM donor was started on iron replacement following donation, his haemoglobin 
had fully recovered at 4 weeks post donation. 2/26 donors that were not started on 
iron replacement had not recovered their haemoglobin at 4 weeks (defined as 
haemoglobin < 13 g/dl in men and < 11.5 g/dl in women). Both donors were started 
on iron replacement at 4 weeks following donation.  
 
The mean time to recovery for BM donors was 14.3 days as opposed to 5.2 days for 
PBSC donors (p < 0.001) (figure 4.3).  Only 50% of BM donors felt they had recovered 
after 1 week and 68.8% had returned to work, compared to 90.3% and 98.3% of 
PBSC donors respectively (p < 0.001). Pain was experienced significantly more in 
BM donors compared to PBSC donors 1 week following donation (p < 0.001). 75% 
(207/278) of PBSC donors required analgesia during G-CSF administration and 2.5% 
of donors still required analgesia 7 days following donation, as opposed to 10% of 
BM donors still needing analgesia at 7 days (3/29). BM donors also reported more 
adverse reactions in general compared to PBSC donors 1 week following donation (p 
< 0.001).  When asked the questions about how donors felt physically or emotionally 
1 week after donation, BM donors felt physically worse compared to PBSC donors (p 
= 0.001), but felt similar emotionally (figure 4.4).  
 
Three donors experienced a serious adverse reaction (0.9%); all were PBSC donors. 
One young, male donor developed grade 3 back pain after administration of the 2nd 
dose of G-CSF. He required intravenous morphine, but was able to continue G-CSF 
injections at the same dose whilst receiving codeine and paracetamol at home. A 
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second donor developed gout 1 day after PBSC donation. He had never experienced 
gout before and it was felt that this was likely associated with G-CSF administration. 
A third donor developed palpitations following PBSC donation. This was further 
investigated and she was diagnosed as having a sinus tachycardia most likely to be 
related to psychological stress. Her symptoms, however, only resolved after several 
weeks. 
 
Figure 4. 3  Probability of self-reported complete recovery after PBSC vs. BM donation 
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Figure 4. 4  Physical and emotional well-being 1 week following donation in BM and PBSC 
donors 
 
4.3.2 Demographic and collection characteristics predicting time to complete recovery  
4.3.2.1 PBSC donors  
The factors influencing time to recovery in univariate analysis were gender and age 
(figure 4.5 a, b and table 4.3); donors of younger age or male gender were more likely 
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to recover more rapidly.  There was no significant association between BMI (p = 0.23), 
marital status (p = 0.23), being a blood donor (p = 0.37), number of days of collection 
(p = 0.1), volume of blood processed on day 1 (p = 0.51) or day 2 (p = 0.77) or pre-
harvest white blood cell count (p = 0.85) and time to recovery. There was a trend 
towards statistical significance for the number of dependants (p = 0.057) (figure 4.5 c 
and table 4.3); donors with fewer dependants were more likely to recovery faster 
compared to donors with more dependants. The absence of a central line also has a 
borderline association with a faster recovery (p = 0.067) (figure 4.5 d and table 4.3).  
 
Figure 4. 5 Factors predicting probability of self-reported recovery after PBSC donation 
Figure 4. 5a. Gender predicts probability of self-reported complete recovery after PBSC 
donation 
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Figure 4. 5 b Age predicts probability of self-reported complete recovery after PBSC 
donation 
 
Figure 4. 5c. Number of dependants and probability of self-reported complete recovery after 
PBSC donation 
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Figure 4. 5d Presence of a central line and probability of self-reported complete recovery 
after PBSC donation 
 
 
Table 4. 3 Univariate analysis of factors influencing time to recovery following PBSC 
donation. Time to complete recovery documented for 266 donors (missing data n = 9). 
Factors (n) Time to complete 
recovery (days)  
Mean (range)  
p-value 
Gender  
Male (202/266) 
Female (64/266) 
 
4 (0-35) 
6 (0-42) 
= 0.027 
Age  
 ≤ 30 (116/266) 
30-40 (91/266) 
> 40 (59/266) 
 
3.5 (0-28) 
4.3 (0-28) 
6.8 (0-42) 
= 0.003 
Number of dependants 
0 (140/266) 
1-2 (58/266) 
3 or more (15/266) 
 
3.94 (0-30) 
5.16 (0-42) 
8.64 (1-30) 
= 0.057 
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Missing data (53/266) 
Central line 
Yes (13/266) 
No (252/266) 
Missing data (1/266) 
 
8.08 (1-30) 
4.35 (0-42) 
= 0.067 
 
Younger age remained significantly associated with a faster time to complete 
recovery in multivariate analysis (table 4.4); the probability of a faster recovery was 
50% higher in donors aged ≤ 40 compared to donors aged > 40 (HR 1.5; 95% CI 1.1-
2.0; p = 0.009). 
 
Table 4. 4 Multivariate analysis of factors influencing time to recovery following PBSC 
donation (using age as categorical variable) 
Factor p-value HR (95% CI) 
Age (Categorical) 
   ≤ 40 
    > 40 
= 0.009  
1.5 (1.1-2.0) 
1 
Gender 
   Male 
   Female 
= 0.087  
1.3 (0.96-1.7) 
1 
 
4.3.2.2 BM donors 
There was no statistically significant association between gender (p = 0.18), age (p 
= 0.42), BMI (p = 0.88), marital status (p = 0.62), number of dependants (p = 0.21) 
and time to recovery. Although not statistically significant, male gender and a lower 
number of dependants appeared to be associated with faster recovery (figure 4.6 a, 
b and table 4.5). There was no significant association between duration of the 
procedure (p = 0.98), volume of BM harvested per kg donor weight (p = 0.95), 
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haemoglobin following donation (p = 0.57), the difference between pre and post 
haemoglobin (p = 0.80) and time to recovery 
 
Figure 4. 6 Factors associated with self-reported recovery after BM donation 
Figure 4. 6a. Gender and probability of self-reported complete recovery after BM donation 
 
 
Figure 4. 6b. Number of dependants and probability of self-reported complete recovery after 
BM donation 
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Table 4. 5 Univariate analysis of factors influencing time to recovery following BM donation 
Factors (n) Time to complete recovery (days)  
Mean (range)  
p-value 
Gender  
Male (30) 
Female (4) 
 
12.6 (0-56) 
23.5 (10-42) 
= 0.18 
Number of dependants 
0 (15) 
1-2 (7) 
3 or more (4) 
 
13 (0-42) 
13 (4-21) 
28.75 (10-56) 
= 0.21 
 
4.3.3 Demographic and collection characteristics predicting adverse reactions 
4.3.3.1 PBSC donors 
Table S1 appendix 1 shows the univariate analysis of demographic and collection 
characteristics influencing adverse reactions at different time points following PBSC 
donation. Only factors that remained significant (or borderline significant) in the 
multivariate analysis are shown in table 4.6. Table 4.7 displays the multivariate 
analysis of factors influencing the occurrence of any adverse reaction at different time 
points. Factors taken into account include age, gender, BMI, being a blood donor, 
number of dependants, presence of a central line, one versus two day collection and 
pre-harvest white blood cell count. 
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Table 4. 6 Multivariate analysis of factors influencing adverse reactions at different time 
points following PBSC donation. All time points are defined as the day of donation (D 0), 2-3 
days after donation (D2-3) and weekly after donation up until full recovery. Factors taken into 
account include age, gender, BMI, being a blood donor, number of dependants, presence of 
a central line, number of days of collection and pre-harvest white cell count. 
Outcome: 
Symptom and 
time point  
Factor p-value OR (95% CI) 
Bruising D0 Central line 
   Yes  
   No 
= 0.016  
6.9 (1.4-33.2) 
1 
Fatigue D 0 Gender 
   Male 
   Female 
= 0.014  
1 
2.2 (1.2-4.0) 
Headache D 0 
 
 
Gender 
   Male 
   Female 
 
Number of dependants 
   0 
   1-2 
   3 or more 
= 0.005 
 
 
 
=0.039 
 
1 
2.8 (1.4-6.9) 
 
 
1 
1 
4.0 (1.1-14.5) 
Nausea D 0 Age (continuous) = 0.011 0.91 (0.85-0.98) 
Summary Pain D 0 Gender 
   Male 
   Female 
= 0.018 
 
 
 
1 
2.5 (1.2-5.5) 
Bruising D 2-3 BMI (continuous) 
 
Central line 
   Yes 
   No 
0.006 
 
= 0.007 
 
 
1.1 (1.03-1.2) 
 
 
7.0 (1.7-29.2) 
1 
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Second day collection 
   Yes 
   No 
 
< 0.002 
 
 
 
4.1 (2.0-8.3) 
1 
Headache D 2-3 BMI (continuous) = 0.026  1.1 (1.02-1.3) 
Bruising 1 week Central line 
   Yes 
   No 
= 0.027  
9.2 (1.3-65.3) 
1 
All time points 
fatigue  
Gender (F/M) 
   Male 
   Female 
 
Age (continuous) 
= 0.028 
 
 
 
= 0.018 
 
1 
1.9 (1.07-3.5) 
 
1.04 (1.01-1.07) 
All time points 
bruising  
Central line 
   Yes 
   No 
 
Second day collection 
   Yes 
   No 
= 0.002 
 
 
 
= 0.005  
                       
 
26.7 (3.4-208.2) 
1 
 
 
2.3 (1.3-4.1) 
1 
All time points 
bleeding 
Central line 
   Yes 
   No 
= 0.004  
43.6 (3.3-572.6) 
1 
All time points 
headache 
Number of dependants 
   0 
   1-2 
   3 or more 
= 0.052 
 
 
 
1 
1 
3.1 (0.99-9.5) 
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Table 4. 7  Multivariate analysis of factors influencing the occurrence of any adverse 
reaction at D0 or D2-3 following donation. Factors taken into account include age, gender, 
BMI, being a blood donor, number of dependants, presence of a central line, number of days 
of collection and pre-harvest white cell count. 
Outcome: 
Symptom and time 
point  
Factor p-value OR (95% CI) 
Summary all adverse 
reactions D 0 
Gender  
   Male 
   Female 
= 0.018 
 
 
 
1 
2.8 (1.1-7.3) 
Summary all adverse 
reactions D 2-3 
Gender  
   Male 
   Female 
 
BMI (continuous) 
= 0.041 
 
 
 
= 0.067 
 
1 
2.2 (1.03-4.5) 
 
1.06 (0.97-1.1) 
 
4.3.3.1.1 Gender 
Women had an odds ratio of experiencing fatigue of 1.9 (95% CI 1.07-3.5; p = 0.028) 
at all time points compared to men. Experiencing any type of pain (including back 
pain, headache, myalgia or other pain) on the day of donation was also associated 
with female gender with an odds ratio of 2.5 (95% CI 1.2, 5.5; p = 0.018). Women 
were even more likely to experience any adverse reaction on the day of donation 
compared to men (OR 2.8, 95% CI 1.1, 7.3; p = 0.018) and on day 2-3 following 
donation (OR 2.2, 95% CI 1.03, 4.5; p = 0.041). They were also more likely to 
experience bleeding symptoms at all time points (p = 0.047) in univariate analysis, 
but this lost significance in multivariate analysis, when taking the presence of a central 
line into account.  
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4.3.3.1.2 Age 
Younger age was the only factor significantly associated with nausea on day 0 (p = 
0.011) with younger donors being more likely to experience nausea. Fatigue at any 
time point was also associated with age (p = 0.018); donors aged > 40 had on odds 
ratio of experiencing fatigue of 1.9 (95% CI 1.02-3.5) compared to donors aged ≤ 40. 
 
4.3.3.1.3 BMI 
Donors with a higher BMI were more likely to experience headache following donation 
(p = 0.026).   
 
4.3.3.1.4 Number of dependants 
Headache on the day of donation or at any time point was associated with the number 
of dependants. Donors who had 3 or more dependants had an odds ratio of 4 of 
experiencing headache (95% CI 1.1-14.5; p-value 0.039) on the day of donation 
compared to donors with less than 3 dependants.  
 
4.3.3.1.5 Presence of central line 
A central line was inserted in 5% of PBSC donors. The insertion of a central line was 
associated with bruising (OR 26.7, 95% CI 3.4-208.2; p = 0.002) and bleeding 
symptoms (OR 43.6, 95% CI 3.3-572.6; p = 0.004) at any time point.  
 
4.3.3.2 BM donors 
Table S3 appendix 1 displays the univariate analysis of demographic and collection 
characteristics associated with individual adverse reactions. Factors taken into 
account for the multivariate analysis include age, gender, BMI, being a blood donor, 
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number of dependants, duration of the procedure and volume of BM harvested per 
kg donor weight. 
 
4.3.3.2.1 Age 
Younger age was the only factor associated with symptoms of vomiting at any time 
point (p < 0.001). Younger age was also associated with increased symptoms of 
anorexia following donation (p < 0.001), but this lost significance in multivariate 
analysis (p = 0.31).  
 
4.3.3.2.2 Number of dependants 
A higher number of dependants was associated with myalgia (p = 0.002) at any time 
point following donation in univariate analysis, but this lost significance in multivariate 
analysis (p = 0.99).  
 
4.3.3.2.3 Volume BM harvested per kg donor weight 
A larger volume harvested per kg donor weight was associated with anorexia at any 
time point (p = 0.003) and this remained borderline significant in multivariate analysis 
(p = 0.069). 
A larger volume harvested per kg donor weight was associated (p = 0.03) with 
symptoms of bruising at any time point in univariate analysis, but this lost significance 
in mulitivariate analysis (p = 0.19). 
 
4.3.3.2.4 Duration of procedure 
A longer duration of the procedure was the only factor associated with fatigue 
following donation in univariate analysis (p = 0.013). 
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4.4 Discussion 
This chapter prospectively assesses the donation experience in AN donors and 
defines groups at increased risk of poorer donation experiences, based on donor 
demographic factors and collection characteristics. To allow for a more detailed 
understanding of the donation experience, I introduced comprehensive data tools into 
our register. These tools include assessments modelled on key toxicities donors 
regularly experience and their CTCAE grading. Assessments took place on the first 
3 days of G-CSF administration, the day of donation, 2-3 days following donation and 
weekly until complete recovery. Nearly 100% of the day of donation assessments 
were obtained, as well as > 85% of assessments of day 2-3 and weekly assessments. 
Complete recovery was determined on the day 2-3 or weekly questionnaire and 
defined as the absence of ongoing symptoms as well as return to pre-donation health 
(self-reported). 
 
This study found that the majority of both PBSC and BM donors reported ARs, 
however ARs were mainly classified as mild and the incidence  was consistent with 
those previously described by other centres (Karlsson et al., 2004, de la Rubia et al., 
2008, Pulsipher et al., 2013, Pulsipher et al., 2009b, Murata et al., 1999, Chen et al., 
2011, Miller et al., 2008, Holig et al., 2009, Fortanier et al., 2002, Martino et al., 2009, 
Gandini et al., 2001, Nishimori et al., 2002, Favre et al., 2003, Stroncek et al., 1993). 
I found that 5% of donors required the insertion of a central line, this is in accordance 
with the experiences from most other centres (Pulsipher et al., 2013, Anderlini et al., 
1999), although some centres have reported lower (Leitner et al., 2009, Holig et al., 
2009) or higher (Miller et al., 2008) rates. Our policy allows for central venous lines to 
be placed in the donor if blood flow from the standard peripheral venous line is not 
adequate. The placements of central lines are one of the leading causes of SARs and 
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should generally be discouraged. One study reported that 5 of the 39 SARs were 
complications from central line placements (Miller et al., 2008). In addition, one 
unrelated donor death reported to the WMDA was caused by a traumatic jugular vein 
catheter insertion (Shaw et al., 2013). No SARs were related to the insertion of central 
lines in this cohort. We did not consistently document data on the position of central 
lines. Women were much more likely to require a central line, this was also observed 
in a previous study (Pulsipher et al., 2013) and may be explained by their smaller 
body sizes and smaller veins compared to men. 
 
The peak of discomfort was on the third day of G-CSF for PBSC donors and on day 
2-3 following collection for BM donors, these results are similar to data from a large 
prospective NMDP trial (Pulsipher et al., 2013). The majority of ARs were CTCAE 
grade 1, this is also consistent with previous reports (Pulsipher et al., 2013). Our 
register did not document adverse reactions on the 4th day of G-CSF and the 
incidence of ARs may have been even higher on this day. BM and PBSC donors 
experienced approximately the same levels of pain on their peak day of discomfort. 
However, a significant number of BM donors still experienced pain 1 week following 
donation and BM donors recovered significantly slower compared to PBSC donors 
(14.3 versus 5.2 days). This is in keeping with previous reports (Pulsipher et al., 2013, 
Favre et al., 2003, Heldal et al., 2002, Bredeson et al., 2004, Siddiq et al., 2009). All 
donors recovered fully after some period of time and the longest time to self-reported 
recovery was 56 days for a BM donor. 
 
0.9% of PBSC donors experienced a SAR, this again is similar to published reports 
(Pulsipher et al., 2014, de la Rubia et al., 2008, Pulsipher et al., 2009b, Miller et al., 
2008, Holig et al., 2009). No BM donor experienced a SAR.  
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There were no PBSC collection characteristics that influenced the time to complete 
recovery. The only donor factor that influenced recovery time in multivariate analysis 
for PBSC donors was donor age, with donors > 40 recovering significantly slower. 
Older age was also associated with increased symptoms of fatigue following 
donation. This has been previously reported (Yuan et al., 2010, Pulsipher et al., 
2013). Our BM cohort was too small to obtain any statistically significant results when 
examining the relationship between the different characteristics and recovery, but 
female gender and having a higher number of dependants appeared to be associated 
with a slower recovery. Our BM cohort was also too small to assess the influence of 
the different characteristics on individual adverse reactions in multivariate analysis. 
 
Female PBSC donors were more likely to experience any adverse reaction, in 
particular pain and fatigue. This has also been previously reported (Martino et al., 
2009), Pulsipher et al., 2013, Pulsipher et al., 2009b, Murata et al., 1999, Chen et al., 
2011, Stroncek et al., 1996). The explanation for these findings is likely multifactorial. 
Higher pain scores in a number of conditions in women have been described in 
research in other medical specialties (Ruau et al., 2012). This may signify a gender 
difference in pain experience (Ruau et al., 2012) and physical performance (Taenzer 
et al., 2000). In addition, women have been found to experience more drug side 
effects, this may be explained by hormonal, immunological and pharmacokinetic 
differences (Rademaker, 2001). Yuan et al stated that a smaller total blood volume in 
women may partially explain the increased incidence of citrate toxicity (Yuan et al., 
2010). Despite the increased risk of adverse reactions, gender was not significantly 
associated with recovery in PBSC donors in the multivariate analysis.  
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Donors with a higher BMI were more likely to experience headache following PBSC 
donation. This may be a result of relatively higher doses of G-CSF received in this 
group (Chen et al., 2011) since extracellular fluid and haematopoietic mass do not 
increase in direct proportion to BMI. The headache was mainly classified as grade I. 
I did not find an increase in other adverse reactions, as opposed to some other studies 
(Pulsipher et al., 2009b, Pulsipher et al., 2013). This finding is reassuring, given that 
more and more registries allow heavier donors to donate, including our register and 
donors with BMIs up to 40 were included in this cohort.  
 
My data did not show a negative relationship between pre-harvest white blood cell 
count and recovery or adverse reactions. This is in keeping with current advice stating 
that there is no indication for monitoring white cell counts during administration of G-
CSF, as no conclusive evidence of a link between baseline haematology results and 
ARs exists (Chen et al., 2011, Pulsipher et al., 2013). Donors who are found to be at 
unacceptably high risk of adverse reactions are generally excluded from donation. 
For example the knowledge that G-CSF can cause exacerbations of auto-immune 
disease (Pamphilon et al., 2008) has led to stricter eligibility criteria concerning auto-
immune diseases within many stem cell registries. Selection criteria could be altered 
in the future based on the awareness that certain donors are at increased risk of 
adverse reactions. Some registers have already started to concentrate on the 
recruitment of male donors. Although this is often driven by increased availability and 
stem cell yields amongst males and a decreased incidence of graft-versus-host 
disease (Spierings et al., 2013) in the recipient, it may also result in fewer ARs (Ings 
et al., 2006, Vasu et al., 2008, Platzbecker et al., 2005, Miflin et al., 1996) in the donor. 
On the other hand, restricting the recruitment to male donors may influence the 
numbers of donors on the register and consequently availability of HSCs and the 
overall HLA repertoire. Similarly, the finding that older donors (40 years was the cut-
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point found in my study) are at a higher risk of a delayed recovery and experiencing 
SARs, could further enhance the trend towards recruiting younger donors. 
Additionally, younger donors are less likely to have dependants, and this was found 
to be a risk factor for headache following donation. The practice of registries recruiting 
younger donors is currently mainly driven by the finding that transplant outcomes are 
improved when using these donors (Kroger et al., 2013, Ayuk et al., 2013, Kollman et 
al., 2001), but has clear additional advantages. Some studies have shown that donors 
who are overweight (BMI > 25) or obese (BMI > 30) experience more bone pain 
(Pulsipher et al., 2013, Chen et al., 2014). Given that several studies have reported 
a positive correlation between donor weight and stem cell yields (Anderlini et al., 
1997, Martino et al., 2006), restricting recruitment to “lighter” donors would carry an 
inherent conflict. However, both my data and the studies mentioned above show that 
these adverse reactions are mainly graded I, meaning they are mild. Based on this, 
accepting donors with higher BMIs may be acceptable practice as long as these 
donors are well informed. Giving a lower dose of G-CSF to overweight donors or 
calculating the dose based on ideal body weight, could also be considered. Further 
research will have to establish whether this practice provides sufficient HSCs. 
 
The management of donors’ expectations is important, especially in donors at 
increased risk of adverse reactions. PBSC donors at higher risk such as overweight, 
female or older donors must be made aware of this at the time of their medical 
assessment and pre-operative patient education has demonstrated improved 
recovery times in surgery (Ibrahim et al., 2013, GTA, 2005). It may be that improved 
pre-donation education regarding symptom anticipation and management would 
reduce anxiety and improve the overall donation experience. Other possible 
interventions for high risk donors may include the use of pre-emptive analgesia, an 
approach that has proven to be effective in BM donors (Chern et al., 1999) and 
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general surgery patients (Mardani-Kivi et al., 2013, Duellman et al., 2009). This is a 
strategy overweight PBSC donors may benefit from. In addition, a more stringent 
short-term follow-up could be considered in donors who are at increased risk to allow 
early intervention. This may for example involve regular phone calls following 
donation.  
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 Chapter 5. A prospective study to investigate the predictors 
of the donation experience in unrelated haematopoietic stem 
cell donors: Part II 
A paper based on the findings of the study was published in the journal of Biology of 
Blood and Marrow Transplantation in February 2015 entitled “Pre-donation health 
related quality of life scores predict time to recovery in haematopoietic stem cell 
donors” (See Appendix 3) 
 
5.1 Introduction 
The previous chapter identified several donor characteristics such as gender and age 
that can influence donor recovery and adverse reactions. Part II of my prospective 
study will focus on the influence of baseline health related quality of life (HRQOL), 
including physical and mental health on the donation experience. Research in 
orthopedic surgery has shown a significant relationship between pre-operative 
HRQOL and recovery (Browne et al., 2014, Gong and Dong, 2014). Specifically, 
negative mood was shown to exacerbate pain. Given that pain is the most common 
side-effect in the peri-donation period, investigation into the relationship between pre-
donation HRQOL and recovery may also be relevant in the haematopoietic stem cell 
donation setting.  
 
I describe the role of pre-donation HRQOL scores, using the SF-36 form, and 
determine whether HRQOL scores could be used in addition to, or even replace, 
donor or collection characteristics in determining the donation risk. I will also explore 
the option of risk-stratifying donors and will prepare a proposal for a tailored approach 
for donors in different risk groups.  
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In addition, I will describe the changes in HRQOL, using the SF-36 form, following 
donation by examining the evolution of HRQOL scores at baseline, 4 weeks and 3 
months following donation and compare the scores between PBSC and BM donors. 
This chapter will also aim to identify factors that may influence long-term physical or 
emotional health following donation.  
 
5.2 Materials and methods 
The full material and method can be found in chapter 2 (section 2.4). In brief, the SF-
36 questionnaire measures the following 8 dimensions: physical functioning (PF), role 
limitations due to physical health problems (RP), bodily pain (BP), general health 
perception (GH), vitality (VT), social functioning (SF), role limitations due to emotional 
problems (RE) and general mental health (MH). The Physical Component Summary 
(PCS) and Mental Component Summary (MCS) scores provide a broad physical and 
mental health perspective (Ware, 2008). Norm based scoring was used to interpret 
the different dimensions’ and summary scores (Ware, 2008). This scoring is created 
by computing the 0-100 score for a scale and then adjusting this score by the general 
population’s average and standard deviation on that scale.  As a consequence, the 
population mean and standard deviation of all scores are 50 and 10 respectively with 
higher scores reflecting more positive health states. 
 
5.3 Results 
5.3.1 HRQOL forms 
The response rates for the SF-36 questionnaires for PBSC donors were 72% 
(198/275) before donation, 72% (199/275) 4 weeks after and 72% (198/275) 3 months 
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after donation. Fifty-eight percent of PBSC donors returned all three questionnaires. 
16/275 donors were not provided with SF-36 forms as they had not provided verbal 
consent. 14/16 were not contactable; they did not respond to at least three telephone 
calls or at least one e-mail. The remaining two donors did not provide verbal consent, 
as they stated they were not interested in the study. The remaining non returned 
forms were from donors who had consented to participate in the study but who didn’t 
return the questionnaire, despite reminders. Donors not returning the forms were 
more likely to be younger (p < 0.001) and male (p < 0.05) (table 5.1). There was no 
statistical difference between collection characteristics in those returning compared 
to not returning forms (table 5.1).  
 
Table 5. 1 Demographic and collection characteristics in respondents and non-respondents 
(PBSC) 
Measurement Age 
(years) 
Mean 
(range) 
Gender 
(% 
male) 
Total 
volume of 
blood 
processed 
(range) 
Donors with a 
2 day 
collection (% 
of total) 
Presen
ce of a 
central 
line 
(%) 
Baseline       
Respondents 
(n = 198) 
34.1 (17-
60) 
73% 14.2 (1.5-32) 27% 5.5% 
Non 
respondents (n 
= 77) 
30.6 (20-
63) 
86% 14.8 (1.3-30.6) 27% 4% 
p-value < 0.005 < 0.05 0.39 0.99 0.77 
4 weeks 
following 
donation 
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Respondents 
(n = 198) 
34.6 (17-
63) 
72% 14.1 (1.5-32) 28% 5% 
Non 
respondents (n 
= 77) 
29.4 (20-
50) 
88% 15.0 (1.3-30.6) 25% 5% 
p-value < 0.001 < 0.005 0.24 0.65 0.99 
3 months 
following 
donation 
  
Respondents 
(n = 197) 
34.6 (17-
63) 
72% 14.5 (1.3-32) 30% 5.5% 
Non 
respondents (n 
= 78) 
30.1 (20-
50) 
85% 14.3 (8.7-27.2) 21% 4% 
p-value < 0.001 < 0.05 0.77 0.11 0.78 
All 3 
questionnaires 
  
Respondents 
(n = 157) 
34.7 (17-
60) 
71% 14.3 (1.5-32) 29% 5% 
Non 
respondents (n 
= 118) 
31.0 (20-
63) 
83% 14.5 (1.3-30.6) 25% 5% 
p-value < 0.001 < 0.05 0.72 0.49 0.99 
 
The response rates for the questionnaires for BM donors were 75% (28/37) before 
donation, 59.5% (22/37) 4 weeks after donation and 67.6% (25/37) 3 months after 
donation. Forty-nine percent (18/37) of BM donors returned all three questionnaires. 
Only 1 out of 37 donors did not provide verbal consent, as he stated that he was too 
busy to participate in the study. There were no statistical differences in demographic 
and collection characteristics in those returning vs. not returning forms (table 5.2).  
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Table 5. 2 Demographic and collection characteristics in respondents and non-respondents 
(BM) 
Measurement Age (years) 
Mean 
(range) 
Gender 
(% 
male) 
Duration of BM 
harvest (min) 
Mean (range) 
Marrow 
harvested per 
unit of 
donor’s 
weight (ml/kg) 
Mean (range) 
Baseline      
Respondents (n = 
28) 
32.1 (19-55) 89.7% 42.5 (20-120) 14.6 (3.9-23.0) 
Non respondents (n 
= 9) 
31.1 (22-46) 88.9% 35 (30-45) 14.7 (7.7-22.1) 
p-value 0.79 0.95 0.46 0.93 
4 weeks following 
donation 
    
Respondents (n = 
22) 
31.3 (19-55) 86.4% 39.5 (20-100) 15.3 (4.2-23.0) 
Non respondents (n 
= 15) 
32.6 (22-47) 93.8% 31.8 (25-120) 13.6 (3.9-20.3) 
p-value 0.71 0.62 0.80 0.24 
3 months following 
donation 
 
Respondents (n = 
25) 
32.0 (19-55) 92% 44.2 (20-120) 14.1 (4.2-22.0) 
Non respondents (n 
= 12) 
31.6 (22-46) 84.6% 33.3 (25-40) 13.8 (3.9-22.1) 
p-value 0.90 0.60 0.25 0.38 
  Chapter 5 – HRQOL and the donation 
experience  
146 
 
All 3 questionnaires  
Respondents (n = 
18) 
32.9 (19-55) 90% 39.8 (20-100) 14.9 (4.2-22.0) 
Non respondents (n 
= 19) 
30.9 (22-47) 88.9% 31.2 (25-120) 14.3 (3.9-22.1) 
p-value 0.56 0.99 0.88 0.65 
 
5.3.2 Baseline HRQOL scores predicting time to complete recovery 
5.3.2.1 PBSC donors 
Donors with a higher baseline physical component summary (PCS) score were more 
likely to recover more rapidly (p = 0.002) (table 5.3, figure 5.1). When assessing the 
individual components of the physical component summary, higher physical 
functioning (PF) (p < 0.01), less role limitations due to physical health problems (RP) 
(p < 0.05) and lower bodily pain (BP) (p = 0.005) were associated with a more rapid 
recovery. Baseline mental component summary score (p = 0.29) was not significantly 
associated with time to recovery.  
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Table 5. 3 Univariate analysis of factors influencing time to recovery following PBSC 
donation. Time to complete recovery documented for 266 donors (missing data n = 9). 
Factors (n) Time to complete recovery 
(days)  
Mean (range)  
p-value 
PCS 
≤ 56 (49/266) 
56-58 (43/266) 
58-60 (57/266) 
> 60 (43/266) 
Missing PCS data 
(74/266) 
 
5.8 (0-30) 
4.3 (0-35) 
3 (0-28) 
3 (0-21) 
= 0.002 
 
 
Figure 5. 1 Physical component summary score predicts probability of self-reported 
complete recovery after PBSC donation 
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When I repeated the multivariate analysis considering the PCS and donor 
demographic factors (described in chapter 4), baseline PCS score and age remained 
significant (table 5.4), while gender lost its significance.  
 
Table 5. 4 Multivariate analysis of factors influencing time to recovery following PBSC 
donation (age and PCS as continuous variables) 
Factor p-value HR (95% CI) 
PCS (continuous) = 0.013 1.057 (1.01-1.1) 
Age (continuous) = 0.026 0.98 (0.97-0.99) 
Gender 
   Male 
   Female 
= 0.26  
1.2 (0.87-1.7) 
1 
 
Donors with a baseline PCS higher than 56 had a 50% higher probability of faster 
recovery compared to donors with scores lower or equal to 56 (lowest quartile) (HR 
1.5; 95% CI 1.06-2.06; p = 0.023). Donors aged less or equal to 40 had a 50% higher 
probability of faster recovery compared to donors over 40 (HR 1.5; 95% CI 1.06-2.06; 
p = 0.023). 
 
5.3.2.2 BM donors 
The only factor influencing time to recovery was the baseline mental component 
summary (MCS) score (p = 0.046); donors with higher scores were more likely to 
recover more rapidly (table 5.5, figure 5.2). There was a borderline significant 
association between physical component summary score (p = 0.077) and time to 
recovery.  
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Table 5. 5 Univariate analysis of factors influencing time to recovery following BM donation 
Factors (n) Time to complete 
recovery (days) 
Mean (range) 
p - value 
MCS 
≤ 46 (7/28) 
46 – 53 (7/28) 
53 – 58 (9/28) 
> 58 (5/28) 
Missing MCS data (n = 9) 
 
28 (4-56) 
13.7 (6-28) 
10 (2-21) 
9.4 (2-21) 
p = 0.046 
 
Figure 5. 2 Mental component summary score predicts probability of self-reported complete 
recovery after BM donation 
 
 
As mentioned in 4.3.2.2, no demographic or collection characteristics were 
significantly associated with recovery. In multivariate analysis, donors with baseline 
MCS scores higher than 46 had a 3.8 times higher probability of faster recovery 
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compared to donors with scores lower or equal to 46 (lowest quartile) (HR 3.7; 95% 
CI 1.2-11.7; p = 0.011) (table 5.6). 
 
Table 5. 6 Multivariate analysis of factors influencing time to recovery following BM donation 
using MCS as a continuous or categorical variable 
Factor p-value HR (95% CI) 
MCS (continuous) p = 0.035 1.07 (1.005-1.15) 
MCS (categorical) 
   ≤ 46 
   >46 
p = 0.011  
1 
3.8 (1.2-11.7) 
 
5.3.3 Baseline HRQOL scores predicting adverse reactions 
5.3.3.1 PBSC donors 
Tables S1 and S2 appendix 1 show the univariate analysis of factors influencing 
adverse reactions at different time points following PBSC donation. All time points are 
defined as the day of donation (D 0), 2-3 days after donation (D2-3) and weekly after 
donation up until full recovery. Table 5.7 displays the multivariate analysis. All factors 
with a p-value ≤ .0.20 in the univariate analysis were included in the multivariate 
stepwise logistic regression analysis. Only factors that remained significant (or 
borderline significant) in the multivariate analysis are shown. 
 
5.3.3.1.1 PCS score 
Donors with pre-donation SF-36 PCS scores in the lowest quartile were more likely 
to experience fatigue (OR 4.7, 95% CI 1.8-12.7; p = 0.002) on day 2-3 following 
donation or at any time point following donation (OR 2.9, 95% CI 1.2-7.1; p = 0.016) 
compared to donors with PCS scores in the highest quartile. 
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The baseline PCS score was also associated with dizziness at any time point 
following donation. Donors with a baseline PCS score below or equal to the median 
had an odds ratio of 2.9 (95% CI 1.2, 7.2; p = 0.016) compared to donors with a score 
above the median. 
 
Lower baseline PCS scores was associated with experiencing any type of pain at any 
time. Donors with baseline PCS scores in the lowest quartile had an odds ratio of 5.6 
(95% CI 1.8, 17.6; p = 0.011) of experiencing pain compared to donors with baseline 
PCS scores in the highest quartile.  
 
Donors with pre-donation SF-36 PCS scores in the lowest quartile were more likely 
to experience any adverse reaction (OR 3.0, 95% CI 1.1-8.5; p = 0.008) on day 2-3 
following donation compared to donors with PCS scores in the highest quartile. 
 
5.3.3.1. 2 MCS score 
Donors with a pre-donation MCS score in the lowest quartile were more likely to 
experience pain at any time point compared to donors with scores in the highest 
quartile (OR 2.8, 95% CI 1.1-7.1; p = 0.027).  
 
5.3.3.1.3 Gender 
Experiencing any type of pain (including back pain, headache, myalgia or other pain) 
on the day of donation was associated with female gender with an odds ratio of 2.5 
(95% CI 1.2-5.2; p = 0.012)  
 
5.3.3.1.4 Age 
Fatigue at any time point was associated with higher age (p = 0.034).  
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Table 5. 7 Multivariate analysis of factors influencing adverse reactions at different time 
points following PBSC donation. All time points are defined as the day of donation (D 0), 2-3 
days after donation (D2-3) and weekly after donation up until full recovery. Factors taken into 
account include PCS, MCS, age, gender, BMI, being a blood donor, number of dependants 
and marital status. 
Outcome: 
Symptom and 
time point  
Factor p-value OR (95% CI) 
Back pain D0 MCS (continuous) = 0.037 0.89 (0.81-0.99) 
Dizziness D0 PCS (continuous) = 0.005 0.79 (0.67-0.93) 
Headache D0 MCS (continuous) 
 
Gender 
   Male 
   Female 
 
Number of dependants 
   0 
   1-2 
   3 or more 
= 0.06 
 
= 0.024 
 
 
 
= 0.04 
0.93 (0.86-1.003) 
 
 
1 
2.8 (1.1-6.7) 
 
 
1 
1 
5.0 (1.1-22.9) 
Myalgia D0 PCS (continuous) = 0.05 0.91 (0.83-1.0) 
Summary pain 
D0 
MCS (continuous) 
 
Gender 
   Male 
   Female 
= 0.03 
 
= 0.012 
0.93 (0.87-0.99) 
 
 
1 
2.5 (1.2-5.2) 
Dizziness D2-
3  
PCS (continuous) = 0.059 0.88 (0.76-1.005) 
Fatigue D2-3 PCS (continuous) 
 
= 0.002 
 
0.85 (0.76-0.94) 
 
1.06 (1.02-1.1) 
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Age (continuous) = 0.001 
Myalgia D 2-3 PCS (continuous) = 0.029 0.89 (0.81-0.98) 
Summary pain 
D 2-3 
PCS (continuous) = 0.008 0.88 (0.79-0.97) 
Summary all 
adverse 
reactions D 2-
3 
PCS (continuous) = 0.008 0.83 (0.72-0.95) 
Back pain 1 
week 
PCS (continuous) = 0.039 0.8 (0.64-0.99) 
Fatigue 1 
week 
PCS (continuous) = 0.041 0.87 (0.76-0.99) 
Summary all 
adverse 
reactions 1 
week 
PCS (continuous) = 0.033 0.88 (0.78-0.99) 
All time points 
fatigue 
PCS (continuous) 
 
Age (continuous) 
= 0.016 
 
= 0.034 
0.89 (0.81-0.98) 
 
1.04 (1.003, 1.07) 
All time points 
dizziness 
PCS (continuous) 
MCS (continuous) 
= 0.016 
= 0.059 
0.84 (0.73-0.96) 
0.91 (0.84-1.003) 
All time points 
myalgia 
PCS (continuous) 
 
= 0.009 0.87 (0.78-0.96) 
All time points 
pain 
PCS (continuous) 
MCS (continuous) 
= 0.011 
= 0.027 
0.88 (0.79-0.97) 
0.92 (0.86-0.99) 
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5.3.3.2 BM donors 
Tables S3 and S4 appendix 1 display the univariate analysis of demographic and 
collection characteristics associated with individual adverse reactions. Factors taken 
into account for the multivariate analysis include age, gender, BMI, being a blood 
donor, number of dependants, duration of the procedure, volume of BM harvested 
per kg donor weight, PCS and MCS score. 
 
5.3.3.2.1 PCS score 
A lower PCS score was associated with increased symptoms of anorexia following 
donation (p = 0.028), but this lost significance in multivariate analysis (p = 0.12).  
 
5.3.4 Changes in SF-36 score from pre-donation, through 4 weeks and 3 months 
post-donation 
As shown in Table 5.8,  PCS scores declined significantly from pre-donation to  4 
weeks post-donation (p < 0.001), with a return to pre-donation values at 3 months. 
This was shown both for PBSC and BM donors, but the decline in PCS scores was 
much greater for BM donors (table 5.9).  At 4 weeks following donation, the PF (p = 
0.001), RP (p < 0.001) and BP (p = 0.002) subscores were worse for BM donors 
compared to PBSC donors. Mental summary score did not change throughout 
donation for PBSC donors, but was significantly lower at 4 weeks for BM donors (p < 
0.01); this returned to normal levels at 3 months. 
 
The most significant subscore change in PBSC donors was for RP score with a mean 
difference  between 4 week score and pre-donation of – 1.6 (p < 0.001). When 
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assessing the individual subscore changes in BM donors, the most significant 
decrease between pre-donation and 4 weeks within the physical scores, was for RP 
(mean -7.8; p = 0.004), followed by BP (mean – 5.8; p = 0.021) and PF (mean -1.5; p 
= 0.049). The most significant decrease between pre-donation and 4 weeks within 
the mental scoring (BM donors), was for VT (vitality) scores with a mean decrease of 
8.1 on the norm based vitality score (p < 0.001), followed by SF (social functioning) 
component (mean – 6.0; p = 0.001). There were no changes in general health 
perception (GH) (p = 0.27), role limitations due to emotional problems (RE) (p =0.074) 
or mental health (MH) score (p = 0.42). 
 
Table 5. 8 Changes in pre-donation and post-donation scores 
Type of 
donation 
Scoring 
type 
Mean of 
difference 
between score at 
4 weeks and 
baseline (range) 
p-value Mean of 
difference 
between 
score at 3 
months and 
baseline 
(range) 
p-value 
PBSC PCS - 0.92 (-14.9, 13.2) < 0.0011 0.009 (-12.5, 
16.0) 
0.982 
MCS - 0.2 (- 26.3, 29.5) 0.641 -0.1 (-19.5, 21.2) 0.792 
BM PCS -5.02 (-18.4, 8.6) = 0.0093 - 0.3 (-12.2, 9.6) 0.714 
MCS -3.9 (-28.5, 9.5) = 0.0173 -1.2 (-21.0, 7.4) 0.374 
1calculated comparing pairs with pre and 4 week scores (n = 169) 
2calculated comparing pairs with pre and 3 month scores (n = 151) 
3calculated comparing pairs with pre and 4 week scores  (n = 18) 
4calculated comparing pairs with pre and 3 month scores (n = 23) 
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Table 5. 9 Differences in HRQOL scores between BM and PBSC donors 
Time point Dimension BM 
Mean  
PBSC 
Mean  
p-value 
Pre 
donation 
Physical functioning 56.0 56.8 0.13 
Role limitation due to physical 
health problems 
56.7 56.5 0.61 
Bodily pain 58.4 57.0 0.28 
General health perception 56.7 57.8 0.42 
Vitality 54.2 55.5 0.42 
Social functioning 54.6 55.9 0.11 
Role limitations due to 
emotional problems 
52.8 54.8 0.07 
General mental health 52.6 54.6 0.08 
PCS 58.3 57.5 0.29 
MCS 52.0 54.1 0.24 
4 weeks 
after 
donation 
Physical functioning 47.0 52.9 0.001 
Role limitation due to physical 
health problems 
41.9 50.9 < 0.001 
Bodily pain 44.1 53.1 < 0.005 
General health perception 48.5 53.6 0.14 
Vitality 42.4 51.2 < 0.05 
Social functioning 42.5 51.8 0.001 
Role limitations due to 
emotional problems 
43.1 51.4 < 0.01 
General mental health 45.0 51.2 0.32 
PCS 45.1 51.8 < 0.005 
MCS 42.4 49.1 0.34 
3 months 
after 
donation 
Physical functioning 56.1 56.2 0.90 
Role limitation due to physical 
health problems 
56.7 56.0 0.27 
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Bodily pain 58.2 58.3 0.93 
General health perception 58.2 57.2 0.57 
Vitality 55.9 54.8 0.55 
Social functioning 54.1 54.7 0.74 
Role limitations due to 
emotional problems 
53.0 54.8 0.12 
General mental health 54.1 54.1 0.98 
PCS 58.2 57.8 0.64 
MCS 52.6 53.6 0.47 
 
5.3.5 Factors predicting physical and emotional health 4 weeks following PBSC 
donation  
Based on the finding that HRQOL is significantly affected 4 weeks following donation, 
I aimed to clarify whether I could establish predictive factors for PCS and MCS scores 
4 weeks following donation using multivariate linear regression analysis. I found that 
there were no demographic factors predictive of HRQOL following donation. Only a 
lower pre-donation PCS and experiencing any kind of pain 2-3 days following 
donation were associated with lower PCS outcomes at 4 weeks in PBSC donors 
(Table 5.10).  
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Table 5. 10 Associations between pre-donation demographics and donation related 
problems on day 2-3 following PBSC donation and PCS scores at 4 weeks 
Explanatory 
variablea 
Coefficient 
(beta) 
p-value 95% CI 
Pre-donation 
PCS score 
0.64 < 0.001 0.44, 0.84 
Any pain on day 
2-3 
-1.721 = 0.03 -3.2, -0.2 
a: Explanatory variables included gender, age, BMI, number of dependents, marital status, 
being a blood donor, pre-donation PCS score, any side-effect on day 2-3 summary score 
and any pain on day 2-3. 
 
Similarly, a lower pre-donation MCS score and experiencing any kind of pain 2-3 days 
following donation were associated with lower MCS outcomes at 4 weeks (Table 
5.11).  
 
Table 5. 11 Associations between pre-donation demographics and donation related 
problems on day 2-3 following PBSC donation and MCS scores at 4 weeks 
Explanatory 
variableb 
Coefficient 
(beta) 
p-value 95% CI 
Pre-donation 
MCS score 
0.71 < 0.001 0.53, 0.87 
Any pain on day 
2-3 
-2.2 = 0.01 - 4.3, - 0.18 
b: Explanatory variables included gender, age, BMI, number of dependents, marital status, 
being a blood donor, pre-donation MCS score, any side-effect on D2-3 summary score and 
any pain on D2-3. 
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5.4 Discussion 
In this prospective study, I found that pre-donation HRQOL markers were important 
factors associated with recovery and the development of adverse reactions in 
unrelated donors. Certain demographic factors such as age and gender also 
remained significantly associated with recovery and/or adverse reactions when taking 
HRQOL into account. To my knowledge, there have been no studies addressing the 
influence of pre-donation HRQOL on recovery and adverse reactions in HSC donors. 
The importance of both pre-donation general physical well-being (measured with the 
PCS subscore) and mental wellbeing (MCS) in determining recovery and adverse 
events was demonstrated with quartiles providing cut-points as splitting into quartiles 
allows for an simpler interpretation of odds or hazard ratios. If treated as continuous 
variables, significant results were also obtained. A lower pre-donation PCS score and 
higher donor age were the main factors associated with delayed recovery for PBSC 
donors in multivariate analysis. Three scales (physical functioning, role limitations due 
to physical health problems and bodily pain) correlate most strongly with the physical 
component and contribute most to scoring of the PCS measure.  Lower PCS scores 
indicate more limitations in physical functioning, role participation due to physical 
problems, a higher degree of bodily pain and a poorer self-reported general health. 
Interestingly, mean pre-donation PCS scores were well above the mean of the 
general population (+ 0.76 SD; p < 0.001), reflecting the strict medical assessment of 
donors. Examples of reasons for lower pre-donation PCS scores in this cohort 
included mild limitations to perform work or vigorous activities or having a history of 
mild or moderate bodily pains. Despite these mild limitations, lower pre-donation PCS 
scores were associated with a slower recovery. Experiencing very common adverse 
reactions, such as pain, fatigue and dizziness were also associated with a lower pre-
donation PCS score.  
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Lower pre-donation MCS scores were associated with an increased likelihood of 
experiencing pain in PBSC donors. Similar to the PCS scores, mean pre-donation 
MCS scores were above the mean of the general population (+ 0.41 SD; p < 0.001). 
For the MCS measure, a lower score is indicative of more frequent psychological 
distress, social and role disability due to emotional problems and a poorer general 
health. Examples of reasons for lower pre-donation MCS scores in this cohort 
included feeling nervous, downhearted or worn out a lot of the time. A negative 
association between mental or emotional health and an altered pain experience has 
been described previously (Gong and Dong, 2014, Browne et al., 2014, Segal et al., 
2014, Lautenbacher and Krieg, 1994, Syrjala et al., 2014, Sullivan et al., 2001, Banks 
SR, 1996, Sheinfeld Gorin et al., 2012). Moreover, psychosocial interventions are 
often part of a multimodal approach of the management of pain (Sheinfeld Gorin et 
al., 2012) and negative mood has emerged as a strong and reliable predictor of 
postoperative outcomes (Sullivan et al., 2001). I found similar results in the BM cohort; 
a lower pre-donation MCS score was the only and most important factor associated 
with delayed recovery. A possible explanation of the finding that MCS scores 
predicted recovery in BM donors but not in PBSC donors, may be related to the very 
distinct nature of the two procedures. As BM donation was associated with pain 
symptoms at later time points, I would speculate that pre-existing symptoms of anxiety 
or low mood would have a significant impact on this outcome.   
 
When examining the evolution of HRQOL during the donation process, I found a 
decrease in general health for BM and PBSC donors at 4 weeks with a return to 
normal levels 3 months following donation. The 3 month values were well above the 
mean of the general population (+ 0.79 SD for PCS, + 0.34 SD for MCS; p < 0.001). 
Most scores at 4 weeks were significantly lower for BM donors compared to PBSC 
donors, reflecting the delayed recovery and the increased symptoms of pain at later 
time intervals for BM donors described in chapter 4.  At 4 weeks following donation, 
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BM donors had scores for PCS and MCS that were comparable to scores of patients 
with chronic medical conditions (Cheng et al., 2003). Based on the above findings, 
the potential donor experience should be taken into account when deciding on the 
stem cell source, especially if there is no specific patient indication for a BM source. 
I did not find improved mental scores following donation, as described in a recent 
study (Switzer et al., 2014). To the best of my knowledge this is the first study to show 
that, even in PBSC donors, physical health is significantly (although minimally) 
reduced 4 weeks following donation compared to pre-donation. The largest decrease 
was within the RP subscore. The RP scale covers an array of physical health-related 
role limitations, including limitations and reductions in the amount of time spent at 
work or other activities (such as sports). Despite the significant decrease in physical 
state compared to baseline, PCS scores at 4 weeks were still comparable with scores 
of the general population (+ 0.18 SD; p = 0.11). There were no significant changes in 
MCS scores during the donation process for PBSC donors, as opposed to BM donors. 
The main MCS subscore affected in BM donors was the vitality score. These findings 
may reflect an association between physical morbidity and vitality and are in keeping 
with a delayed physical recovery in BM versus PBSC donors. Despite considerable 
pain in BM donors, mental health scores remained high, indicating that donors did not 
feel distressed by pain. This had also been previously reported (Nishimori et al., 
2002). Moreover, several studies found that the vast majority of BM and PBSC donors 
indicated they would be willing to donate again in the future (Switzer et al., 2001, 
Heldal et al., 2002). Only one donor (PBSC) in this cohort asked us to be removed 
from the register following donation.  
 
Taking into account the finding that HRQOL were significantly decreased at 4 weeks, 
I aimed to predict which adverse reactions were associated with poorer outcomes 
when accounting for pre-donation HRQOL. I found that experiencing pain on day 2-3 
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was a significant predictor of general physical and mental health at 4 weeks following 
donation in PBSC donors, regardless of pre-donation physical and mental health. This 
information could be very valuable in order to monitor this high risk group more 
closely.  
 
There are certain limitations in my study that must be acknowledged: The SF-36 only 
captures part of overall HRQOL and a more comprehensive psychological 
assessment tool or formal qualitative interview process may need to be the focus of 
future studies. Additionally, pre-donation ambivalence has been found to be one of 
the major determinants in the donation experience. Donation ambivalence involves 
doubts and worries about donation and this is not covered by the SF-36 score. 
Furthermore, the influence of socio-economic status (SES) in relation to the donation 
experience and the SF-36 score would have been a useful variable to study. 
Unfortunately, I only documented the profession of donors, not their household 
income, which did not allow me to record the SES reliably. A recent CIBMTR study 
reported a minimal influence of SES on the donation experience (verbal 
communication from Prof. B. Shaw, article in press). Also, I included a limited number 
of BM donors, which limited the analysis in this group. For example, the number of 
BM donor participants was too small in order to obtain significant results in 
multivariate analysis when assessing the factors affecting individual adverse 
reactions at different time points. The numbers were also too small to assess the 
factors predicting physical and emotional health 4 weeks following donation. 
 
In conclusion, I found that pre-donation quality of life markers contribute significantly 
to recovery and toxicity profile following BM or PBSC donation. I believe they should 
be used alongside demographic markers in order to risk stratify the donor population 
and to help identify donors at risk for poorer outcomes. HRQOL questionnaires such 
as the SF-36 are highly standardised and their introduction at the time of donor 
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medical screening should be considered in order to establish which donors are 
potentially at risk of delayed recovery 
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Chapter 6 – Factors influencing yields in BM donors 
 
6.1 Introduction 
A secondary end point of the prospective study described in the previous chapters 
was to evaluate the frequency of PBSC (chapter 3) and BM collections meeting the 
transplant centre’s requested dose. I examined the role of potential donor and 
collection characteristics including age, gender, BMI, weight, difference between 
donor and recipient weight, volume of harvest and duration of harvest procedure. 
 
Commonly accepted doses for BM harvests vary between 3-5 x 108 total nucleated 
cells (TNC) per kg recipient weight. Higher TNC doses have been associated with 
improved graft function and patient survival (Sierra et al., 1997, Rocha et al., 2002, 
Dominietto et al., 2002, Barrett et al., 2000). Cell doses of < 2 x 108 have previously 
been described as unacceptably low (Wang et al., 2011). Because patients have 
already received therapy by the time donor cells are collected, the lack of availability 
of adequate stem cells is a significant problem. It is therefore of great clinical 
importance to establish the donor and collection characteristics associated with not 
meeting the requested HSC dose. Table 1.7 lists all the factors that have been 
previously found to affect the BM yield (using either CD34+ or TNC count) or quality 
of the harvest in allogeneic donors.  
 
6.2. Methods 
The full material and method can be found in chapter 2 (section 2.4.3.3). 
 Chapter 6 – Factors influencing BM yields 
 
166 
 
 
6.3 Results 
6.3.1 The frequency BM collections that meet the transplant centre’s requested dose 
and predictors 
6.3.1.1 Donor and collection characteristics 
Donor and collection characteristics are outlined in table 6.1 (n = 110).  
 
Table 6. 1 Donor and collection characteristics 
Characteristic  
Age (Years) 
Median (range) 
 
28 (18-56) 
Gender (Male/Female) 80/30 
Weight (kg) 
Median (range) 
 
82 (53-119) 
BMI 
Median (range) 
 
25.8 (18.1-36.1) 
Volume collected (mls) 
Median (range) 
 
1200 (450-1900) 
Duration of procedure (mins) 
Median (range) 
 
30 (7-120) 
Pre-donation haemoglobin (g/dl) 
Median (range) 
 
15.0 (10.2-16.8) 
Post-donation haemoglobin (g/dl) 
Median (range) 
 
12 (7.9-14.8) 
Pre-donation minus post-donation haemoglobin (g/dl) 
Median (range) 
 
2.8 (0.7-5.9) 
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In view of the small number of BM donors included in my prospective study (n = 37), 
I added all donors who donated BM in 2013 but were not included in the study (n = 
35) as well as all donors who donated BM in 2012 (n = 38).  
 
The distribution of BM procedures between the 4 collection centres was 66% (n = 73), 
20% (n = 22), 10% (n = 11) and 4% (n = 4). When comparing donor and collection 
characteristics between donations in 2012 and 2013, I found that the volume of BM 
collected per kg donor weight was higher in the 2013 donors (table 6.2).  
 
There was no difference in the TNC yield/kg recipient weight or actually meeting the 
requested yield when comparing 2012 vs 2013 donors (53% vs 48%; p = 0.7). When 
comparing study participants versus non-study participants, I found that there were 
significantly more male donors in the study participant group (table 6.2). Donors for 
paediatric recipients were included in the analysis. This was decided partially due to 
the high number of these donors in this cohort (n = 46). Also, an important end point 
of this analysis (TNC count per ml) eliminates the confounding factor of recipient 
weight.  
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Table 6. 2 Comparison of donor and collection characteristics of donors who donated in 
2012 versus 2013 and of prospective study participants versus non-participants 
Measure
-ment 
Age 
(years) 
Mean 
(range) 
Gender  
(% male) 
Donor 
minus 
recipient 
weight  
Mean 
(range) 
Volume 
harvested/ 
kg donor 
weight 
Mean 
(range) 
Duration 
of 
procedure 
Mean 
(range) 
TNC dose 
requested 
(x 108 TNC 
cells/kg 
recipient 
weight) 
Mean 
(range) 
TNC 
dose 
collected 
(x 108 
TNC 
cells/kg 
recipient 
weight) 
Mean 
(range) 
Comparison of donors who donated in 2012 and 2013 
Donations 
in 2012 (n = 
45) 
32 
(20, 
53) 
66% 35.9 (-28, 
96) 
12.9 
(4.76, 
19.7) 
33.4 (7, 
120) 
4.6 (3, 10) 9.7 (1.4, 
84.4) 
Donations 
in 2013 (n = 
65) 
30.4 
(18, 
56) 
77% 26.7 (-33, 
94) 
15.5 
(4.4, 
23) 
34.2 (18, 
90) 
4.8 (2, 12) 8.6 (1.4, 
100.1) 
p-value 0.39 0.28 0.13 0.002 0.79 0.66 0.74 
Comparison of donors who participated in prospective study and non-study participants 
Non-study 
participants 
(n = 73) 
31.2 
(18, 
56) 
64% 34.5 (-28, 
96) 
13.9 
(4.8, 
23) 
33.0 (7, 
120) 
4.7 (2, 12) 9.9 (1.4, 
100.1) 
Study 
participants 
(n = 37) 
30.7(
18, 
53) 
89% 22.5 (-33, 
94) 
15.5 
(4.4, 
23) 
35.5 (18, 
90) 
4.9 (3, 10) 7.5 (1.4, 
69.7) 
p-value 0.78 0.006 0.06 0.069 0.43 0.63 0.48 
 
6.3.1.2 Association between demographic data and reaching the target TNC count  
The median cell dose requested was 4 x 108 TNC cells/kg recipient weight (range 2-
12). The median TNC dose collected was 4.2 x 108/kg (range 1.4-100.1) and 
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requested TNC dose was achieved in 49% of harvests (54/110). The collected CD34+ 
dose (x 106)/kg recipient weight was only reported in limited cases (n = 34). The 
median CD34+ dose collected was 3.33 x 106/kg (range 1-28).  
 
The only donor characteristic that was significantly associated with reaching the TNC 
dose in univariate analysis was a larger difference in weight between donor and 
recipient (19.2 kg vs 42.1 kg; p < 0.001) (table 6.3).  
 
Table 6. 3 Univariate analysis of factors associated with reaching the requested TNC dose. 
Values are expressed using mean (range) for continuous variables. 
Variable Requested TNC dose achieved 
 
 Not achieved 
(n = 56)  
Achieved 
(n = 54)  
p-value 
Continuous Age  30.8 (18-53) 31.3 (18-56) =0.78 
 Donor  weight (kg)  82.9 (53-119) 81.5 (55-108) =0.59 
 Donor  minus 
recipient weight 
(kg) 
19.2 (-31-86) 42.1 (-32.9-
95.7) 
< 0.001 
 BMI 26.3 (18.3-34.9) 26.3 (18.1-
36.1) 
0.99 
 Volume collected 
(mls) 
1252 (450-1710) 1044 (450-
1900) 
< 0.001 
 Procedure duration 
(minutes) 
36.4 (15-120) 31.2 (7-90) =0.075 
Categorical Gender (M/F) 41/15 39/15 0.99 
 Collection centre 
(1/2/3/4) 
1/37/6/12 3/36/5/20 0.74 
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The odds ratio for reaching the target for donors > 20 kg heavier than their recipient 
was 3.5, compared to donors ≤ 20 kg heavier than their recipient (OR 3.5, 95% CI 
1.6-7.9; 0 = 0.002). Higher volume harvests were significantly less likely to achieve 
the requested TNC dose (1252mls vs 1044 mls; p < 0.001) in univariate analysis. The 
odds ratio for reaching the target for a collected volume of ≤ 1200 mls was 3.7 (95% 
CI 1.7-8.1; p = 0.001) compared to a collected volume of > 1200 mls. There was a 
trend towards statistical significance for shorter duration of the procedure and 
reaching the requested TNC dose (36.4 mins vs 31.2 mins; p = 0.075).  
 
After stepwise binary logistic regression analysis (table 6.4), a larger difference in 
weight between donor and recipient and a lower volume of blood collected remained 
significantly associated with requested TNC dose being met. 
 
Table 6. 4 Multivariable logistic regression of factors influencing the likelihood of reaching 
the requested TNC dose with variables expressed as a continuous or categorical variable. 
Variable OR 95% CI p-value 
Continuous Donor minus recipient weight (kg) 1.02 1.00-1.033 =0.05 
 Volume collected (mls) 0.99 0.99-1.00 =0.033 
Categorical Donor minus recipient weight (kg) 
     Donor minus recipient weight ≤ 20 
     Donor minus recipient weight > 20 
 
1 
2.8 
 
 
(1.2-6.5) 
 
 
=0.019 
 Volume collected (mls) 
     Volume collected ≤ 1200 
     Volume collected > 1200 
 
2.9 
1 
 
(1.3-6.7) 
 
= 0.011 
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6.3.2 Factors affecting the quality of the BM harvest 
The TNC count/ml collected marrow was used as a marker of quality of the harvest. 
The median TNC/ml collected was 18.2 x 106/ml (range 9-182 x 106/ml). I found that 
a greater positive difference between donor and recipient weight (p = 0.004; figure 
6.1), a higher BMI (p = 0.038; figure 6.2) and a lower volume of BM collected (p < 
0.001; figure 6.3) were significantly associated with a better harvest quality in 
univariate analysis. Donor weight (p = 0.37), donor age (p = 0.48), duration of the 
procedure (p = 0.93) and gender (p = 0.19) were not significantly associated with 
quality of the harvest.  
 
Figure 6. 1 Association between difference in weight between donor and recipient and 
TNC/ml 
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Figure 6. 2 Association between donor BMI and TNC/ml 
 
 
Figure 6. 3 Association between the collected BM harvest volume and TNC/ml 
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A lower volume of BM collected and a higher BMI remained significantly associated 
with better harvest quality in multivariate linear regression analysis (table 6.5). 
 
Table 6. 5 Multivariate linear regression analysis. Explanatory variables included all factors 
significant (p < 0.05) in univariate analysis. 
Explanatory variable Coefficient (beta) p-value 
Volume collected -0.51 < 0.001 
Donor BMI 0.21 = 0.018 
  
A significant variation in harvest quality was observed when comparing the different 
collection centres (p = 0.001; figure 6.4). The collection centre with the smallest 
number of BM harvests (n = 4) was excluded from this analysis. Centre 3 provided 
the worst quality harvest; the difference was highest between centre 1 and 3 (0.28 vs 
0.15 x 106/ml; p = 0.001) and centre 2 and 3 (0.25 vs 0.15 x 106/ml; p = 0.001). There 
was no significant difference between the different collection centres in donor BMI (p 
= 0.68) and donor minus recipient weight (p = 0.93); the donor characteristics that 
were implicated in a better harvest quality. I found a borderline significant difference 
in the volume collected per kg donor weight between centre 1 and 3 (13.9 vs 15.8 
mls/kg; p = 0.054), but not between centre 2 and 3 (14.5 vs 15.8 mls/kg; p = 0.40). 
The duration of the procedure was significantly longer in centres 1 (32 vs 28 mins; p 
= 0.007) and 2 (41 vs 28 mins; p = 0.01) compared to centre 3.   
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Figure 6. 4 TNC/ml displayed per collection centre. Box plot with the horizontal line 
representing the median, the box the 25th percentile and the whiskers the 75th percentile. 
 
6.4 Discussion 
This study investigated the donor and collection factors that are implicated in reaching 
the requested TNC dose for BM donors. I also investigated the factors implicated in 
the quality of the harvest (TNC/ml). The latter has been used as a marker of quality 
of the harvest.  
 
My study found that a larger difference between donor and recipient weight and a 
lower volume of marrow collected were associated with reaching the requested TNC 
dose in multivariate analysis. Similar to previous studies, age and gender were not 
found to be associated with reaching the requested dose (Favre et al., 2003, Gandini 
et al., 2001). I did not find an association between BMI and reaching the requested 
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dose in multivariate analysis. One study had previously reported a positive 
relationship between BMI and CD34+ yield (Favre et al., 2003).  
 
Similar to the PBSC donors, my study showed that a larger positive difference 
between donor and recipient weight was significantly associated with reaching the 
requested cell dose. This finding was most significant for donors who were more than 
20 kg heavier than their recipient. This result can help guide physicians in selecting 
an optimal donor to provide a sufficient BM cell dose. This practice will become 
increasingly relevant with the number of volunteer HSC donors increasing worldwide. 
A recent NMDP report noted that 56% of patients have ≥10 suitable HLA matched 
donors in the current NMDP files (Confer, 2007). Once the donor is chosen, the yield 
of the collected BM depends on the harvest procedure.  
 
The only harvest procedure characteristic significantly associated with reaching the 
requested dose was a lower volume of BM collected. Additionally, when using the 
quality of the harvest as an outcome, lower volume harvests were strongly associated 
with higher TNC counts per ml in multivariate analysis. TNC count per ml is a better 
indicator for the analysis of donor and collection characteristics in BM donors because 
of eliminating the confounding factors of collected marrow volume and recipient 
weight (especially since donors for paediatric recipients were included in this 
analysis). A negative correlation between the TNC/ml and the total volume harvested 
has been previously reported (Kao et al., 2009, Wang et al., 2011) and can be 
explained by a decreased contamination with peripheral blood in smaller samples. 
Peripheral blood contamination and high volume aspirates should be avoided, given 
the risk of immune mediated transfusion reactions in the recipient if there is a major 
ABO mismatch between the donor and the recipient. Also, peripheral blood cell 
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contamination leads to anaemia (Nishimori et al., 2002) and increased symptoms of 
fatigue in the donor. Peripheral blood contamination is often caused by aspirating too 
much BM from one puncture hole. Several authors have reported that small volume 
aspirations and multiple puncture sites are associated with minimal contamination by 
peripheral blood and higher TNC counts (Spitzer et al., 1994, Bacigalupo et al., 1992, 
Batinic et al., 1990). This practice may however be associated with an increased risk 
of back pain following donation. In addition, increasing the number of puncture holes 
may lead to longer harvest procedures, which are associated with increased side 
effects and complications of anaesthesia (Lannert et al., 2008).  
 
One way to improve the quality of the harvest, without increasing the length of the 
procedure, may be by using a multi-hole aspiration needle. This practice is associated 
with fewer puncture holes and could potentially be less traumatic for the donor. Wang 
et al reported an improved TNC per ml using this device (Wang et al., 2011). They 
restricted the volume per aspiration to 30 mls per aspiration (approximately 5 
mls/needle hole). Another study reported a 50% reduction in operating times using 
this device (Lannert et al., 2008). They did not find an improvement in TNC yields, 
but this could result from the effect of haemodilution by a large amount of aspiration 
per puncture site used in the study (200 mls per aspiration). Moreover, the small 
number of cases in this study may have caused the study to have insufficient power. 
 
Another strategy that could potentially improve the quality of the harvest is by 
performing midway TNC counts, as reported by Wang et al (Wang et al., 2011). The 
influence of the midway TNC count may result from the fact that staff were aware of 
the unsatisfactory TNC counts and attempted to improve the harvest by further 
decreasing the volume of aspiration to reduce haemodilution, using new puncture 
locations. Conversely, satisfactory midway TNC counts may result in reduced 
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unnecessary puncture holes and volume aspirated. A requirement for midway TNC 
counts is a timely laboratory turnaround time, which may have practical implications 
for collection centres. Several studies found increased yields and improved 
engraftment with G-CSF stimulated BM. However, this method will significantly 
increase the cost of BM harvesting and also raises concerns with regards to donor 
ARs. 
 
The only donor factor that was significantly associated with TNC count per ml was 
donor BMI. The mechanism behind this phenomenon is not clear and this has also 
not been previously reported. It is possible that this donor feature reflects a robust 
haematopoiesis inside the bone marrow so that higher concentrations of nucleated 
cells can be collected.  
 
Finally, I found a significant variation of BM harvest quality between centres. This has 
also been reported in another study (Spitzer et al., 1994). Interestingly, the centre 
performing the worst was found to have the highest volumes aspirated per kg donor 
weight and the shortest procedure time. These findings strongly suggest that high 
volumes were aspirated per puncture hole. Fewer puncture holes mean a shorter 
procedure time in order to achieve the required volume. High volume aspirations are 
associated with dilution with peripheral blood and a reduced quality of the harvest. 
Unfortunately, our centres did not document the number of puncture holes, so I am 
not able to confirm this. However, this information reiterates the importance of the 
procedure technique and the need for exploring devices such as the multi-hole 
aspiration needle. Given the declining number of requests for BM harvests, it is crucial 
these are performed by the most experienced centres and that systems exist to 
ensure operators retain their expertise. 
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Chapter 7: A qualitative analysis of the donation experience  
 
7.1 Part I: Exploration of health related quality of life (HRQOL) during the 
donation process and donor preparedness  
7.1.1 Introduction 
Chapters 4 and 5 described the influence of pre-donation HRQOL and demographic 
factors on recovery and adverse reactions (ARs). One of the most important 
conclusions was the finding that baseline HRQOL scores, measured using the SF-36 
questionnaire, can significantly predict recovery following donation. The baseline 
Physical Component Summary (PCS) was found to be an especially important factor 
in determining recovery and ARs in peripheral blood stem cell (PBSC) donors. The 
first part of this qualitative study was developed in order to further explore the 
influence of pre-donation physical health on the donation process in PBSC donors, 
the largest group of participants in the prospective study. This qualitative analysis 
involved in-depth telephone interviews with 14 PBSC donors (who participated in the 
original study), seven with low pre-donation PCS scores and seven with high PCS 
scores. The SF-36 is a self-reported general health measure and some of the 
questions are formulated in a way that may be subjective, for example “Have you 
accomplished less than you would like in the last 4 weeks as a result of your physical 
(or mental) health” or “Have you had difficulty performing work or other activities”. 
These questions may be answered differently by two people who have similar mental 
and physical health, depending on what they see as normal for them. Qualitative 
exploration may allow a more complete picture of participants’ general health and the 
factors associated with recovery. I also aimed to explore the physical and 
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psychological reactions to the donation process and assess how well donors coped 
with ARs following donation, and identify if donors felt inadequately informed about 
the donation process.  
 
7.1.2 Methods 
The full material and method can be found in chapter 2 (section 2.5).  
 
7.1.3 Results 
The characteristics of the participants (n = 14) are shown in table 7.1. Participants 1 
to 7 were selected based on pre-donation PCS scores in the lowest quartile (≤56), 
participants 8 to 14, based on pre-donation PCS scores in the highest quartile (> 60). 
Pre-donation MCS scores were not taken into account when selecting donors. 
 
Table 7. 1 Donor and HRQOL characteristics of qualitative study participants, Marital status 
includes M(arried), S(ingle) or having a P(artner) 
ID Age Gender Ethnicity Marital 
status 
Depen
-dants 
(n) 
Blood 
donor 
Pre-
donatio
n PCS 
score 
Pre-
donation 
MCS 
score 
p1 40s M White 
Northern 
European 
Missing 
data 
0 N 45.33 56.8 
p2 30s F White 
Northern 
European 
M ≥ 3 Y 51.5 55.97 
p3 40s M Jewish M ≥ 3 N 47.45 50.64 
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p4 40s M White 
Northern 
European 
M Missin
g data 
N 50.1 58.05 
p5 60s F White 
Northern 
European 
M 0 Y 48.92 61.13 
p6 40s M White 
Northern 
European 
P ≥ 3 N 49.3 56.97 
p7 30s M White 
Northern 
European 
S 0 Y 44.84 55 
p8 40s F White 
Northern 
European 
M 1-2 N 60.45 58.45 
p9 40s M White 
Northern 
European 
Missing 
data 
≥ 3 N 60.62 58.97 
p10 30s M White 
Northern 
European 
M 1-2 Y 63.04 49.89 
p11 20s M White 
Northern 
European 
S 0 Y 61.88 54.31 
p12 30s M White 
Northern 
European 
Missing 
data 
Missin
g data 
Y 61.79 53.61 
p13 20s M Other 
(White) 
P 0 N 61.52 54.33 
p14 20s M White 
Northern 
European 
Missing 
data 
1-2 Y 63.71 48.38 
 
7.1.3.1 HRQOL during the donation process  
Table 7.2 displays the donors’ responses when asking about their pre-donation 
physical health. Donors with lower scores (p 1-7) were very healthy in general, but 
often had mild limitations explaining their lower PCS scores. The main reason for 
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scoring slightly lower than the other donors was often due to pain symptoms, usually 
back pain, limiting daily life activities to a minor degree. Only one donor (p4) reported 
considerable limitations in daily life due to back pain. There was a close agreement 
between the information that was derived from the interview and the answers on the 
pre-donation SF-36 form, filled out 1-1.5 years earlier (table 7.2 italic). Donor (p7) was 
an exception, but he later remembered having finished a 30-mile walk two days prior 
to filling out his SF-36 form. Donors with high scores (p 8-14) were in extremely good 
shape and were often marathon runners or engaged in physical exercise on a daily 
basis.  
  
Donors were asked about their worst symptoms, physical or psychological, during the 
donation process. Donors with lower scores experienced more severe symptoms in 
general, reflecting the main findings of my prospective study. These symptoms often 
significantly influenced daily work and social life. Two donors mentioned low mood as 
their most serious side effect following donation (p 3 and p7); both had lower pre-
donation PCS scores. Donors with high scores had a generally excellent donation 
experience with limited impact on their daily life.  
 
 
 
 
 
 
 
  Chapter 7: Qualitative analysis 
 
183 
 
Table 7. 2 Pre-donation physical health, data derived from the interview (retrospective) and 
the SF-36 form completed at the time of the prospective study (italic) and physical and 
psychological reactions to the donation process 
Participant 
ID 
Pre-donation physical health Reaction to donating 
p1 Knees little bit stiff when standing 
up for long periods of time 
(required for his job) 
“I got an awful lot of pain, it felt like a 
pressure in my tummy like maybe 
there was something going to burst”  
He took time off work (he was 
advised not to work because of 
symptoms) 
SF-36: Mild pain symptoms, 
interfering with work some of the 
time 
p2 Mild symptoms back and joints 
interfering with some activities like 
bending  
“I had quite a lot of headaches, they 
lasted for a couple of weeks” 
She had to cut down on social 
activities SF-36: Mild pain symptoms, 
limited work a little of the time 
p3 Back pain, interfering with high 
impact sports (running and 
squash) 
Quite a lot of bone pains during 
injections and feeling low 
He worked from home around the 
time of injections and the day after 
donation 
SF-36: Mild pain, interfering with 
work little of the time. Limited a lot 
in vigorous activities 
p4 Back pain, on tramadol and 
codeine pre-donation, interfering 
with daily activities 
“I developed bad hip pain and 
needed a shot of morphine” 
He took the week off (this was 
decided beforehand) SF-36: Moderate bodily pains, 
limiting work some of the time 
p5 Chronic back pain, on morphine 
patches, but very active lifestyle 
(Swimming and gym 3 times a 
week) 
“I developed quite a lot of pain in my 
bones” 
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SF-36: Moderate pain interfering 
a bit with normal activities 
She had to take more rest and take 
everything slower as it was very 
painful 
p6 In very good health, very active 
 
Low in mood and quiet following 
donation for some time  
He took it easier around the time SF-36: Mild pain, limited a little in 
work 
p7 Very active, cycles to work every 
day  
“I developed severe back pain and 
was advised to go to A&E for pain 
control” 
He was signed off from work during 
the donation process and  took it 
easy 
SF-36: Severe bodily pains, 
interfering with work  
p8 Skiing, surfing and daily cycling  
 
“The headaches were horrendous. I 
was cranky and less patient and I 
shouted more easily”  
Significantly impacting work and 
social life 
SF-36: No restrictions 
p9 Mountain bikes a lot 
 
Fatigue following donation  
He went mountain biking after work 
the day after donation SF-36: No restrictions 
p10 Very fit, recently ran a marathon 
 
No symptoms at all, he continued to 
play cricket all day during the 
injections 
“It was like a day out in London 
really” 
SF-36: No restrictions 
p11 Very healthy and active with no 
limitations 
Limited back pain, it didn’t restrict 
normal activities at all 
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SF-36: No restrictions 
p12 Fitter than most other people 
 
Bit of sore back not impacting work 
or social life 
SF-36: No restrictions 
p13 Healthy and fit 
 
Bit of stiffness for 2 hours with no 
impact on work or life whatsoever 
SF-36: No restrictions 
p14 Plays rugby 3 times a week 
 
Bit of a cold, but not sure it was 
donation related  
“It was almost identical to platelet 
donation, instead of one needle, 
there are two” 
SF-36: No restrictions 
 
7.1.3.2 Donor preparedness 
When asked how well informed they felt about the donation, all donors felt that they 
had received the right amount and type of information before donation. One donor 
mentioned that the duration of the actual apheresis procedure was longer than 
anticipated (p7), but he felt otherwise well informed. All donors with high PCS scores 
reported that the donation was better or easier than expected. They experienced 
minimal pain or other ARs and often resumed normal activities shortly after donation. 
The responses for the donors with lower scores were more varied and 3 donors 
experienced unexpected ARs (p3) or more severe ARs than anticipated (p 2, p5). 
“I think people react differently. I felt a little bit low after the donation. It was a strange 
feeling that I wasn’t expecting.” (p3) 
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 “I had quite a lot of headaches. I hadn’t necessarily known that they were going to 
happen. I knew there were going to be side effects but not necessarily to that degree.” 
(p2) 
Even though several donors experienced considerable ARs, most donors said they 
were not worried, as they had been warned about them. 
 “It didn’t worry me as such. They explained me that it wasn’t serious and that the pain 
would go once the injections had stopped.” (p4) 
“I was warned about the side effects. It didn’t worry me at all.” (p3) 
“Because I knew it was a temporary thing because of the injections and it wasn’t a 
symptom of more severe back disease I sort of carried on as normal and I didn’t pay 
much notice.” (p12) 
Only one donor commented on feeling worried about the pain he experienced.   
“It felt like a pressure in the abdomen. The nurse said it was normal, but I just sort of worried 
so in the end I didn’t go to work for a couple of days.” (p1) 
 
7.1.4 Discussion 
The results show that pre-donation physical health was very good in general, both for 
donors with pre-donation SF-36 scores in the lowest and in the highest quartiles. This 
is what would be expected, given the population average is set at a score of 50 and 
even the lowest quartile scores ≤ 56 are above average physical health. A close 
agreement between physical health derived from the SF-36 form (prospectively) and 
the retrospective interview was observed in all but 1 donor. This donor participated in 
heavy exercise shortly before filling out the questionnaire. This highlights a possible 
disadvantage of the form we used, as the SF-36 has a recall period of 4 weeks, which 
makes it possible to be influenced by recent, transient events (for example having a 
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cold). However, it may be that the current pre-donation state is more closely linked to 
the donation experience than long-standing physical health prior to donation. The SF-
36 was able to distinguish between “extremely fit” donors or donors with scores in the 
highest quartile and “fit” donors or donors with scores in the lowest quartile in a 
quantitative and user-friendly manner. Even more importantly, pre-donation scores 
correlated strongly with outcomes following donation (as seen in my prospective 
study); donors with scores in the lowest quartiles experienced considerable ARs 
whereas donors in the highest quartile reported a significantly better donation 
experience. This is interesting, given both groups of donors were of above average 
physical fitness.  
 
Despite experiencing significant ARs, most donors did not feel worried as they felt 
well prepared. The adequacy of preparation for donation has been shown to influence 
the donation experience and inadequate donor education may be associated with 
poorer donation experiences (Pillay et al., 2012). Three of the seven donors with low 
scores felt the donation was worse than they expected and this group may have 
benefitted from more detailed information and counselling beforehand. Research in 
surgery has also confirmed the benefits in recovery when providing detailed 
information about procedures and their ARs (Devine and Cook, 1983). A pilot study 
that is proposed in the next chapter suggests a tailored approach to donors with low 
PCS scores and this includes providing more in-depth information about delayed 
recovery and potential ARs. Despite sometimes experiencing considerable ARs, 
donors remained positive about the donation experience and were all willing to donate 
again in the future. It is possible that the more time lapses, the more positively donors 
remember their donation experience, possibly because altruistic feelings of having 
performed a good deed may be more prominent. 
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7.2 Part II: A thematic analysis of donor resilience 
7.2.1 Introduction 
The second part of this qualitative study involves an analysis of “resilience factors”, 
or the ability to bounce back from a profound experience. Previous research has 
shown that the psychosocial response to donating bone marrow (BM) is usually a 
positive one (Butterworth et al., 1993). Most donors see donation as worthwhile and 
most would be willing to donate again in the future. This is often despite experiencing 
ARs during the donation process. Butterworth reported that donors who developed 
severe back pain following BM donation, were as likely to experience the donation as 
positive emotionally than their counterparts who did not experience back pain 
(Butterworth et al., 1993). PBSC donation is usually tolerated better than BM 
donation, but is nevertheless associated with common ARs. My prospective study 
found that both BM and PBSC donors experienced considerable ARs and showed 
that, even in PBSC donors, physical health was significantly reduced 4 weeks 
following donation compared to pre-donation. Physical health had returned to pre-
donation values at 3 months following donation. Mental health was significantly 
reduced at 4 weeks in BM donors, but remained high throughout in PBSC donors. All 
apart from one donor in my study were willing to donate again in the future. This part 
of the analysis will focus on the factors that may explain these physical and 
psychological outcomes in our donors, using thematic analysis.  
 
7.2.2 Methods 
The full material and method can be found in chapter 2 (section 2.5). A full interview 
transcript with extracted codes and overarching themes is shown in document S2. An 
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overview of codes and themes is shown in table S5 appendix 1 (initial draft) and S6 
(final draft).  
 
7.2.3 Results 
Five themes were identified: intrinsic motivation, determination, relationship with 
recipient, strong feeling of fairness and ease of decision. Table S6 appendix 1 
displays the five themes with their constituent codes. No differences were observed 
between the donors with low (p1-p7) and high (p8-p14) pre donation PCS scores, 
therefore no distinction is made between the two groups for the thematic analysis. 
 
7.2.3.1 Theme 1: Intrinsic motivation 
Altruism as a personality trait 
Most donors were highly motivated in their decision to donate and were driven by an 
intrinsic commitment. In particular, the central importance of altruism as a personality 
trait was remarkable and altruistic acts appeared to be fairly typical for several donors.  
“I have always been a very generous person. I thought it would be a good thing to do.” 
(p11) 
“I would donate a kidney as well. I would do it to help others. I think my wife would not 
be too pleased, but you would still be alive afterwards, right?” (p6) 
 “I have been giving blood since I was 18 and grew up with my dad being a regular 
blood donor. And so, it was just quite a normal thing to join, that kind of made sense.” 
(p2) 
“You have to help others, don’t you? If you see someone lying on the street, you 
wouldn’t walk away, would you? And it is not just the individual, it is the whole family. 
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It doesn’t matter who they are or which race it is. You have to do it for others, without 
knowing who they are.” (p6) 
 
Two donors commented on how guilty they had felt about not being blood donors. 
“I have been a blood donor several years ago. I found it very uncomfortable. I should 
have persisted really but I didn’t. I feel guilty about it.” (p1) 
“I feel very guilty about not being a blood donor. I remember it every 6 months and 
think I need to get a grip!” (p8) 
Several donors commented on how they did not expect anything in return, highlighting 
a true altruistic motivation of joining the register. 
“You don’t become a donor to try and get a reward from it or anything. I think you need 
to keep that boundary between the donor and the recipient.” (p10) 
“I was meant to write a card, but I don’t want to put an expectation onto the recipient 
or any kind of thanks.” (p2) 
“I didn’t do it to get a congratulation or to get a well done. I just wanted to help 
somebody.” (p14) 
 
Opportunity to save someone’s life 
Participants viewed donation as a chance to save someone’s life and an opportunity 
to show kindness and help another person. Of note, several stated that they felt 
“honoured” to have been selected as donors. 
“I think it is a great thing and I think it is an honor to be able to donate. And it is 
wonderful to have that opportunity to make a difference in somebody’s life.” (p7) 
“At the time of the letter, I felt very blessed, blessed to give someone the chance.” 
(p8) 
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“To suddenly have this opportunity to do something that was so positive and hopeful 
and wasn’t connected to what we had been going through. It was an amazing time for 
me as well. It was really good timing to do something that was so positive.” (p2) 
“It a good opportunity so save someone regardless. Who the person is, is irrelevant 
really” (p13) 
 
Hoping to rely on others’ donations if ever in need  
Some donor statements implied the relative costs to themselves and benefits (to 
themselves or the recipient) of donating and expressed hope that should they or their 
family were in a similar desperate situation others would do the same for them. 
“If anyone in my family needed a donation and there wasn’t a family match, I would 
like somebody else to help my family” (p10) 
“I think it is a bit like giving blood. You give blood because you know one day you 
hope that if something happened to you someone will be there to help you out” (p7) 
 “I asked myself a couple of very simple questions: If this were one of my children, 
would I not want someone to do whatever they could to save my child? And if that is 
what I want for my children, I have to do the same for someone else. In this world, 
you can’t get by without helping each other and if we are not able to take that step, 
why the hell would someone else in your situation do it?” (p3) 
“Maybe someone would do it for me in the future” (p11) 
 
Religious identification and the decision to donate 
While many donors reported altruism to be a motivating factor, they also saw 
themselves as belonging to specific social groups that impacted their decision to 
donate. Religious beliefs were often cited as a major influence in deciding to donate.  
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“And I think, as a Christian, you have to go through these kind of things. It says in the 
bible: treat people as you want to be treated and I would hope someone would do the 
same for me.” (p7) 
“The only thing necessary for the evil to prevail is for good men to stand by and do 
nothing” (p7) 
“I am a Christian. I teach girls in a catholic school and teach them to try and save 
lives” (p8) 
 
Community sense and the decision to donate 
Other donors described how being part of a cultural community inspired them to 
become a donor.  
“I have never been in London before. I live in a small community and there was a 
young local girl in need of a donor” (p6) 
“I joined because there was an advert in the local paper about a patient who required 
a donation and I naively though that I could be a match” (p1) 
“Someone in our (Jewish) community was dying from leukaemia. There was an 
actual need in the community” (p3) 
 
Personal circumstances 
Rather than general altruism being the main motivating force, some donors viewed 
their donation as precipitated by specific personal circumstances. These donors 
tended to relate to the recipient and have empathic feelings towards them. 
“My son had meningitis and there was nothing I could do. Knowing what it is like to 
have a sick child, I though, it must be terrible for a parent to be in a similar sort of 
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situation and not being able to help. I joined because I could potentially help 
somebody.” (p14) 
“I was thinking of my children and of how I almost lost my son. I really related to the 
woman (in need of a transplant), as she might be a mom, she might have children!” 
(p8) 
“One of my high school friends was diagnosed with leukemia, that is the reason I 
joined” (p13) 
“My nephew was diagnosed with leukaemia when he was 3 and a half. He was the 
reason I am on the register” (p9) 
 
Promotion of donation 
The intrinsic motivation to donate was reflected in the finding that many donors 
remained actively involved in AN recruitment events and fundraising activities.  
“I organised an AN recruitment event to about 3000 people in the local area following 
donation. I have sent e-mails to AN saying that I am happy to be an ambassador, but 
I haven’t heard anything.” (p3) 
“I have been involved with several fundraising activities for AN” (p6) 
“I try to get all my friends to join the register, just for the chance that they may be a 
match at some point.” (p10) 
“I have tried to convince many people to join the register. I got loads of my friends 
signed up. I think it was a very important thing for me to do.” (p11) 
“I am so passionate about people joining. I tell people that you can also donate via 
the PBSC method and they are surprised. If that was better communicated, far more 
people would join.” (p13) 
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7.2.3.2 Theme 2: Determination 
Sense of duty 
Some donors felt that donating was almost an obligation or duty. Not donating was 
simply not an option, regardless of the difficulties they might encounter as a donor. 
“Not for a second did I think, do I fancy this? Am I going to do this? That was never a 
possibility. I couldn’t live with myself if I didn’t go ahead. I just wouldn’t be able to live 
with myself.” (p1) 
“I suffer from needle phobia. It has been impossible doing blood tests in the past. My 
wife had to take my hand during the donation process. They gave me one or maybe 
two valiums as well. For this cause, I was willing to take on the challenge of the needle 
phobia.” (p3) 
“I wasn’t going to give up” (p7) 
 
Not influenced by other people 
Even though most donors felt encouraged and supported by their family or friends in 
their decision to donate, most donors commented that they made the decision 
independently, without being influenced by other people. Some family members 
expressed worries and concerns, but this did not influence the donor’s decision to 
donate. 
“My husband was very worried, but it wasn’t going to change my mind. I was going to 
do it.” (p8) 
“My wife was worried about something going wrong, but I have the (donor) card in my 
wallet and that is my final decision.” (p6) 
 
Worries about not being able to donate 
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When donors were asked about concerns related to the donation process, several 
responded they were mainly worried about not being able to donate, rather than 
feeling worried about their own health. They were worried about the possibility of 
becoming unable to donate due to health reasons, or not being a good match for the 
recipient. 
“I was concerned that I needed to be in better physical health. I was wondering 
whether the medical would show anything that would stop me donating. That would 
have been devastating to me.” (p3) 
“I was hoping I would still be able to continue with the injections (despite the tonsillitis), 
but it was fine in the end.” (p7) 
“Knowing that I am not in good physical health at the moment worries me as it is not 
a good situation for yourself or someone else to be in. You wouldn’t be in the best 
position or best physical condition (in case you can donate again). (p3) 
“My only worry was not being a good enough match for that woman.” (p8) 
 
Playing down ARs 
Despite the fact that these donors experienced considerable ARs, they did not 
perceive them as having a large impact after completing the donation. 
 Despite experiencing severe headaches up to a week following donation: 
“I think I was quite lucky with the side effects” (p3)  
Despite experiencing considerable pain:  
“I don’t feel like it has been a huge cost or anything, not like I donated an organ or 
anything.” (p2) 
“All I had to do was sort of roll up my sleeve and have a needle in my arm for a couple 
of hours. That was all that was to it.” (p1) 
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“It wasn’t bad at all” (p5) 
Despite having been advised to go to A&E for pain control: 
“It wasn’t a bother to me” (p7) 
“It wasn’t bad at all, I just saw it as a bit of pain that was related to the process” (p7) 
  
7.2.3.3 Theme 3: Development of relationship with recipient 
Emotional reactions to donation process  
Most donors reported experiencing intense emotions in response to the donation 
process. Both positive and negative experiences were reported. 
“When I found out I was a match, I was excited, but at the same time upset and sad, 
as it meant there was someone going through this all. So very mixed emotions, but at 
least knowing that potentially I could help that person outweighed the more sad 
feelings at the end of the day” (p13) 
“I felt low after the donation and went very quiet for several weeks afterwards.” (p6) 
“At the time of the letter, I felt very blessed, blessed to give someone the chance. After 
the donation, for the next 4 months, it was like let’s hope it has worked and I really 
wanted to know (the outcome).” (p8) 
 
One donor reacted quite differently and commented that he experienced some 
closure after the experience. 
“Whenever I donated stem cells, I finished in my mind, it was over. And then I had to 
give more a couple of months later and that was very difficult, because in my mind I 
had made some closure. I was happy to do it again, but when I finished I thought I am 
glad this is over.” (p11) 
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Wanting to know the outcome 
Most interviewees wanted to know as much as possible about the person who 
received their cells. Donors showed a special personal interest in their recipients and 
were concerned about them. Although realising the potential of receiving bad news, 
all donors asked to be informed about the outcome of the donation for the recipient. 
One donor commented that knowing less about the recipient would help him cope 
better with a potential recipient death, whereas another donor commented that having 
more information relating to the circumstances of a recipient’s death might help him 
manage his grief. 
“I would really like to meet the person and see how much of a difference it has made.” 
(p14) 
“I think I wanted to know more whether it worked or not rather than who it was. Maybe 
it would upset me more if it was for a small child and if it hadn’t worked…” (p12) 
“I would like to know what his health outlook like.” (p2) 
“I don’t like the unknown, good or bad, I want to know.” (p14) 
“If I wouldn’t get updates about the recipient, I would end up thinking a lot. I just want 
to know for better or for worse.” (p12) 
“It would be easier to deal with the recipient’s death if you knew more about the 
person. You would want to know whether someone is depending on them.” (p6) 
 
Fantasising about recipient 
Several donors fantasised about recipients’ characteristics and personality traits and 
some wondered if they shared traits with the recipient beyond their HLA match. 
“I have related a lot to that woman. We were of the same weight and she was one 
year older than me. And a woman. And I just thought, she might be a mum! She might 
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have children. And I was thinking about my children and how I almost lost my son. 
And I really thought of her. I thought I hope her children are fine.” (p8) 
“I received a letter from recipient 3 months ago. He sounded like a family person. I 
think I put myself in the same situation and how important it would have been for my 
family (to survive)” (p9) 
“I was thinking a lot about the recipient, wondering whether it was someone who lived 
nearby.” (p6) 
“I was told it was an adult male and a male can be from 16 up until whatever age. I 
got a thank you card and I was wondering: Is he a 16-18 year-old and is it his mum or 
someone aged 40 or 50 and his wife wrote the card? You know what I mean? You 
are left in suspense until you finally meet them.” (p6) 
 
Reactions when recipient dies 
Given this background, it is not astonishing that donors are affected by recipients' 
deaths. Only one donor in this cohort was told that his recipient had died. This donor 
expressed feelings of grief. 
“It was pretty devastating. It is a strange feeling. Somebody passing who you don’t 
even know but somehow you have a major connection. That’s why maybe I have been 
quite a bit upset since I was notified several months ago.” (p3) 
This donor also commented on the lack of preparedness and the lack of emotional 
support or counselling following the news. 
“Going through a test is easy but finding out bad news is not. I am not sure I was 
sufficiently prepared. I was notified by letter and maybe it would have been better to 
have spoken to somebody. Some degree of counselling would have been good. I 
understand time and funds are limited, but part of the aftercare for the donors should 
maybe be looked into.” (p3) 
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He nevertheless explained that he perceived the attempt to save the recipient’s life 
as worth the effort and noted a wish to donate again in the future. 
 
Remaining realistic about possible outcome for the recipient 
Even though most donors experienced strong emotions, they often demonstrated a 
capacity to manage strong feelings and impulses and their thinking remained rational. 
“I gave it a best chance, but it is a shame it didn’t work. And I was the best match, if 
more people would have been on the register, they would have found a better match. 
So I think it is also a message to try say that we need more donors on the list.” (p8) 
“Actually you have given them quite a chance, because if you hadn’t done anything 
their chances of survival would have been depleted even more. (p7) 
“If the recipient wouldn’t make it, I could still say that I had done the best I could.” (p5) 
(p10) 
“If I hadn’t been on the register, the next one wouldn’t have been as good (a match), 
so the chances of survival would have been even less. I set up in my mind, that they 
had the best chances” (p10) 
“They talk about guilt and everything, but I don’t believe in that. I have done all I can 
essentially. I gave them an opportunity of a lifetime, an opportunity to survive 
potentially.” (p13) 
“I would take away that I have given them time to spend with their family, even if they 
wouldn’t survive. I certainly wouldn’t regret doing it.” (p12) 
“The news my donor didn’t survive was pretty devastating. But what I did prolonged 
his life and it was maybe for a bleeping moment, a ray of hope for his family.” (p3) 
“I am just a donor, it is not my responsibility (when the recipient dies). I do wish her 
all the best, but if she would not make it, it is not my fault.” (p1) 
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7.2.3.4 Theme 4: Strong feeling of fairness 
Donors who did not always feel supported by work, felt frustrated or upset. They felt 
it was not right to be treated in this way given the altruistic gesture they had shown.  
“Work was not generous and didn’t give me the time off. I was very upset with a 
catholic school dealing with it so poorly really. The whole value of caring, really…” 
(p8) 
“My work wasn’t supportive. It made me frustrated because I felt I was doing all 
possible to save somebody’s life and they didn’t really see it as that.” (p10) 
“My old employer was not supportive, that was probably part of the reason why I left 
them. They acted like they were doing me a favour by giving me the time off. They 
offered me unpaid leave, I felt that was wrong.” (p13) 
 
7.2.3.5 Theme 5: Ease of decision 
No conscious motivation 
Some donors seemed to have decided to donate “automatically” without careful 
thought about the potential costs of donation or even their own motivations in 
becoming a volunteer.  
“Joining the register was as simple as buying a packet of crisps. You buy it and you 
don’t really look at the packet thinking did I really need to buy it, you know, you just 
open them and eat them. That’s it.” (p1) 
“It was a no brainer, it is a good cause with not much effort really” (p9) 
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7.2.4 Discussion 
The second part of the qualitative study explored the factors that may explain “donor 
resilience” or explain why donors are able to remain positive despite sometimes 
experiencing significant ARs.  
 
I found that most donors were driven by a strong, intrinsic motivation. Character traits 
such as altruism appeared to be a major determinant in the decision to donate. While 
intrinsic motivation does not occur in isolation and is in part a response to a public or 
social role to donate it appeared that many interviewees were motivated by a genuine 
desire to help others. It has been suggested  that donation to strangers may be 
considered an example of more extreme altruism than that to family members 
(Switzer et al., 1996). Yet the literature to date remains divided on the existence of a 
purely altruistic act and one major issue centres on the self-rewards that seem to 
result from helping behaviour (Simmons et al., 1993). Piliavin and Callero suggest 
that individuals may obtain specific rewards from donating, such as enhanced self-
esteem, greater happiness and a heightened sense of fulfilment and meaning in their 
lives (Piliavin, 1991). In this context, self-esteem may be self-reinforcing and may lead 
to future altruism. Nevertheless, most would argue that the possibility that altruism 
may be self-rewarding in no way belittles the altruism itself. Some donor statements 
implied the awareness of the relative costs to the donor themselves and benefits (to 
themselves or the recipient) of donating, what has been called an ‘exchange-related 
motive’ (Switzer et al., 1997). Others viewed donation as a chance to save someone’s 
life, help another person and an opportunity to show kindness and help another 
person. Valued social identities were closely implicated in the decision to become a 
donor. These identities included religious connections (based on the belief that 
helping is emphasised by religion) and community sense. Some donors were 
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motivated by past personal events (such as the illness of a child) and these donors 
appeared to be motivated by feelings of empathy towards their recipient. Other donors 
commented on how they almost joined the register “automatically” without giving it 
much thought. Switzer et al described this kind of motivation as an “idealized helping” 
motivation (Switzer et al., 1997). 
 
Donors appeared extremely determined in their decision to donate and donation even 
seemed like a moral duty to some. The decision to donate was largely made without 
deliberation with family members and friends and several donors commented on how 
they were not influenced by others in making the decision. The majority of participants 
in this study were white and these findings contrast with an Asian study, where 
decisions were often influenced by peers and friends (Holroyd and Molassiotis, 2000). 
This dedication to donation was also illustrated by the finding that several donors 
were worried about not being able to donate, more so than expressing worries about 
potential ARs or risks to their own health. If ARs were experienced, they were 
perceived as being minimal. This may also be a consequence of the retrospective 
nature of this study, as donors were interviewed 1 to 1.5 years following donation. 
 
The strong intrinsic motivation and determination observed reflects very low levels of 
ambivalence. Ambivalence involves feeling unsure about donation and has been 
extensively studied by Switzer et al (Switzer et al., 1996, Switzer et al., 2014). High 
ambivalence encompasses the feeling of relief if donors find out they cannot donate, 
doubts and worries about donating or wishing that the patient was getting the stem 
cells from someone else. Switzer et al. found that low levels of ambivalence was the 
best predictor of positive donation-related outcomes (Switzer et al., 1996, Switzer et 
al., 2003). The same author showed that respondents with lower intrinsic commitment 
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to join the donor registry (those who did not feel morally obligated to join and those 
who would not have been disappointed in themselves had they not joined) reported 
higher ambivalence. Donors who had been encouraged to or discouraged by others 
from joining the registry reported higher ambivalence as well as donors who believed 
they were not well informed about the donation process. These results are consistent 
with the low levels of ambivalence and the generally positive donation experience 
observed in this study. 
 
Even though donors are not related to the recipients, a strong emotional bond was 
often observed. In accordance with WMDA guidance, unrelated donors are permitted 
to find out about the outcome of the donation and to exchange letters anonymously 
via the donor registries and transplant centres. Two years after donation, anonymity 
between donors and recipients can be removed if both sides agree and no legal 
restrictions of the recipient country require on-going anonymity (Wanner et al., 2009). 
Similar to previous studies (Atkinson, 2005, Wanner et al., 2009), all donors 
interviewed wanted to know the outcome for the recipient. Only one donor in this 
cohort received bad news and he experienced significant symptoms of grief as a 
consequence. These unexpected, intense feelings of grief have been described 
previously (Butterworth et al., 1992, Wanner et al., 2009). The explanation for this 
strong affective response may be due to the strong emotional relationship most 
donors develop with their recipient, even if unknown to them. Another explanation 
may be that the donor’s altruistic act has failed, leaving them disappointed. One might 
argue that donor centres could avoid such negative consequences for donors by not 
informing donors about recipients' deaths. However, there is general agreement that 
donor centres should inform donors who request this information on the health status 
of their respective recipients. This also applies to information about recipients' deaths 
(Goldman, 1994). One study also reported that donors preferred the knowledge of 
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the failure to uncertainty, even if this knowledge caused grief (Butterworth et al., 
1992). Donors' hopes regarding the positive outcomes of transplantation may be 
unrealistic. It is therefore important that registries or collection centres provide realistic 
information during donation preparation and inform prospective donors openly about 
the possibility of failure. One author reported that donors who felt poorly informed 
prior to donation significantly less often consider the message regarding the 
recipient's death to be helpful and informative (Wanner et al., 2009). The way this 
information is communicated is important – of note, most donors prefer to be 
contacted by telephone (Atkinson, 2005). Registries should be encouraged to 
implement this and the role of trained counsellors in this respect should also be 
considered. The relevance of personal coping resources and referring donors to their 
family and friends has also been suggested (Wanner et al., 2009). Some registries 
have reported that sharing experiences with other donors may be therapeutic and 
therefore opportunities for donors to meet within a support group may be beneficial. 
Despite the death of a recipient, most donors in previous studies were happy to have 
donated and said they would be willing to donate again (Wanner et al., 2009). Even 
though an emotional bond with the recipient is often developed, this study found that 
donors seemed able to manage strong feelings and emotions, an important 
prerequisite to resilience.  
 
A limitation of this qualitative study is the retrospective nature mentioned earlier. 
Another potential limitation is the epistemological position that was adopted; one of 
essentially accepting what participants say as a genuine reflection of their experience. 
For example, donors may not have been consciously aware of rewards gained from 
the donation process or perhaps not willing to acknowledge such rewards in an 
interview as thinking of themselves as highly altruistic and presenting themselves to 
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the world as such. Another limitation lies within the donor recruitment method, as only 
donors with PCS scores in the highest and lowest quartile were selected. This may 
limit the ability of its results to be generalized to the rest of the donor population. 
 
This qualitative study identified several donor characteristics, including strong intrinsic 
motivation, altruism, sense of duty, determination, low levels of ambivalence and the 
ability to develop a strong emotional relationship with an (unknown/anonymous) 
recipient whilst being able to manage strong feelings and emotions. These personality 
traits may explain the resilience that has been observed previously in HSC donors. It 
should be borne in mind that this study recruited donors who had already donated 
and thus can be expected to be different from potential donors presenting at 
recruitment or confirmatory typing (CT) stage. As expected, Switzer et al reported 
higher levels of ambivalence at earlier stages in the donation process (Switzer et al., 
2003, Switzer et al., 2005, Switzer et al., 2013) and identified this as the main risk 
factor for donor attrition or opting out of the register. The finding that most donors in 
this cohort joined as a result of an intrinsic commitment, rather than as a result of 
extrinsic pressures, means that strategies could be considered to create a recruitment 
context that emphasises the former. Some strategies have already been considered 
by the NMDP and include creating materials that reinforce the message of intrinsic 
and long-term commitment to donation and avoiding recruitment settings that may 
involve high levels of extrinsic pressure to join, e.g. recruitment drives in schools 
(Switzer et al., 2003). Strategies to enhance commitment at recruitment could also 
involve a two-stage process, where the decision to join the register needs to be 
reaffirmed. Other approaches may include making it easier for donors to opt out of 
the register. Although most of the donor characteristics in this cohort are related to 
inherent personality traits, several aspects of the donation process may help to build 
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a “resilient donor population”. Possibilities include raising awareness of potential poor 
outcomes in the recipient and offering improved counselling services if the recipient 
dies. Donors who display high levels of ambivalence at CT stage after having been 
matched to a patient, could be offered ambivalence reducing interventions. One 
author employed telephone calls to discuss remaining concerns about donation in 
solid organ donors (Dew et al., 2012). However, any interventions to reduce 
ambivalence would need to take particular care to strike a balance between reduction 
of ambivalence and addressing misconceptions without being coercive in 
encouraging donation. 
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 Chapter 8 - Conclusions 
 
8.1 Summary 
This thesis presents a broad investigation of the physical and psychological donation 
experience and of factors influencing recovery and adverse reactions (ARs) following 
PBSC and BM donation. It focuses on the association between baseline health-
related quality of life (HRQOL) scores and the donation experience and outlines the 
changes in HRQOL throughout the donation process. A diverse group of activities 
contribute to its final structure: I have written a review of factors implicated in the 
donation experience that was subsequently published in a peer-reviewed journal; I 
have designed and carried out 3 research studies, 2 of which have been published; 
and I have initiated a significant service development project in-house at Anthony 
Nolan (see 8.3 below). In this chapter, the outcomes of these studies and projects are 
summarized. I will also briefly discuss some of the challenges I faced in this work and 
present future work.  
 
Chapter 1 provides an overview of the literature in the field of the donation experience. 
It outlines the physical and psychological reactions to the donation process as well 
as demographic factors influencing the donation experience. Chapters 4 and 5 update 
this through a large prospective study involving 275 PBSC and 37 BM donors. This 
study found that the majority of both PBSC and BM donors reported ARs, however 
ARs were mainly classified as mild. BM donors recovered significantly slower 
compared to PBSC donors (14.3 versus 5.2 days) and experienced pain for a longer 
time following donation.  
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There are few studies that have prospectively examined factors influencing recovery 
and adverse reactions (Pulsipher et al., 2013, Miller et al., 2008, Nishimori et al., 
2002). There are several retrospective studies (table 1.3) investigating the donation 
experience, but they are often limited by an underreporting of adverse reactions (due 
to the lack of standardised checklists of donor adverse reactions). Time to complete 
recovery as a study endpoint has only been previously used by Pulsipher et al 
(Pulsipher et al., 2013). My study was the first study to investigate the influence of 
pre-donation HRQOL, the number of dependants, marital status and being a blood 
donor on the donation experience. 
 
The only demographic factor in my study associated with slower recovery in PBSC 
donors was higher donor age. Higher age was also associated with increased 
symptoms of fatigue. Having a higher BMI or having more dependants was 
associated with headache in PBSC donors. Female PBSC donors were more likely 
to experience any adverse reaction, in particular pain and fatigue. Both female gender 
and having a higher number of dependants appeared associated with slower recovery 
in BM donors.  
 
The key finding of the study is that pre-donation HRQOL markers are strong 
predictors of time to recovery and ARs. Poorer pre-donation physical health 
(measured using the physical component summary or PCS score) was associated 
with longer recovery (p = 0.017) and symptoms of pain, fatigue and dizziness in PBSC 
donors. Poorer pre-donation mental health was associated with longer recovery in 
BM donors (p = 0.03) and pain following PBSC donation (p = 0.003). A possible 
explanation of the finding that MCS scores predicted recovery in BM donors but not 
in PBSC donors, may be related to the very distinct nature of the two procedures. As 
BM donation was associated with pain symptoms at later time points, I would 
speculate that pre-existing symptoms of anxiety or low mood would have a significant 
  Chapter 8: Conclusions 
 
209 
 
impact on this outcome. I believe that HRQOL markers should be used alongside 
demographic markers in order to risk stratify the donor population and to help identify 
donors at risk for poorer outcomes. These donors may benefit from modification of 
joining policies or different supportive measures or follow-up procedures (see 8.3 
Future work below). 
 
To the best of my knowledge this is the first study to show that, even in PBSC donors, 
physical health is significantly (although minimally) reduced 4 weeks following 
donation compared to pre-donation. This decline was shown both for PBSC and BM 
donors (p < 0.001 and p = 0.009 respectively), but most scores at 4 weeks were 
significantly lower for BM donors compared to PBSC donors, reflecting the delayed 
recovery in the former. Mental health measured using the mental component 
summary or MCS score was significantly reduced at 4 weeks for BM donors, but not 
for PBSC donors. One earlier study has investigated HRQOL using the SF-36 form 
pre-donation, 1 week and 4 weeks following donation (Bredeson et al., 2004). This 
study equally found that BM donation was associated with more physical morbidity 
and negative effects on HRQOL compared to PBSC donation. This study did not find 
significant HRQOL changes when comparing pre and 4-week post donation scores 
in PBSC donors.  
 
My qualitative study in chapter 7 found that there was a good correlation between the 
pre-donation HRQOL measured using SF-36 scores and information derived through 
detailed donor interviews. The interviews showed that PBSC donors felt well prepared 
for the donation and were not generally worried about adverse reactions. Thematic 
analysis demonstrated that donors exhibited a strong, intrinsic motivation to donate 
as well as a remarkable determination and low levels of ambivalence. These factors 
may explain the “donor resilience” or the positive attitude that was observed in donors 
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despite often experiencing significant adverse reactions. Donors had often developed 
a strong emotional relationship with their recipient and significant symptoms of grief 
were observed in cases where the recipient passed away. Raising awareness of 
potential poor outcomes in the recipient and offering improved counseling services if 
the recipient dies are strategies that have shown to be beneficial and ought to be 
implemented by donor registries in order to improve the donation experience. 
 
Chapters 3 and 6 evaluate the factors affecting the frequency with which PBSC 
(chapter 3) and BM (chapter 6) collections meet the transplant centre’s requested 
dose. This was the first study to examine the influence of the difference between 
donor and recipient weight. I found that male gender, lower donor age, higher BMI, 
higher baseline platelet counts and a positive difference between donor and recipient 
weight were significantly associated with meeting the target yield in PBSC donors. 
This knowledge could affect future donor recruitment and selection strategies as well 
as mobilisation regimens in PBSC donors. Improved strategies may limit the numbers 
of days of apheresis or potential emergency bone marrow harvests procedures; 
factors associated with increased donor ARs. The most important factors in meeting 
the transplant centre’s requested dose for BM donors were a larger difference 
between donor and recipient weight and lower volume of BM collected. Larger 
volumes collected are often associated with high volume aspirations and peripheral 
blood contamination and hence poorer quality harvests. Improved BM harvest 
techniques such as using multi-hole aspiration needles may improve the quality of 
the harvests and reduce the duration of the harvest procedure and number of 
puncture holes and hence improve the donation experience. Table 8.1 lists the main 
findings of this thesis. 
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Table 8. 1 Main thesis findings 
Main thesis findings 
 Most PBSC and BM donors experience adverse reactions (ARs), although majority 
of ARs is mild 
 BM donors recover significantly slower following donation compared to PBSC 
donors 
 PBSC Donors at risk of delayed 
recovery or increased donation 
toxicity 
 
 Older age 
 Female gender 
 Higher BMI 
 Higher number of dependants 
 Physical health (measured using PCS score) is significantly reduced 4 weeks 
following donation, both for PBSC and BM donors, compared to pre-donation with 
a return to pre-donation values 3 months following donation 
 Mental health (measured using MCS score) is significantly reduced 4 weeks 
following donation for BM donors (not for PBSC donors) compared to pre-donation 
with a return to pre-donation values 3 months following donation 
 Pre- and 3 month post-donation PCS scores are higher compared to the general 
population, both in PBSC and BM donors 
 When comparing BM and PBSC donors, PCS and MCS scores are significantly 
lower for BM donors compared to PBSC donors 4 weeks following donation; BM 
scores at 4 weeks are comparable to scores of patients with chronic medical 
conditions. PBSC scores at 4 weeks are still comparable with scores of the general 
healthy population. 
 Lower pre-donation PCS scores (especially scores in the lowest quartile) are 
associated with a delayed recovery and very common adverse reactions (such as 
pain and dizziness) in PBSC donors; these “lower” scores are still above the 
average of the general population, illustrating the high fitness levels of donors.  
 Lower pre-donation MCS scores (especially scores in the lowest quartile) are 
associated with pain in PBSC donors and a slower recovery in BM donors 
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 Donors appear very resilient and are willing to donate again in the future despite 
often experiencing significant ARs  
 Donors are driving by a strong, intrinsic motivation to donate, they display high 
levels of altruism and low levels of ambivalence 
 A strong emotional relationship with the recipient is developed 
 Factors associated with reaching 
target yield in PBSC donors 
 
 Higher donor weight/BMI 
 Donor heavier than recipient 
 Male gender 
 Younger age 
 Factors associated with reaching 
target yield in BM donors 
 Donor heavier than recipient 
 Lower volume of marrow collected 
 Lower harvest volumes in BM donors are associated with higher TNC counts per 
ml; this is likely due to a reduced contamination with peripheral blood and better 
harvest techniques. 
 
8.2 Challenges 
Inevitably there were many challenges faced in these projects. 
Data collection, particularly for the prospective study, required many different 
information sources. Often several different spreadsheets were required to provide 
the necessary information and donor and patient paper notes were used to validate 
much of these data. This proved very time consuming. A single system used for all 
departments (along with a facility to extract data in an automated fashion) is currently 
in the development stage at Anthony Nolan and will hopefully be introduced in the 
near future.  
 
Missing data were also problematic. I went to great lengths to obtain all the relevant 
information, but there were many key variables that the registry did not reliably hold. 
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Another challenge was the difficulty in achieving adequate responses to the SF-36 
forms. This required several telephone calls and e-mails. The fact that this was all 
executed by myself led to inevitable “gaps” in donor recruitment, as there was nobody 
available to cover during periods of leave. Another cause of missing data was the 
slow introduction of the health care provider form mentioned in chapter 3 (section 
3.2.3.1). I was dependant on external companies for the introduction of this form and 
the delay led to the low response rate to this form during my study period.  
 
Setting up the qualitative study and performing the thematic analysis was another 
major challenge, as I hadn’t been involved with this type of research before. It required 
a significant amount of reading and assistance from my supervisors within the UCL 
psychology department. 
 
8.3 Future work: Pilot project “Improving donor recovery following donation” 
8.3.1 Background and objectives 
Understanding that ARs vary with certain donor characteristics gives AN  the 
opportunity to investigate possible interventions that may result in donors 
experiencing fewer ARs or reduce the time a donor takes to recover post donation. 
This would have several clear advantages. Most importantly, the act of donating BM 
or PBSC for HSCT is a gesture rewarded only by the potential sense of satisfaction 
derived from a humane act. Hence, care must be taken to optimise donor safety. 
There may also be benefits to the organisation with regards to safeguarding the 
overall reputation of HSC donation, but also possible reductions in covering donor 
loss of earning costs, time spent supporting donors who have not recovered from their 
donation and associated medical costs. For example, during the financial year of 
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2013-2014 AN has spent £49,000 on loss of earnings and £11,000 on consultant 
specialist fees (predominantly post donation) totalling £60,000 over 500 donors.  
 
In initiating this pilot project, I involved our donor relationship advisor and the heads 
of our donor follow-up and donor provision department in the further development. 
The objectives of the project are listed in table 8.2.  
 
Table 8. 2 Objectives of the “Improving donor recovery following donation” project 
Objectives 
Provide donors with tailored information and counselling pre-donation 
Provide donors with a tailored follow-up that offers education and a more 
stringent follow-up of high risk groups 
Aim to reduce adverse reactions 
Aim to shorten time to complete recovery 
Aim to improve donation experience 
Aim to reduce costs associated with covering loss of earnings or medical 
consultations 
8.3.2 Pilot project  
8.3.2.1 High risk groups 
I proposed to change our approach to the high risk donors, but to continue our existing 
management for the other donors. My study found that PBSC donors with PCS scores 
in the lowest quartile (scores ≤ 56) recovered significantly more slowly compared to 
other donors (on average 6 vs 3.4 days); BM donors with MCS scores in the lowest 
quartile (scores ≤ 46) also recovered significantly more slowly (on average 28.6 vs 
11.4 days). These 2 groups are what I consider to be the high risk groups. 
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The only demographic characteristic implicated in a delayed recovery was older donor 
age; I found that PBSC donors > 40 recovered significantly slower compared to 
donors ≤ 40 (6.8 vs 3.9 days). I could not demonstrate this in BM donors, but this may 
be due to the low number of donors in this group. Several other studies have shown 
a delayed recovery and increased SARs in older BM donors (Miller et al., 2008, 
Pulsipher et al., 2013). Although donors > 40 could be included in the intervention 
group, we decided not to based on the finding that fatigue was the main AR 
associated with higher donor age and this is likely the cause of a delayed recovery in 
this group. As the use of pre-emptive analgesia will be one of the key interventions, it 
will unlikely be effective in this group of donors. Given that we want to standardise 
interventions within the PBSC and BM group, the inclusion of this group was less 
practical.  
 
Our registry coordinates on average 500 UK donations per year. 90% of these donors 
are PBSC donors and 10% BM donors. Approximately 25% of PBSC donors will have 
PCS scores ≤ 56 and approximately 25% of BM donors will have MCS scores ≤ 46. 
If we assume a 70% response rate of baseline SF-36 questionnaires, this would mean 
a total of 79 PBSC and 9 bone marrow donors that would need intervention on an 
annual basis (table 8.3). 
 
Table 8. 3 Expected numbers of donors to be included in pilot project 
Characteristic Expected number of donors (n) 
PCS score ≤ 56 (PBSC) 25 x [(70 x 450)/100]/100 = 79  
MCS score ≤ 46 (BM) 25 x [(70x50)/100]/100 = 9  
 
 
 
  Chapter 8: Conclusions 
 
216 
 
8.3.2.2 Intervention 
I did not find any interventional studies in the area of HSC or organ donation reported 
in the literature and I have based my project proposal on research in general surgery; 
importantly patient education and pre-emptive analgesia appear to have made a 
considerable impact on recovery in the surgical field.  
 
Reviews of psychological and educational preparation for surgery strongly support 
the effectiveness of a variety of interventions, across a variety of procedures, in 
reduction of post-surgical pain, use of analgesics, psychological distress, days until 
discharge and overall cost (Devine, 1992, Devine and Cook, 1983, Hathaway, 1986, 
Anderson and Masur, 1983, Ibrahim et al., 2013, GTA, 2005). A meta-analysis of 49 
published and unpublished studies showed that the average hospital stay was 
reduced by 12%, a mean of 1.25 days (Devine and Cook, 1983). Interventions can 
be grouped into several types: information about the procedure, cognitive coping 
strategies, relaxation and hypnosis, reassurance and support. Most reviewers have 
confirmed the generally beneficial effects for all forms of preparation, but found that 
information about procedures and their side effects provided the most widespread 
benefits in recovery.  
 
Other possible interventions for high risk donors may include the use of pre-emptive 
analgesia, an approach that has proven to be effective in general surgery patients. 
Mardani-Kivi et al (Mardani-Kivi et al., 2013) described improved pain scores following 
knee arthroscopy with pre-emptive celecoxib. Another study demonstrated a 
decreased length in hospital following joint arthroplasty when using pre-emptive 
analgesia (Duellman et al., 2009). Chern et al reported a significant reduction in pain 
following BM harvest by infiltrating the harvest site with  10 ml of 0.5% bupivacaine 
immediately following bone marrow harvest (Chern et al., 1999). The interventions I 
suggested for our donors are shown in table 8.4. 
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Table 8. 4 Suggested interventions for high risk groups 
Intervention 
group 
Intervention 
PBSC (PCS 
score ≤ 56) 
 Detailed medical information and donor education at the time 
of medical (document S3) explaining the increased recovery 
time (approximately 1 week) and the increased risk of 
adverse reactions including fatigue, dizziness and pain 
 Use of pre-emptive paracetamol (1 g QDS) from the first day 
of G-CSF up until the day of donation 
 Stringent donor follow-up: weekly telephone calls if not 
recovered after 1 week up until full recovery (rather than e-
mail follow-up)  
BM (MCS score 
≤ 46) 
 Detailed medical information at the time of medical 
(document S4) explaining the increased recovery time 
(approximately 4 weeks) and the increased risk of pain 
symptoms 
 Use of paracetamol (1 g QDS) from the day of the bone 
marrow harvest up until 5 days after donation + supply donor 
with prescription of co-codamol or codeine 
 Stringent donor follow-up: for weekly telephone calls up until 
full recovery (rather than e-mail follow-up) 
 
8.3.2.3 Costing 
Table 8.5 outlines the project plan and associated costs of the project. The total 
annual added cost to the organisation would be estimated around £5100. This 
excludes staff time as part of the project team (the medical officers and donor 
relationship advisor) and the external statistical analysis.  
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Table 8. 5 Project plan and costing. Teams can be either the Donor Provision Team (DP) or 
the Donor Follow-up Team (FU) within Operations. 
Task Team Donors 
(n) 
Time Taken  Cost  
Work Up process to be 
altered to introduce SF-36 
form for all donors 
SF36 to be sent to all donors 
with covering message as 
soon as day of medical 
consultation is confirmed  
SF-36 forms to be e-mailed 
(preferential) or  posted 
DP 500 5 mins per donor  
42 hours in total 
annually 
£840 
Scoring of SF-36 assuming a 
70% response rate 
FU or 
DP 
350  10 mins per form 
60 hours in total 
annually 
£900 (FU) 
or 
£1200 
(DP) 
PBSC donor follow up – 
phone call if needed + repeat 
SF-36 at 4 weeks 
FU 79 15 mins  
20 hours in total  
£300  
BM donor follow up – weekly 
phone call up until full 
recovery + repeat SF36 at 4 
weeks 
FU 9 25 mins 
4 hours in total 
£60 
Licencing of SF36 forms and 
scoring software (based on 
smart survey as interface) 
NA  NA £2999 
(price for 
up to 600 
copies) 
TOTAL in addition to usual 
processes 
   £5100 
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The potential savings for AN are harder to calculate. First of all, we can only make 
assumptions of potential improvements regarding the number of days of loss of 
earnings claimed. Based on the experience in surgery, implementation of providing 
adequate information beforehand reduced hospital stay by 12%. Additionally, 
providing pre-emptive analgesia improved hospital stays with on average 15%. It is 
unknown what the additional value of combining these interventions would be. Also, 
it is unsure whether these figures can be extrapolated to days off work in our donor 
population. Even if we would hypothesise this to be x days in PBSC donors and y 
days in BM donors, we would still not have sufficient information. AN is currently not 
recording how many days donors claimed and whether the days claimed were for 
PBSC or BM donors. The only figure available is the total amount of loss of earnings 
covered for the financial year. We can intuitively expect that the amount claimed by 
BM donors will be significantly higher compared to PBSC donors, but BM donors only 
make up 10% of the donor population. In conclusion, an estimate of potential savings 
with regards to loss of income seems not possible with the current available 
information. 
 
8.3.2.4 Outcomes 
As per our registry’s routine donor follow-up, the time to complete recovery will be 
documented as well as adverse reactions on the first 3 days of G-CSF, on the day of 
donation, 2-3 days following donation and weekly after donation until full recovery. In 
addition, records will be kept of the cost of loss of earnings cover and post donation 
medical costs. 
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I will continue to be involved with this project and with the initial analysis in 1 year’s 
time. 
 
8.4 Conclusion 
This thesis clarifies the donor and collection characteristics associated with poorer 
donation experiences. This is a first step towards creating targeted strategies 
concerning donor recruitment, selection, work-up and donor follow-up and will 
contribute significantly to improving the donor physical and psychological donation 
experience. Additionally, illuminating donor and collection characteristics that are 
associated with not reaching the required yield, is important as different approaches 
for these donors may avoid unnecessary additional procedures and adverse 
reactions. Such strategies that improve the donation experience will contribute to 
improved donor outcomes, help to safeguard the reputation of the process and 
ultimately benefit the general transplant community. 
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Figure S 1 Your guide to the donor health and recovery project 
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Figure S 2 Home care provider form 
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Figure S 3 Toxicity guide 
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Figure S 4 PBSC visit form 
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Figure S 5 BM visit form 
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Figure S 6 Day 2 or 3 telephone call form 
ANTHONY NOLAN 
DONOR EVALUATION PBSC 
Donor Name Donor Number Date of collection Date of call 
 Have you fully recovered from your donation? Y/N 
 Are you back at work and participating in normal activities? Y/N 
 Were you discharged the same day? 
 Did you require a second day collection? 
 Were any medications started following donation?  
Please specify 
 
Collection related adverse reactions 
 0 1 2 3 4 
Allergy      
Anorexia (Loss of appetite)      
Bruising      
Dizziness      
Fatigue      
Fever      
Headache      
Infection      
Insomnia (difficulty sleeping)      
Myalgia (muscle ache)      
Nausea (feeling sick)      
Rash      
Vomiting      
Any other pain      
Other adverse reactions: 
Would the donor like to receive recipient progress reports? Y/N 
Does the donor want to communicate with the recipient? Y/N 
Call donor if something arrives Y/N 
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Mention surveymonkey – e-mail address verified Y/N – surveymonkey link sent Y/N 
Comments: 
 
Name:                                                                                                              Date: 
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Figure S 7 SF-36 questionnaire 
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Table S 1 Univariate analysis of demographic and collection characteristics influencing 
adverse reactions at different time points following PBSC donation. All time points are 
defined as the day of donation (D 0), 2-3 days after donation (D2-3) and weekly after 
donation up until full recovery. The number of cases (n) are displayed for categorical 
variables; means are given for continuous variables. 
End point  Gen-
der 
(M/F) 
BMI 
 
Age Blood 
donor 
(Y/N)  
No of 
depen-
dents (0, 
1-2, 3 or 
more)  
Central 
line 
(N/Y) 
Days 
of 
col-
lectio
n 
(1/2) 
Pre-
harvest 
white 
blood 
cell 
count (x 
109/l) 
Allergy D 0 Yes 
(0) 
        
 No 
(264) 
        
 p-
value 
NA NA NA NA NA NA NA NA 
Anorexia D 
0 
Yes 
(14) 
9/5 27.3 31.6 7/7 7/2/1 13/1 12/2 41.9 
 No 
(250) 
193/5
7 
26.3 33.1 152/95 132/56/1
3 
241/10 184/6
6 
41.1 
 p-
value 
0.33 0.41 0.54 0.41 0.82 0.46 0.25 0.84 
Back pain 
D 0 
Yes 
(21) 
16/5 28.0 32 11/10 12/4/2 18/3 12/9 41.6 
 No 
(227) 
176/5
1 
26.3 33.3 138/86 118/52/1
0 
222/6 172/5
5 
42.0 
 p-
value 
0.99 0.087 0.53 0.49 0.58 0.031 0.071 0.90 
Bleeding D 
0 
Yes 
(1) 
        
 No 
(261) 
        
 p-
value 
NA NA NA NA NA NA NA NA 
Bruising D 
0 
Yes 
(16) 
8/8 27.7 31.4 12/4 11/3/1 12/4 11/5 41.8 
 No 
(248) 
194/5
4 
26.3 31.1 147/98 128/55/1
3 
242/7 185/6
3 
42.0 
 p-
value 
= 
0.028 
0.23 0.54 0.30 0.79 0.002 0.57 0.97 
Dizziness 
D 0 
Yes 
(16) 
13/3 24.8 35.8 7/8 9/1/2 16/1 13/4 46.2 
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 No 
(248) 
189/5
9 
26.5 32.9 152/94 130/57/1
2 
238/10 183/6
4 
41.6 
 p-
value 
0.77 0.17 0.20 0.28 0.15 0.53 0.99 0.16 
Fatigue D 
0 
Yes 
(84) 
55/29 25.7 32.3 50/32 44/15/6 80/4 60/24 42.5 
 No 
(180) 
147/3
3 
26.7 33.4 109/70 95/43/8 174/7 136/4
4 
41.7 
 p-
value 
= 
0.005 
0.13 0.37 0.99 0.43 0.75 0.55 0.62 
Fever D 0 Yes 
(12) 
8/4 26.2 33.1 9/3 5/3/1 11/1 8/4 43.2 
 No 
(252) 
194/5
8 
26.4 33.0 150/99 134/55/1
3 
243/10 188/6
4 
41.9 
 p-
value 
0.48 0.90 0.98 0.38 0.76 0.41 0.51 0.70 
Headache 
D 0 
Yes 
(68) 
40/28 27.1 33.1 39/27 34/14/8 66/2 46/21 43.3 
 No 
(196) 
162/3
4 
26.1 33.0 120/75 105/44/6 188/9 150/4
7 
41.1 
 p-
value 
< 
0.001 
0.10 0.97 0.77 0.027 0.73 0.26 0.28 
Infection D 
0 
Yes 
(0) 
        
 No 
(264) 
        
 p-
value 
NA NA NA NA NA NA NA NA 
Injection 
site 
reaction D 
0 
Yes 
(15) 
11/4 28.1 31.9 8/7 12/0/0 15/0 11/4 43.1 
 No 
(249) 
191/5
8 
26.3 33.2 151/95 127/58/1
4 
239/11 185/6
4 
41.9 
 p-
value 
0.76 0.13 0.35 0.59 0.037 0.99 0.99 0.73 
Insomnia D 
0 
Yes 
(44) 
30/14 26.8 34.9 28/16 22/10/2 41/3 34/10 44.3 
 No 
(220) 
172/4
8 
26.3 32.7 131/86 117/48/1
2 
213/8 162/5
8 
41.4 
 p-
value 
0.17 0.49 0.14 0.74 0.95 0.40 0.71 0.20 
Myalgia D 
0 
Yes 
(85) 
63/22 25.6 32.6 48/36 43/15/5 84/2 63/23 41.5 
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 No 
(179) 
139/4
0 
26.8 33.2 111/66 96/43/9 170/9 133/4
5 
42.2 
 p-
value 
0.54 0.054 0.58 0.42 0.69 0.51 0.88 0.68 
Nausea D 
0 
Yes 
(22) 
15/6 26.9 27.8 11/10 16/2/2 20/2 18/4 43.2 
 No 
(241) 
185/5
6 
26.4 33.5 146/92 122/56/1
2 
232/9 177/6
3 
41.9 
 p-
value 
0.60 0.57 = 
0.00
5 
0.49 0.17 0.23 0.61 0.67 
Any other 
pain D 0 
Yes 
(69) 
50/19 26.3 31.7 39/30 39/15/6 64/6 50/20 42.4 
 No 
(194) 
151/4
3 
26.4 33.5 119/72 100/43/8 189/5 145/4
8 
41.7 
 p-
value 
0.41 0.88 0.17 0.47 0.44 0.073 0.63 0.74 
Rash D 0 Yes 
(1) 
        
 No 
(263) 
        
 p-
value 
NA NA NA NA NA NA NA NA 
Vomiting D 
0 
Yes 
(1) 
        
 No 
(263) 
        
 p-
value 
NA NA NA NA NA NA NA NA 
Pain 
summary 
D 0 
Yes 
(153) 
109/4
4 
26.5 32.7 85/66 81/31/13 148/6 110/4
3 
42.5 
 No 
(108) 
90/18 26.2 33.5 73/34 56/26/1 103/5 84/24 41.1 
 p-
value 
< 
0.05 
0.53 0.48 0.069 0.029 0.77 0.32 0.54 
Summary 
all adverse 
reactions D 
0 
Yes 
(190) 
137/5
3 
26.5 33.6 114/73 95/45/13 182/8 140/5
0 
42.2 
 No 
(71) 
62/9 26.1 31.4 44/27 42/12/1 69/2 54/17 41.6 
 p-
value 
< 
0.01 
0.54 0.08
4 
0.99 0.091 0.73 0.75 0.75 
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Allergy D 
2-3 
Yes 
(1) 
        
 No 
(243) 
        
 p-
value 
NA NA NA NA NA NA NA NA 
Anorexia D 
2-3 
Yes 
(20) 
14/6 27.1 35.2 10/10 6/3/2 118/2 15/5 44.1 
 No 
(223) 
172/5
1 
26.3 33 136/84 123/47/1
1 
211/11 164/5
8 
41.9 
 p-
value 
0.58 0.45 0.30 0.34 0.28 0.29 0.99 0.46 
Back pain 
D 2-3 
Yes 
(9) 
7/2 27.7 31.2 3/6 5/3/0 9/0 7/2 3/6 
 No 
(230) 
175/5
5 
26.4 33.4 140/87 120/47/1
3 
216/13 169/6
0 
140/87 
 p-
value 
0.99 0.42 0.50 0.16 0.62 0.99 0.99 0.16 
Bleeding D 
2-3 
Yes 
(1) 
        
 No 
(240) 
        
 p-
value 
NA NA NA NA NA NA NA NA 
Bruising D 
2-3 
Yes 
(81) 
56/25 27.2 33.2 46/34 41/17/3 71/10 48/33 42.5 
 No 
(162) 
130/3
2 
26.0 33.2 100/60 88/33/10 158/3 131/3
0 
41.9 
 p-
value 
0.077 = 
0.05 
0.99 0.49 0.75 0.001 < 
0.001 
0.74 
Dizziness 
D 2-3 
Yes 
(24) 
18/6 27.0 37.0 14/9 13/4/2 23/1 15/9 41.7 
 No 
(219) 
168/5
1 
26.3 32.8 132/85 116/46/1
1 
206/12 164/5
4 
42.1 
 p-
value 
0.80 0.52 < 
0.05 
0.99 0.72 0.99 0.22 0.88 
Fatigue D 
2-3 
Yes 
(98) 
74/24 26.4 36.1 58/39 44/22/6 93/5 69/29 43.2 
 No 
(145) 
112/3
3 
26.4 31.2 88/55 85/28/7 136/8 110/3
4 
41.3 
 p-
value 
0.76 0.92 < 
0.00
1 
0.79 0.38 0.99 0.3 0.28 
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Fever D 2-
3 
Yes 
(3) 
2/1 32.8 33.2 ½ 1/1/1 3/0 3/0 39.5 
 No ( 
241) 
184/5
7 
26.3 33.2 145/93 129/49/1
2 
227/13 177/6
3 
42.1 
 p-
value 
0.56 < 
0.05 
0.99 0.56 0.15 0.99 0.57 0.68 
Headache 
D 2-3  
Yes 
(24) 
17/7 27.6 35.6 16/8 10/5/3 22/2 18/6 44.4 
 No 
(219) 
169/5
0 
26.3 32.0 130/86 119/45/1
0 
207/11 161/5
7 
41.7 
 p-
value 
0.46 0.17 0.19 0.66 0.19 0.62 0.99 0.32 
Infection D 
2-3 
Yes 
(0) 
        
 No 
(244) 
        
 p-
value 
NA NA NA NA NA NA NA NA 
Injection 
site 
reaction D 
2-3 
Yes 
(0) 
        
 No 
(240) 
        
 p-
value 
NA NA NA NA NA NA NA NA 
Insomnia D 
2-3 
Yes 
(19) 
16/3 26.2 31.7 12/7 9/5/0 18/1 14/5 43.3 
 No 
(224) 
170/5
4 
26.4 33.3 134/87 120/45/1
3 
211/12 165/5
8 
41.9 
 p-
value 
0.58 0.82 0.47 0.99 0.45 0.99 0.99 0.64 
Myalgia 2-
3 
Yes 
(50) 
34/16 27.0 34.0 30/19 27/10/4 47/3 38/12 43.4 
 No 
(193) 
152/4
1 
26.2 33.0 116/75 102/40/9 182/10 141/5
1 
41.7 
 p-
value 
0.13 0.24 0.48 0.99 0.69 0.74 0.86 0.40 
Nausea D 
2-3 
Yes 
(17) 
11/6 27.0 33.0 9/8 10/3/2 13/4 11/6 41.7 
 No 
(226) 
175/5
1 
26.4 33.2 137/86 119/47/1
1 
216/9 168/5
7 
45.6 
 p-
value 
0.24 0.60 0.92 0.61 0.53 0.008 0.39 0.23 
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Any other 
pain D 2-3 
Yes 
(9) 
8/1 28.3 37.3 7/2 5/3/0 8/1 8/1 45.4 
 No 
(234) 
178/5
6 
26.3 33.0 139/92 124/47/1
3 
221/12 171/6
2 
41.9 
 p-
value 
0.69 0.20 0.18 0.49 0.60 0.40 0.45 0.45 
Rash D 2-3 Yes 
(2) 
1/1 27.7 33.9 1/1 1/1/0 2/0 2/0 62.1 
 No 
(242) 
185/5
7 
26.4 33.2 145/94 129/49/1
3 
228/13 178/6
3 
41.8 
 p-
value 
0.42 0.46 0.91 0.99 0.71 0.99 0.99 0.01 
Vomiting D 
2-3 
Yes 
(2) 
2/0 27.7 35.9 0/2 0/1/0 2/0 1/1 51.1 
 No 
(242) 
184/5
8 
26.4 33.1 146/93 130/49/1
3 
228/13 179/6
2 
41.9 
 p-
value 
0.99 0.70 0.67 0.15 0.24 0.99 0.45 0.24 
Pain 
summary 
D 2-3 
Yes 
(72) 
52/20 27.2 33.5 42/29 35/16/6 69/3 53/19 42.2 
 No 
(171) 
134/3
7 
26.1 33.0 104/65 94/34/7 160/10 126/4
4 
42.0 
 p-
value 
0.32 0.067 0.71 0.77 0.33 0.76 0.99 0.89 
Summary 
all adverse 
reactions D 
2-3  
Yes 
(165) 
119/4
6 
26.8 34.1 99/64 82/36/9 154/11 116/4
9 
41.7 
 No 
(78) 
67/11 25.5 31.2 47/30 47/14/4 75/2 63/14 42.7 
 p-
value 
< 
0.05 
< 
0.05 
< 
0.05 
0.99 0.55 0.24 0.061 0.59 
Allergy 1 
week 
Yes 
(0) 
0/0        
 No 
(239) 
182/5
7 
       
 p-
value 
NA NA NA NA NA NA NA NA 
Anorexia 1 
week 
Yes 
(2) 
0/2 20.5 35.4 1/1 1/0/1 1/1 0/2 49.5 
 No 
(237) 
182/5
5 
26.4 33.3 143/92 126/53/1
3 
229/9 172/6
5 
41.3 
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 p-
value 
0.056 < 
0.05 
0.76 0.99 0.056 0.082 0.078 0.47 
Back pain 
1 week 
Yes 
(5) 
3/2 24.4 34.6 2/3 3/0/1 4/1 3/2 49.9 
 No 
(231) 
177/5
4 
26.4 33.4 141/88 121/53/1
3 
223/9 167/6
4 
41.1 
 p-
value 
0.34 0.39 0.78 0.38 0.23 0.20 0.62 0.12 
Bleeding 1 
week 
Yes 
(1) 
        
 No 
(238) 
        
 p-
value 
NA NA NA NA NA NA NA NA 
Bruising 1 
week 
Yes 
(16) 
10/6 24.8 34.0 11/5 7/4/1 11/5 10/6 47.3 
 No 
(223) 
172/5
1 
26.4 33.3 133/88 120/49/1
3 
219/5 162/6
1 
41.0 
 p-
value 
0.22 0.18 0.77 0.60 0.87 < 0.001 0.40 0.12 
Dizziness 
1 week 
Yes 
(1) 
        
 No 
(238) 
        
 p-
value 
NA NA NA NA NA NA NA NA 
Fatigue 1 
week 
Yes 
(21) 
15/6 26.3 37.2 10/11 10/3/3 20/1 14/7 45.4 
 No 
(218) 
167/5
1 
26.3 33.0 134/82 117/50/1
1 
210/9 158/6
0 
41.0 
 p-
value 
0.60 0.95 < 
0.05 
0.24 0.12 0.99 0.61 0.16 
Fever 1 
week 
Yes 
(0) 
0/0        
 No 
(239) 
182/5
7 
       
 p-
value 
NA NA NA NA NA NA NA NA 
Headache 
1 week 
Yes 
(3) 
2/1 24.3 32.2 2/1 2/0/1 3/0 2/1 42.0 
 No 
(236) 
180/5
6 
26.4 33.4 142/92 125/53/1
3 
227/10 170/6
6 
41.4 
 p-
value 
0.56 0.43 0.83 0.99 0.13 0.99 0.99 0.96 
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Infection 1 
week 
Yes 
(1) 
        
 No 
(238) 
        
 p-
value 
NA NA NA NA NA NA NA NA 
Injection 
site 
reaction 1 
week 
Yes 
(2) 
1/1 25.4 30.0 2/0 1/1/0 1/1 1/1 51.1 
 No 
(237) 
181/5
6 
26.3 33.4 142/93 126/52/1
4 
229/9 171/6
6 
41.2 
 p-
value 
0.42 0.77 0.61 0.52 0.74 0.082 0.48 0.22 
Insomnia 1 
week 
Yes 
(3) 
3/0 27.9 37.7 ½ 1/1/0 3/0 3/0 52.5 
 No 
(236) 
179/5
7 
26.3 33.3 143/91 126/52/1
4 
227/10 169/6
7 
41.3 
 p-
value 
0.99 0.32 0.42 0.56 0.74 0.99 0.56 0.16 
Myalgia 1 
week 
Yes 
(6) 
3/3 23.4 36.1 3/3 3/0/2 5/1 3/3 48.3 
 No 
(233) 
179/5
4 
26.4 33.3 141/90 124/53/1
2 
225/9 169/6
4 
41.2 
 p-
value 
0.15 0.14 0.47 0.68 0.011 0.23 0.35 0.16 
Nausea 1 
week 
Yes 
(2) 
1/1 24.2 31 2/0 2/0/0 2/0 1/1 46.9 
 No 
(237) 
181/5
6 
26.3 33.4 142/93 125/53/1
4 
228/10 171/6
6 
41.3 
 p-
value 
0.42 0.52 0.72 0.52 0.59 0.99 0.48 0.48 
Any other 
pain 1 
week 
Yes 
(6) 
4/2 26.0 31.8 3/3 3/1/1 6/0 3/3 44.6 
 No 
(233) 
178/5
5 
26.3 33.4 141/90 124/52/1
3 
224/10 169/6
4 
41.3 
 p-
value 
0.63 0.89 0.67 0.68 0.53 0.99 0.35 0.62 
Rash 1 
week 
Yes 
(1) 
        
 No 
(238) 
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 p-
value 
NA NA NA NA NA NA NA NA 
Vomiting 1 
week 
Yes 
(239) 
        
 No (0)         
 p-
value 
NA NA NA NA NA NA NA NA 
Pain 
summary 1 
week 
Yes 
(9) 
5/4 26.2 33.5 4/5 5/1/2 8/1 5/4 46.1 
 No 
(226) 
175/5
1 
26.3 33.4 137/86 118/52/1
2 
218/9 165/6
1 
41.2 
 p-
value 
0.22 0.95 0.98 0.32 0.12 0.33 0.27 0.26 
Summary 
all adverse 
reactions 1 
week  
Yes 
(30) 
21/9 25.3 36.4 17/12 13/5/3 26/4 20/10 43.9 
 No 
(205) 
159/4
6 
26.5 33 124/79 110/48/1
1 
200/6 150/5
5 
41.1 
 p-
value 
0.36 0.21 0.06
2 
0.84 0.43 0.026 0.51 0.31 
All time 
points 
Allergy 
summary 
Yes 
(2) 
2/0 29.1 27.7 1/1 2/0/0 2/0 1/1 51.8 
 No 
(272) 
207/6
5 
26.4 33.2 164/10
5 
141/60/1
5 
258/14 199/7
3 
42.1 
 p-
value 
0.99 0.39 0.39 0.99 0.59 0.99 0.47 0.40 
All time 
points 
anorexia 
summary 
Yes 
(32) 
23/9 27.0 32.9 16/16 13/5/2 29/3 24/8 42.3 
 No 
(242) 
186/5
6 
26.3 33.1 149/90 130/55/1
3 
231/11 176/6
6 
42.1 
 p-
value 
0.51 0.40 0.24 0.18 0.78 0.22 0.99 0.96 
All time 
points back 
pain 
summary 
Yes 
(40) 
32/8 27.2 32.7 19/21 22/9/3 37/3 26/14 43.3 
 No 
(230) 
173/5
7 
26.5 33.2 143/84 117/51/1
2 
219/11 170/6
0 
41.9 
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 p-
value 
0.69 0.12 0.75 0.079 0.84 0.44 0.25 0.54 
All time 
points 
bleeding 
summary 
Yes 
(4) 
1/3 26.1 33.6 4/0 4/0/0 1/3 3/1 43.9 
 No 
(270) 
208/6
2 
26.4 33.1 161/10
6 
139/60/1
5 
259/11 197/7
3 
42.1 
 p-
value 
=0.01
3 
0.90 0.92 0.22 0.35 < 0.001 0.99 0.79 
All time 
points 
bruising 
summary 
Yes 
(96) 
65/29 27.1 33.0 59/35 51/19/5 83/13 60/36 43.1 
 No 
(177) 
144/3
6 
25.0 33.2 105/71 92/41/10 176/1 140/3
7 
41.7 
 p-
value 
= 
0.052 
= 
0.062 
0.22 0.70 0.86 < 0.001 0.004 0.42 
All time 
points 
dizziness 
summary 
Yes 
(44) 
35/9 26.2 34.6 22/21 26/5/4 43/2 31/14 43.5 
 No 
(229) 
174/5
5 
26.5 32.8 142/85 116/55/1
1 
216/12 168/6
0 
41.7 
 p-
value 
0.7 0.71 0.25 0.18 0.17 0.99 0.58 0.41 
All time 
points 
fatigue 
summary 
Yes 
(150) 
106/4
4 
26.2 34.4 93/59 72/33/11 145/8 105/4
9 
43.0 
 No 
(125) 
104/2
1 
26.6 31.6 72/47 71/27/4 115/6 95/25 40.9 
 p-
value 
= 
0.016 
0.40 = 
0.00
9 
0.99 0.23 0.99 0.055 0.23 
All time 
points 
fever 
summary 
Yes 
(14) 
10/4 27.3 33.1 9/5 6/4/1 13/1 10/4 42.4 
 N 
(260) 
199/6
1 
26.3 33.1 156/10
1 
137/56/1
4 
247/13 190/7
0 
42.1 
 p-
value 
0.75 0.46 0.99 0.99 0.72 0.53 0.99 0.93 
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All time 
points 
headache 
summary 
Yes 
(82) 
51/31 27.0 33.7 62/39 41/17/9 99/3 72/30 42.6 
 No 
(193) 
159/3
4 
26.0 32.8 103/67 102/43/6 161/11 128/4
4 
41.9 
 p-
value 
< 
0.001 
0.098 0.43 0.99 = 0.039 0.27 0.49 0.68 
All time 
points 
infection 
summary 
Yes 
(1) 
        
 No 
(273) 
        
 p-
value 
NA NA NA NA NA NA NA NA 
All time 
points 
injection 
site 
reaction 
summary 
Yes 
(18) 
12/6 27.3 30.9 11/7 14/1/0 17/1 12/6 45.0 
 No 
(256) 
197/5
9 
26.3 33.3 154/99 129/59/1
5 
243/13 188/6
8 
41.9 
 p-
value 
0.39 0.34 0.28 0.99 0.066 0.99 0.58 0.34 
All time 
points 
insomnia 
summary 
Yes 51/18 26.4 34.1 43/26 36/16/3 66/3 50/19 42.7 
 No 158/4
7 
26.4 32.8 122/80 107/44/1
2 
194/11 150/5
5 
42.0 
 p-
value 
0.62 0.91 0.30 0.89 0.92 0.99 0.99 0.71 
All time 
points 
myalgia 
summary 
Yes 96/34 26.5 33.1 76/52 69/23/8 125/5 94/37 41.8 
 No 
(143) 
112/3
1 
26.3 33.1 88/54 73/37/7 134/9 105/3
7 
42.2 
 p-
value 
0.40 0.71 0.95 0.71 0.39 0.42 0.79 0.72 
All time 
points  
Yes 
(40) 
28/12 27.2 31.5 20/20 26/6/4 36/5 31/10 43.9 
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Nausea 
summary 
No 
(234) 
181/5
3 
26.2 33.4 145/86 117/54/1
1 
224/9 169/6
4 
41.8 
 p-
value 
0.32 0.20 0.24 0.16 0.30 0.042 0.85 0.38 
Any other 
Pain all 
time points 
Yes 
(118) 
90/28 26.7 33.2 72/44 66/25/9 111/7 87/32 41.7 
 No 
(155) 
118/3
7 
26.0 33.1 92/62 76/35/6 148/7 112/4
2 
42.5 
 p-
value 
0.99 0.41 0.87 0.71 0.44 0.60 0.99 0.64 
All time 
points rash 
summary 
Yes 
(6) 
5/1 27.5 35.2 3/3 4/2/0 5/0 6/0 58.1 
 No 
(268) 
204/6
4 
26.4 33.1 162/10
3 
239/58/1
5 
255/14 194/7
4 
41.2 
 p-
value 
0.99 0.20 0.57 0.68 0.790.78 0.99 0.20 0.014 
All time 
points 
vomiting 
summary 
Yes 
(3) 
2/1 27.9 32.9 ½ 1/1/0 2/1 2/1 51.7 
 No 
(271) 
207/6
4 
26.4 33.1 164/10
4 
142/59/1
5 
258/13 198/7
3 
42.0 
 p-
value 
0.56 0.26 0.97 0.56 0.75 0.15 0.99 0.14 
All time 
points pain 
summary 
Yes 
(181) 
133/4
8 
26.7 33.2 115/82 104/41/1
4 
192/8 145/5
5 
42.2 
 No 
(74) 
77/17 25.7 33.1 50/24 19/1 68/6 55/19 41.9 
 p-
value 
0.14 0.088 0.52 0.21 0.15 0.22 0.88 0.87 
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Table S 2 Univariate analysis of HRQOL scores influencing adverse reactions at different 
time points following PBSC donation. All time points are defined as the day of donation (D 
0), 2-3 days after donation (D2-3) and weekly after donation up until full recovery. The 
number of cases (n) are displayed for categorical variables; means are given for continuous 
variables. 
End point  PCS MCS 
Allergy D 0 Yes (0)   
 No (264)   
 p-value NA NA 
Anorexia D 0 Yes (14) 58.1 52.8 
 No (250) 57.5 54.2 
 p-value 0.58 0.40 
Back pain D 0 Yes (21) 56.2 51.8 
 No (227) 57.6 54.4 
 p-value 0.15 0.081 
Bleeding D 0 Yes (1) 59.5 51.1 
 No (261) 57.5 54.1 
 p-value 0.57 0.56 
Bruising D 0 Yes (16) 58.4 53.7 
 No (248) 57.4 54.1 
 p-value 0.36 0.80 
Dizziness D 0 Yes (16) 54.2 53.9 
 No (248) 57.7 54.1 
 p-value = 0.001 0.94 
Fatigue D 0 Yes (84) 57.2 54.1 
 No (180) 57.7 54.1 
 p-value 0.36 0.94 
Fever D 0 Yes (12) 58.0 53.6 
 No (252) 57.5 54.1 
 p-value 0.64 0.76 
Headache D 0 Yes (68) 57.2 52.9 
 No (196) 57.6 54.5 
 p-value 0.50 0.069 
Infection D 0 Yes (0)   
 No (264)   
 p-value NA NA 
Injection site 
reaction D 0 
Yes (15) 57.7 51.9 
 No (249) 57.5 54.2 
 p-value 0.88 0.20 
Insomnia D 0 Yes (44) 58.3 54.9 
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 No (220) 57.4 54.0 
 p-value 0.21 0.37 
Myalgia D 0 Yes (85) 56.8 54.4 
 No (179) 57.8 53.5 
 p-value 0.085 0.27 
Nausea D 0 Yes (22) 57.6 52.8 
 No (241) 57.5 54.3 
 p-value 0.97 0.30 
Any other pain D 0 Yes (69) 57.5 54.9 
 No (194) 57.5 53.2 
 p-value 0.99 0.73 
Rash D 0 Yes (1) 58.6 47.8 
 No (263) 57.5 54.1 
 p-value 0.76 0.21 
Vomiting D 0 Yes (1) 59.5 51.1 
 No (263) 57.5 54.1 
 p-value 0.57 0.56 
Pain summary D 0 Yes (153) 57.1 53.4 
 No (108) 57.9 54.9 
 p-value 0.14 < 0.05 
Summary all 
adverse reactions 
D 0 
Yes (190) 57.2 54.2 
 No (71) 58.3 54.0 
 p-value < 0.05 0.83 
Allergy D 2-3 Yes (1) 56.3 53.1 
 No (243) 57.5 54.0 
 p-value 0.72 0.85 
Anorexia D 2-3 Yes (20) 57.8 54.2 
 No (223) 57.5 54.0 
 p-value 0.73 0.92 
Back pain D 2-3 Yes (9) 53.3 50.2 
 No (230) 57.6 54.2 
 p-value 0.34 0.20 
Bleeding D 2-3 Yes (1) 61.1 54.2 
 No (240) 57.5 54.0 
 p-value 0.30 0.98 
Bruising D 2-3 Yes (81) 57.4 54.3 
 No (162) 57.6 53.9 
 p-value 0.73 0.68 
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Dizziness D 2-3 Yes (24) 55.7 52.6 
 No (219) 57.7 54.2 
 p-value < 0.05 0.27 
Fatigue D 2-3 Yes (98) 56.4 54.2 
 No (145) 58.3 53.9 
 p-value < 0.001 0.74 
Fever D 2-3 Yes (3) 59.2 48.6 
 No ( 241) 57.4 54.1 
 p-value 0.48 0.14 
Headache D 2-3  Yes (24) 57.9 52.3 
 No (219) 57.4 54.3 
 p-value 0.63 0.13 
Infection D 2-3 Yes (0)   
 No (244)   
 p-value NA NA 
Injection site 
reaction D 2-3 
Yes (0)   
 No (240)   
 p-value NA NA 
Insomnia D 2-3 Yes (19) 57.1 52.2 
 No (224) 57.5 54.2 
 p-value 0.75 0.25 
Myalgia 2-3 Yes (50) 56.3 53.5 
 No (193) 57.8 54.2 
 p-value < 0.05 0.43 
Nausea D 2-3 Yes (17) 56.3 52.7 
 No (226) 57.6 54.1 
 p-value 0.25 0.39 
Any other pain D 2-
3 
Yes (9) 57.9 53.8 
 No (234) 57.5 54.1 
 p-value 0.80 0.93 
Rash D 2-3 Yes (2) 59.6 56.4 
 No (242) 57.4 54.0 
 p-value 0.54 0.65 
Vomiting D 2-3 Yes (2) 53.8 50.8 
 No (242) 57.5 54.0 
 p-value 0.29 0.53 
Pain summary D 2-
3 
Yes (72) 56.4 53.8 
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 No (171) 58.0 54.2 
 p-value < 0.005 0.63 
Summary all 
adverse reactions 
D 2-3  
Yes (165) 56.9 54.0 
 No (78) 58.9 54.4 
 p-value = 0.001 0.61 
Allergy 1 week Yes (0)   
 No (239)   
 p-value NA NA 
Anorexia 1 week Yes (2) 54.5 57.1 
 No (237) 57.6 53.9 
 p-value 0.20 0.40 
Back pain 1 week Yes (5) 54.2 60.0 
 No (231) 57.6 54.1 
 p-value < 0.05 0.19 
Bleeding 1 week Yes (1) 58.8 52.5 
 No (238) 57.5 54.0 
 p-value 0.71 0.79 
Bruising 1 week Yes (16) 57.1 54.4 
 No (223) 57.6 53.9 
 p-value 0.62 0.78 
Dizziness 1 week Yes (1) 50.2 61.6 
 No (238) 57.6 53.9 
 p-value 0.08 0.14 
Fatigue 1 week Yes (21) 55.7 53.3 
 No (218) 57.7 54.0 
 p-value < 0.05 0.58 
Fever 1 week Yes (0)   
 No (239)   
 p-value NA NA 
Headache 1 week Yes (3) 50.2 61.1 
 No (236) 57.6 53.9 
 p-value 0.08 0.14 
Infection 1 week Yes (1) 50.1 58.1 
 No (238) 57.6 54.0 
 p-value 0.069 0.43 
Injection site 
reaction 1 week 
Yes (2) 56.3 49.9 
 No (237) 57.5 54.0 
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 p-value 0.61 0.27 
Insomnia 1 week Yes (3) 58.0 52.7 
 No (236) 57.5 54.0 
 p-value 0.81 0.66 
Myalgia 1 week Yes (6) 53.3 53.3 
 No (233) 57.6 54.0 
 p-value 0.14 0.77 
Nausea 1 week Yes (2) 49.6 42.7 
 No (237) 57.6 54.0 
 p-value 0.057 0.091 
Any other pain 1 
week 
Yes (6) 57.8 55.2 
 No (233) 57.5 54.0 
 p-value 0.88 0.64 
Rash 1 week Yes (1) 54.7 50.1 
 No (238) 57.5 54.0 
 p-value 0.42 0.45 
Vomiting 1 week Yes (239)   
 No (0)   
 p-value NA NA 
Pain summary 1 
week 
Yes (9) 54.5 51.9 
 No (226) 57.6 54.0 
 p-value 0.19 0.30 
Summary all 
adverse reactions 1 
week  
Yes (30) 56.1 53.5 
 No (205) 57.8 54.0 
 p-value < 0.05 0.66 
All time points 
Allergy summary 
Yes (2) 58.5 47.0 
 No (272) 57.5 54.2 
 p-value 0.70 0.12 
All time points 
anorexia summary 
Yes (32) 57.8 53.6 
 No (242) 57.5 54.1 
 p-value 0.67 0.62 
All time points back 
pain summary 
Yes (40) 56.4 52.2 
 No (230) 57.7 54.4 
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 p-value 0.28 0.32 
All time points 
bleeding summary 
Yes (4) 58.6 53.0 
 No (270) 57.5 54.1 
 p-value 0.54 0.66 
All time points 
bruising summary 
Yes (96) 57.6 54.1 
 No (177) 57.5 54.1 
 p-value 0.90 0.96 
All time points 
dizziness summary 
Yes (44) 55.4 51.8 
 No (229) 57.9 54.4 
 p-value < 0.001 0.10 
All time points 
fatigue summary 
Yes (150) 56.8 54.1 
 No (125) 58.5 54.0 
 p-value = 0.003 0.88 
All time points fever 
summary 
Yes (14) 58.2 52.9 
 N (260) 57.5 54.2 
 p-value 0.49 0.43 
All time points 
headache summary 
Yes (82) 57.3 52.8 
 No (193) 57.7 54.8 
 p-value 0.43 = 0.021 
All time points 
infection summary 
Yes (1) 50.1 58.1 
 No (273) 57.6 54.1 
 p-value 0.073 0.44 
All time points 
injection site 
reaction summary 
Yes (18) 56.7 50.7 
 No (256) 57.6 54.3 
 p-value 0.41 0.11 
All time points 
insomnia summary 
Yes 57.9 54.0 
 No 57.4 54.1 
 p-value 0.49 0.91 
All time points 
myalgia summary 
Yes 56.7 53.5 
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 No (143) 58.1 54.5 
 p-value = 0.009 0.14 
All time points 
nausea summary 
Yes (40) 56.8 54.3 
 No (234) 57.6 52.7 
 p-value 0.26 0.13 
Any other Pain all 
time points 
Yes (118) 57.3 53.7 
 No (155) 57.7 54.4 
 p-value 0.45 0.36 
All time points rash 
summary 
Yes (6) 57.2 53.6 
 No (268) 57.5 54.1 
 p-value 0.87 0.86 
All time points 
vomiting summary 
Yes (3) 56.6 50.9 
 No (271) 57.5 54.1 
 p-value 0.71 0.17 
All time points pain 
summary 
Yes (181) 57.1 53.5 
 No (74) 58.6 54.9 
 p-value = 0.02 = 0.068 
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Table S 3 Univariate analysis of demographic and collection characteristics influencing 
adverse reactions at different time points following BM donation. All time points are defined 
as the day of donation (D 0), 2-3 days after donation (D2-3) and weekly after donation up 
until full recovery. The number of cases (n) are displayed for categorical variables; means 
are given for continuous variables. 
End point  Gender 
(M/F) 
BMI Age Blood 
donor 
(Y/N) 
No of 
dependants 
(0, 1-2, 3 or 
more) 
Duration 
of proce- 
dure 
Volume 
of BM 
harveste
d per kg 
donor 
weight 
All time 
points 
Allergy 
summary 
Yes 
(0) 
       
 No 
(37) 
       
 p-
value 
NA NA NA NA NA NA NA 
All time 
points 
anorexia 
summary 
Yes 
(6) 
5/1 24.1 22.9 2/4 6/0/0 40 19.1 
 No 
(31) 
28/3 27.5 33.4 22/8 11/7/4 40.7 14.1 
 p-
value 
0.52 0.056 < 
0.00
1 
0.14 0.085 0.97 0.003 
All time 
points back 
pain 
summary 
Yes 
(34) 
30/4 26.9 31.7 21/12 16/6/4 40.7 14.9 
 No 
(3) 
3/0 28 32.0 3/0 1/1/0 40 15.2 
 p-
value 
0.99 0.64 0.96 0.41 0.64 0.98 0.90 
All time 
points 
bleeding 
summary 
Yes 
(12) 
10/2 25.8 32.3 8/3 5/1/2 21.5 15.8 
 No 
(25) 
23/2 27.5 31.4 16/9 12/6/2 24.0 14.5 
 p-
value 
0.58 0.23 0.80 0.30 0.45 0.45 0.37 
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All time 
points 
bruising 
summary 
Yes 
(22) 
18/4 26.5 31.9 17/5 8/4/3 45.1 16.1 
 No 
(15) 
15/0 27.7 31.4 7/7 9/3/1 31.2 13.2 
 p-
value 
0.13 0.37 0.89 0.12 0.59 0.16 0.032 
All time 
points 
dizziness 
summary 
Yes 
(16) 
13/3 26.2 32.3 9/7 8/2/3 42.2 15.8 
 No 
(21) 
20/1 27.5 31.2 15/5 9/5/1 39.7 14.2 
 p-
value 
0.30 0.35 0.74 0.33 0.33 0.79 0.25 
All time 
points 
fatigue 
summary 
Yes 
(32) 
28/4 28.0 31.7 22/9 15/6/4 43.1 15.1 
 No 
(5) 
5/0 26.8 31.2 2/3 2/1/0 27.5 13.5 
 p-
value 
0.99 0.53 0.91 0.36 0.74 0.013 0.42 
All time 
points fever 
summary 
Yes 
(2) 
2/0 24.9 29.6 2/0 1/0/0 120 14.4 
 No 
(35) 
31/4 27.1 31.8 22/12 16/7/4 37.4 14.9 
 p-
value 
0.99 0.47 0.77 0.56 0.72 NA 0.85 
All time 
points 
headache 
summary 
Yes 
(4) 
3/1 29.1 34.3 3/1 2/1/1 35 14.5 
 No 
(33) 
30/3 26.7 31.4 21/11 15/6/3 41.2 15.0 
 p-
value 
0.38 0.26 0.59 0.87 0.79 0.72 0.83 
All time 
points 
infection 
summary 
Yes 
(0) 
       
 Appendix 1 - Supplemental tables and figures 
 
274 
 
 No 
(37) 
       
 p-
value 
NA NA NA NA NA NA NA 
All time 
points 
insomnia 
summary 
Yes 
(7) 
6/1 28.0 31.0 6/1 2/1/2 53.9 14.1 
 No 
(30) 
27/3 26.7 31.9 18/11 15/6/2 35.6 15.1 
 p-
value 
0.99 0.45 0.84 0.43 0.19 0.27 0.56 
All time 
points 
myalgia 
summary 
Yes 
(2) 
2/0 27.4 44.2 2/0 0/0/2 72.5 13.4 
 No 
(35) 
31/4 26.9 31.0 22/12 17/7/2 37.9 15.0 
 p-
value 
0.79 0.87 0.06
8 
0.56 0.002 0.42 0.60 
All time 
points 
nausea 
summary 
Yes 
(7) 
7/0 27.2 33.6 5/2 2/2/2 48.3 15.5 
 No 
(29) 
25/4 26.8 31.3 18/10 14/5/2 40.1 15.0 
 p-
value 
0.57 0.78 0.60 0.83 0.24 0.58 0.78 
Any other 
Pain all 
time points 
Yes 
(5) 
5/0 25.0 35.0 5/0 2/1/1 70 17.6 
 No 
(32) 
28/4 27.2 31.2 19/12 15/6/3 38.1 14.5 
 p-
value 
0.99 0.25 0.43 0.21 0.79 0.48 0.1 
All time 
points rash 
summary 
Yes 
(1) 
       
 No 
(36) 
       
 p-
value 
NA NA NA NA NA NA NA 
All time 
points 
Yes 
(2) 
2/0 28.9 19.7 2/0 2/0/0 20 12.3 
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vomiting 
summary 
 No 
(35) 
31/4 26.8 32.4 22/12 15/7/4 41.5 15.1 
 p-
value 
0.99 0.49 < 
0.00
1 
0.56 0.50 0.37 0.35 
All time 
point throat 
pain  
Yes 
(21) 
18/3 26.7 32 14/6 9/4/3 43.5 14.8 
 No 
(15) 
14/1 27.5 30.3 9/6 8/2/1 38.6 14.9 
 p-
value 
0.63 0.57 0.50 0.57 0.66 0.62 0.95 
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Table S 4 Univariate analysis of HRQOL scores influencing adverse reactions at different 
time points following BM donation. All time points are defined as the day of donation (D 0), 
2-3 days after donation (D2-3) and weekly after donation up until full recovery. Means are 
given. 
End point  PCS MCS 
All time points Allergy summary Yes (0)   
 No (37)   
 p-value NA NA 
All time points anorexia summary Yes (6) 58.0 47.5 
 No (31) 60.5 53.1 
 p-value 0.028 0.12 
All time points back pain summary Yes (34) 58.5 51.6 
 No (3) 58.1 58.2 
 p-value 0.87 0.22 
All time points bleeding summary Yes (12) 58.8 52.2 
 No (25) 58.2 52.0 
 p-value 0.55 0.96 
All time points bruising summary Yes (22) 58.6 52.7 
 No (15) 58.3 51.0 
 p-value 0.80 0.56 
All time points dizziness summary Yes (16) 59.1 50.0 
 No (21) 57.8 54.0 
 p-value 0.24 0.15 
All time points fatigue summary Yes (32) 58.6 51.8 
 No (5) 57.3 53.7 
 p-value 0.52 0.69 
All time points fever summary Yes (2) 54.1 44.9 
 No (35) 58.6 52.3 
 p-value 0.12 0.32 
All time points headache summary Yes (4) 58.7 51.9 
 No (33) 58.4 53.7 
 p-value 0.86 0.19 
All time points infection summary Yes (0)   
 No (37)   
 p-value NA NA 
All time points insomnia summary Yes (7) 58.7 48.7 
 No (30) 58.4 53.1 
 p-value 0.83 0.19 
All time points myalgia summary Yes (2) 58.9 52.1 
 No (35) 58.4 52.1 
 p-value 0.81 0.99 
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All time points nausea summary Yes (7) 58.6 52.6 
 No (29) 58.0 51.9 
 p-value 0.67 0.86 
Any other Pain all time points Yes (5) 58.7 52.2 
 No (32) 58.4 52.1 
 p-value 0.82 0.17 
All time points rash summary Yes (1) 57.7 52.6 
 No (36) 58.5 52.1 
 p-value 0.78 0.94 
All time points vomiting summary Yes (2) 59.1 55.8 
 No (35) 58.4 51.8 
 p-value 0.73 0.46 
All time point throat pain  Yes (21) 58.2 53.1 
 No (15) 59.2 51.3 
 p-value 0.42 0.56 
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Document S 1 Qualitative interview schedule 
 
Before tape is turned on: 
  
 Introduction about interview & questionnaire: 
 Re: possible distress 
 Confidentiality 
 Tape recorded 
 Consent  
 
 Orientation: focus on general health and health perception 
 
Turn tape on: 
 
1.  Getting to know the participant (3 minutes) 
 
 Who do you live with? Tell me a bit about your family?  
 Siblings 
 Children/dependents 
 Do you have a partner/married? Boyfriend or girlfriend? 
 Social network – friends living nearby 
 
2. Assess how well informed and prepared donor felt (15 minutes) 
 
Ok, let’s talk now about your PBSC donation. 
 
 Was the donation like you expected? 
 Was it better or worse than expected? 
 Did you feel you were given the right information and right amount? 
 Amount of contact with AN register since joining – sufficient? Not enough? 
 Is this their first and only experience of donation? If no, what others and when? 
 If not feeling well prepared - Is there anything we could change in the future (as an 
organisation) in order to prepare you better? 
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 How do you feel about the donation now?  
 
3.  Explore general physical HRQOL during the donation process and health perception/illness 
perception (20 minutes) 
 
 How would you rate your health compared to other people of the same age? (before 
and after donation) 
 Do you experience physical limitations (compared to other people of the same age), 
for example when doing moderate activities or vigorous activities (before and after 
donation)  
If yes, explore further + impact on social activities/mood/emotional well being 
 Have you been experiencing pain symptoms? (before and after donation) 
If yes before donation, explore (how often, how severe, how often, underlying cause 
etc. + impact on social life/mood/sleep/work)  
 
 How important would you say that “health” is in your life (comparing it to other values 
such as happiness, wealth, comfortable life, exciting life, world at peace, wisdom, 
freedom etc.)  
 
 What was your most serious symptom(s) following donation 
 How did symptoms affect you? Did you have to take time off work? Social impact? 
Did you cut down on certain activities afterwards? 
 How long did you think the symptoms would last for? Did you feel they were serious? 
 How did you influence/control symptoms 
 How did you feel in response to symptoms (for example depressed, anxious, afraid, 
worried, angry, upset, etc.) 
 Did you feel supported by work or family? 
 
4. Assess ambivalence (10-15 mins)  
 
 What motivated you in becoming a stem cell donor? 
 When/how did donor join the register – how long did it take between initial thought 
and actually joining 
 How certain were you about the decision? Was it a difficult decision? What made it 
easier? What made it more difficult? 
 How important is being a stem cell donor for you? 
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 Who helped you to decide? Consulted family/friends/health professionals? What did 
they say? 
 Did you have doubts or worries about the donation? 
Did you feel there were a lot of risks involved with donating?  
Do you think it is associated with a lot of risks? 
 
Now you have been through it, do you think you would do it again? 
If not, why? 
End of interview 
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Document S 2 Example of interview (p7): initial codes and themes are documented on the 
right side. 
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Table S 5 Themes and codes - first draft 
Themes Codes 
Anthony Nolan (AN) 
ambassador 
Altruism as a personality trait 
Guilt about not being a blood donor 
Favour to be returned if they would end up to be in similar 
situation 
Connection between religious identification and the decision to 
donate 
Connection between community sense and the decision to 
donate 
Donation precipitated by specific personal circumstances 
On asking whether they would still be willing to be on the 
register, even though they weren’t a match for the person they 
originally joined for, responses were the following: 
Determination Not influenced by other people 
Perseverance 
Donors worried about not being able to donate, rather than 
expressing worries about own health 
Playing down side effects 
Relationship with 
recipient 
Very emotional reactions to donation process, both high and 
low 
Fantasising about recipient 
Reactions of grief when finding out recipient has died 
Wanting to know about outcome and recipient in general 
Despite strong (emotional) relationship with recipient, very 
rational behaviour 
Strong feeling of 
rightness/fairness 
 
Not expecting reward  
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Table S 6 Themes and codes - final 
Themes Codes 
Intrinsic motivation Altruism as a personality trait 
Opportunity to save someone’s life 
Hoping to rely on others’ donations if ever in need 
Religious identification and the decision to donate 
Community sense and the decision to donate 
Donation precipitated by personal circumstances 
Promotion of donation 
Determination Sense of duty 
Not influenced by other people 
Worries about not being able to donate 
Playing down side effects 
Relationship with 
recipient 
Emotional reactions to donation process 
Wanting to know the outcome 
Fantasising about recipient 
Reactions of grief when finding out recipient has died 
Remaining realistic about possible outcome for the recipient 
Strong feeling of 
fairness 
 
Ease of decision  
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Document S 3 Donor education sheet for higher risk PBSC donors 
 
The stem cells used in peripheral blood stem cell (PBSC) donation come from the 
bloodstream. A process called apheresis is used to obtain PBSC for transplantation. For 4 
days before apheresis, you will be given a medication to increase the number of stem cells 
released into the bloodstream. This medication will likely cause bone and muscle aches, 
headaches, fatigue, dizziness, nausea, vomiting, and/or difficulty sleeping. During apheresis, 
blood is removed through a large vein in the arm or a central venous catheter (a flexible tube 
that is placed in a large vein in the neck or groin area). The blood goes through a machine 
that removes the stem cells. The blood is then returned and the collected cells are stored. 
Apheresis typically takes 4 to 6 hours. Apheresis itself usually causes minimal discomfort, but 
you may feel dizzy or experience numbness around the lips or cramping in the hands.  
 
Based on previous research within our organisation, we found that some of our PBSC donors 
were at higher risks of side effects. We think you may be at higher risk based on some of the 
answers on your “general health and wellbeing” questionnaire.  
 You may be more likely to experience the following side-effects, although you will 
likely experience them as being “mild”. These symptoms may last for a week or 
sometimes a bit longer. 
o Tiredness 
o Dizziness 
o Pain symptoms 
 If you are a woman, you may be more likely to experience pain symptoms  
 If you are older than 40, you may experience more tiredness after donation (43% of 
donors > 40 vs 21% donors ≤ 40 after 1 week of donation) 
 You may take longer to recover and to be free of any symptoms; most PBSC donors 
that are at higher risk take about a week to feel fully back to normal  
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As an intervention to help you to recover quicker, we ask you to start taking 
paracetamol on the first day of G-CSF. Please take 1 g every 6 hours up until the 
day of donation. 
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Document S 4 Donor education sheet for higher risk bone marrow donors 
 
The stem cells used in bone marrow donors come from the liquid centre of the bone, called 
the marrow. You will be given general anaesthesia which puts you to sleep during the 
procedure. Needles are inserted through the skin over the hip bone and into the bone marrow 
to draw the marrow out of the bone. Drawing the marrow takes about half an hour to an hour. 
You will usually stay in hospital for 2 nights; you will be admitted to hospital the day before the 
donation and you will be discharged the day after the donation. The area where the bone 
marrow was taken out may feel stiff or sore and you may feel tired.  
 
Based on previous research within our organisation, we found that some of our bone marrow 
donors were at higher risks of side effects. We think you may be at higher risk based on some 
of the answers on your “general health and wellbeing” questionnaire.  
 You may be more likely to experience the following side-effects, although you will 
likely experience them as being “mild” 
o Pain symptoms 
 You may take longer to recover and to be free of any symptoms. Although the time 
required for bone marrow donors to recover varies, most bone marrow donors that 
are at higher risk take about 4 weeks to fully recover their strength.  
 
As an intervention to help you to recover quicker, we ask you to start taking 
paracetamol on the day of donation up until 5 days after donation. Please take 1g 
every 6 hours. We will also provide you with a prescription of codeine when you 
leave the hospital in case you would need some stronger painkillers. 
We will also keep a closer eye on you after the donation with regular telephone calls 
up until you have fully recovered. You can also ring us on xxx. 
 
 
 
